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CHAPTER I 
GENERAL INTRODUCTION 
1 
1.1 INTRODUCTION 
Methionine ie an essent ia l amino acid required f o r many cellular 
p roceeees . In par t i cu la r , the presence of the methyl-eul fur moiety 
g ives n e e to unique biochemical pathwaye ( fo r rev iews eee 1-12). 
Methionine is ut i l ized in the cell f o r p ro te in synthes is and i t is 
the p recu rso r of S-adenosylmethionme (AdoMet). AdoMet se rves as the 
predominant biological methyl group donor, as a p recursor in po ly -
amine syn thes is , and as an in termediate in the t ranesu l fura t ion 
pathway leading t o the format ion of homocyste ine, cyetath ione and 
cys te ine (Fig. 1). Next t o t ranesu l fu ra t ion , methionine may also be 
catabol ized via the traneammation pathway. Methanethiol (MT) and 
o ther vo la t i le eulfur compounde have been sugges ted t o be formed via 
the lat ter pathway 
1.2 METHIONINE METABOLISM AND ITS IMPLICATION IN SEVERAL DISORDERS 
1.2.1 THE TRANSSULFURATION PATHWAY 
1.2.1.1 METABOLIC MECHANISMS 
A g a t e w a y t o many v i t a l r e a c t i o n e o f m e t h i o n i n e m e t a b o l i e m ia 
t h e c o n v e r e i o n o f m e t h i o n i n e and t h e a d e n o s y l g r o u p o f ATP i n t o 
A d o M e t , an e n e r g y - r i c h s u l f o m u m c o m p o u n d (Fig 2) . The f o r m a t i o n o f 
A d o M e t is c a t a l y z e d b y m e t h i o n i n e a d e n o e y l t r a n s f e r a s e ( E C 2 5 1 6 ] 
(Fig 1) In humans, t h r e e d i f f e r e n t i s o e n z y m e s o f h e p a t i c m e t h i o n i n e 
a d e n o s y l t r a n s f e r a a e h a v e b e e n d e s c r i b e d (13) In a d u l t s 3% o f t h e 
h e p a t i c m e t h i o n i n e a d e n o a y l t r a n e f e r a s e a c t i v i t y o r i g i n a t e s f r o m a 
f e t a l f o r m w i t h a low Km (high a f f i n i t y ) f o r m e t h i o n i n e (3 uM) and 6% 
f r o m an i n t e r m e d i a t e f o r m w i t h a Km o f 20 uM An adu l t f o r m w i t h a 
high Km(650 uM) c o n t n b u t e e 91% t o t he t o t a l a c t i v i t y 
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РЯОТЕМ IfETMONME 
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Fig. 1. Metabolism of methionine. 
1. methionine adenosyltransferase 
2. methyltraneferaee 
3. S-adenosylhomocyeteine hydrolase 
4. bstaine-homocystsine methyltraneferaee 
5. 5-msthyltstrahydrofolats-homocystslne methyltraneferaee 
6. cyetathionine synthase 
7. t-cystathionass 
Θ. S-adenoeylmsthionine decarboxylase 
9. epermidine synthase and spermine synthase 
10. transaminass 
11. branched-chaln 2-oxo acid dehyd"ogenase 
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AdoMet is an e n e r g y - r i c h and r e l a t i v e l y labile compound which is 
Involved In the e s s e n t i a l s y n t h e s i s of polyamlnes and in the methyla-
t l o n of a g r e a t number of compounds. including nucleic acids, 
c r e a t i n e , choline, p r o t e i n s , carn i t ine, еагсо іп , and phosphat idy l-
choline(8,12,14.15). This t r a n s m e t h y l a t i o n r e a c t i o n can be s t r o n g l y 
inhibited by i t s p r o d u c t S-adenoeylhomocysteme (AdoHcy). However. 
under normal condit ions AdoHcy ie rapid ly metabolized via the 
c leavage of i t s t h l o e t h e r bond by AdoHcy hydrolase[EC 3.3.1 1.], r e -
eulting in adenosine and homocysteine (5,12) 
An important branch point of the t r a n e s u l f u r a t i o n pathway l ies 
a t the level of h o m o c y s t s m s . A s e n s i t i v e mechanism r e g u l a t e s whether 
methionine is regained by r e m e t h y l a t i o n of homocysteine or c a t a b o l i -
zed by t r a n s s u l f u r a t i o n of homocysteine via cystath ionine into 
c y s t e i n e . This mechanism is not only influenced by the d i e t a r y 
c o n t e n t of methionine but also by the avai labi l i ty of o t h e r 
n u t r i e n t s , including c y s t i n e , choline, b e t a i n e , f o l a t e , and vitamin 
B12 (16.17) 
S,10-MEmYLENE· 
, TFTRAHllOROFOLATE 
• S-MEIHYLTETRA-
HVDROFOLATE 
METHIONINE 
CH,-S-CH,-CH,-CH-COCH 
3 2
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1
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I I 
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Fig. 2. Transmethylation. 
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The r e m e t h y l a t f o n of homocysteine Into methionine Is c a t a l y z e d 
by betaine-homocyeteine methyltraneferaeeCEC 2.1.1.5.] or by the 
vitamin B12-containing enzyme S - m e t h y l t e t r a h y d r o f o l a t e - h o m o c y s t e i n e 
m e t h y l t r a n e f e r a e e [EC 2.1.1.13.] (Fig. 2). In th is p r o c e e s , the one 
carbon f ragment may or ig inate f r o m f o r m a t e or formaldehyde, and i t is 
ul t imately reduced via t e t r a h y d r o f o l i c acid t o f o r m the methyl group 
of methlonine(15,1B). Degradation of homocyeteine v ia the t r a n e e u l f u -
r a t i o n pathway Involvee the convereion of homocyeteine into c y e t a -
thionine (Fig. 3). This r e a c t i o n ie cata lyzed by c y s t a t h i o n i n e 
synthaee[EC 4.2.1.22.]. a pyridoxine-requiring enzyme. 
CH, -S-CH, -СИ, -СН-С0Ш 
ж, 
METHIONINE 
S-ADENOSYLMETHIONINE 
S-ADENOSYLHCKEYSTEINE 
HS-(H2-CH2-CH-O0CH 
Ш , 
HMXYSTEINE 
pyridoxal f— 
phosphate 
SERINE 
I 2 2 2 | 
CYSTATHIONINE 
pyridoxal 
phosphate ^ HCMDSEMNE -* α-ΚΕΤΟΒΙΠΎΚΑΤΕ 
2
 I 
•"2 
CYSTEINE 
i 
I 
SULFATE 
Fig. 3. The traneeulfuratlon pathway. 
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The t r a n s e u l f u r a t i o n p a t h w a y is c o m p l e t e d by t h e c l e a v a g e of 
c y e t a t h i o n i n e I n t o 2 - k e t o b u t y r a t s and c y s t e i n e by t - c y e t a t h l o n a e e [ E C 
4 . 4 . 1 . 1 . ] , a n o t h e r p y r l d o x i n e requir ing e n z y m e . C y s t e i n e Is u s e d In 
t h e b i o s y n t h e s i s of s e v e r a l i m p o r t a n t p r o d u c t s of sulfur m e t a b o l i s m : 
e.g. taLTine, co-enzyme A. glutathione, and sulfate. 
1.2.1.2 DISORDERS OF THE TRANSSULFURATION PATHWAY 
The d i f f e r e n t c a u s e s of h y p e r m e t h i o n m e m i a , h o m o c y e t m e m i a , and 
c y a t a t h i o n i n u r i a a r e g i v e n in Table 1. In t h i s s e c t i o n e o m e d i s o r d e r s 
of t h e t r a n s e u l f u r a t i o n p a t h w a y r e l e v a n t t o t h i e t h e e i e a r e d i e -
cuesed. 
Five young p a t i e n t s ( 0 t o 6 y e a r s of a g e ) w i t h h y p e r m e t h i o n m e ­
mia due t o a p a r t i a l h e p a t i c d e f i c i e n c y of p r o b a b l y t h e high Km 
i s o e n z y m e of methionine a d e n o e y l t r a n e f e r a s e h a v e b e e n d e s c r l b e d ( 1 9 -
2 2 ) . A c t i v i t i e s of o t h e r e n z y m e s of t h e t r a n s e u l f u r a t i o n and r e m e t h y -
l a t i o n p a t h w a y w e r e n o t d e f i c i e n t ( 1 9 , 2 0 ) . In n o n - h e p a t i c t i s s u e s of 
t h e s s p a t i e n t s t h e a c t i v i t y of methionine a d e n o e y l t r a n s f e r a s s w a s n o t 
d i f f e r e n t f r o m normal c o n t r o l s . D e s p i t e high methionine l e v e l s ( 0 . 2 5 
t o 1 2 7 mmol/l, normal r a n g s is 0 . 0 1 Θ - 0 . 0 4 4 mmol/l) t h e s e young 
p a t i e n t e did n o t show any clinical p r o b l è m e , a l though u l t r a e t r u c t u r a l 
abnormal i t iee in the o u t e r mitochondrial membranee and in t h e e n d o -
p laemat ic ret iculum w e r e r e p o r t e d ( 1 9 , 2 0 ) . Becauee of t h e e e u l t r a -
e t r u c t u r a l abnormal i t iee and of t h e t o x i c p r o p e r t i e s of methionins, 
g r e a t u n c e r t a i n t y w a s s x p r e e s e d about t h e f u r t h e r deve lopment of 
theee chilck-en(5,19-21). 
Hypermeth ionmemia in p a t i e n t e with l iver d i e e a e e hae been 
a e c r i b e d t o an impaired d e g r a d a t i o n of methionine v ia t h e t r a n e s u l f u -
r a t i o n p a t h w a y , probab ly a leo caueed by a de f ic iency of methionine 
adenoeyltraneferaseC23-25). 
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Table 1. D i f f e r e n t c a u s e s of h y p e r m e t h l o n l n e m l a , h o m o c y e t l n e m i a , and 
c y s t a t h i o n l n u r l a ( M o d i f i e d f r o m Mudd and L e v y . r e f . S ) . 
A. Hypermethioninemla (-urla) 
1. Methionine a d e n o s y l t r a n s f e r a s e deficiency 
2. Cystathionine synthase deficiency 
3. S e v e r s generalized liver diseaee 
4. In aeeociation with hereditary tyrosmemia 
5. Traneient hypermsthioninsmia of infante 
6. B-AzaLTidine t r i a c e t a t e administration 
7 D-MethioninLria due t o D-methionins ingeetion 
8. P e r s i s t e n t and specific, associated with myopathy 
9. P e r s i s t e n t and specific, not a s s o c i a t e d with myopathy 
B. Homocyetmsmia (-cria) 
1. Cyetathionins synthase deficisncy 
2. Vitamin Be deficiency 
3. I m p a i r e d a c t i v i t y of 5 - m e t h y l t e t r a h y d r o f o l a t e - h o m o c y s t e i n e 
msthyltransf e r a s e : 
a. F a i k r e t o form or accumulate methylcobalamm 
b. 5,10-Methylenetetrat iydrofolats r e d u c t a s e deficiency 
c. D e f e c t i v e absorption of vitamin B12 
d. Nutritional vitamm B12 deficiency 
4. 6-AzaLrldine t r i a c e t a t e administration 
5. Art ifactual, due t o bacterial a c t i v i t y in Lrme 
С Cystathioninuria 
1 Transient cystathionuria of (usually p r e m a t u r e ) infante 
2. t - C y e t a t h i o n a e e deficiency 
3. Vitamin Bs deficiency 
4. I m p a i r e d a c t i v i t y of 5 - m e t h y l t e t r a h y d r o f o l a t e - h o m o c y e t s i n s 
msthyltransf e r a s e : 
a. Failtre t o form or accumulate methylcobalamm 
b. 5 , 1 0 - M e t h y l e n e t e t r a h y d r o f o l a t e r e d u c t a s e deficiency 
c. Nutritional vitamin B12 deficiency 
5. Thyrotoxicosis 
6. Liver dieeaee 
7. Neiroblaetoma. ganghoblaetoma, hepatoblastoma 
8. D e f e c t i v e renal t r a n s p o r t 
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Several groups of patients with homocystlnemla have been descri­
bed (5,10). In one group, homocysteine accumulates because of a 
decreased remethylation of homocysteine due to an inability to form 
or to accumulate vitamin B12. In another group of homocystmunc 
patients a deficiency in the synthesis of 5-methyltetrahydrofolats by 
5,1Q-methylenetetrahydrofolate reductaee[EC 1.1 1.BB.] was demon-
stratsd. However, the form of homocyetinuna most frequently encoun­
tered Is caused by a deficiency of cystathionine synthase, the enzyme 
responsibls for the conversion of homocyeteine into cystathionine. In 
these patients, the activity of this snzyms is zero or only 
reeldual(5,10). Bssidss homocystsine, also methionine and other 
derivativas of homocysteine have been described to accumu-
late(5,10.11). Cystathionine synthase deficiency shows itself in a 
large heterogeneity of clinical abnormalities. Frequently seen are 
osteoporosis, mental retardation and dislocation of the eye-lens or 
other ocular abnormalities. Thrombo'smboliems and arteriosclerosis are 
the most lifs-thrsatsning complications in these patients. Although 
no biochemical mechanism has yet been established to explain all 
pathological abnormalities, the treatment has been focused on 
reducing homocysteine І ві (26). For that purpose large dosee of 
pyndoxme have been ueed to stimulate residual cystathionine syn­
thase activity. However, approximately 50% of the patients appeared 
to be nonrssponsivs to pyridoxins therapy. To reduce homocysteine 
levels in these patients a msthionlns r s s t n c t s d dist was prescribed 
and the remethylation of homocysteine to methionine was stimulated by 
using high doses of betame and folic acid(5,10.26). 
Besides the homozygotic form of cystathionine synthase defi­
ciency, aleo a heterozygotic form ie of clinical Interest. The latter 
form (incidence about 1-200) is characterized by a cyetathionine 
synthase activity of approximately 50% ths normal activity. Patients 
with this form also run a higher nek of developing vascular 
dlseass(27), probably caused by moderate homocystmemia. For these 
patients homocyetsms is also considered to be an arteriosclerotic 
agent in spits of much lower concentrations than present in homo-
zygoue homocystinuncedO). It has even been suggested that, when 
compared with young man. the low homocysteine levels in ssrum of 
premenopausal women may account for the low incidence of vascular 
diseases in this group of women(2B). 
About 50 patients with t-cyetathionase deficiency have been 
described. The majority of them are healthy, and it IB doubtful 
whether any clinical abnormalities result specifically from this 
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deficiency (2,5). 
1.2.2 THE POLYAMINE BIOSYNTHESIS 
The s p e c i f i c f u n c t i o n of t h e p o l y a m m e e e p e r m i d m e and s p e r m i n e 
is s t i l l n o t c o m p l e t e l y known. Thsy a r s b e l i e v e d t o b e i m p o r t a n t 
g r o w t h f a c t o r e Due t o t h e i r p o l y b a e i c c h a r a c t e r , p o l y a m m e e can 
s t a b i l i z e nucleic a c i d e , p r o t e i n e , and membrane s t r u c t u r e s ( s e e f o r 
reviews 2 9 , 3 0 ) 
The s y n t h e s i s of t h e s e p o l y a m m e e r e q u i r e s p u t r s s c m e and d e c a r -
b o x y l a t e d A d o M e t (Fio. 4 ) P u t r e s c m e is f o r m e d f r o m o r n i t h i n e by 
ornithine d e c a r b o x y l a e e . An i m p o r t a n t r e g u l a t o r y s t e p in p o l y a m m e 
b i o e y n t h e e i e ιβ t h e d e c a r b o x y l a t i o n of A d o M e t by A d o M e t d e c a r b o x y -
laee[EC 4 1.1 5 0 ] ( s e e f o r r e v i e w 31) Spermidine is f o r m e d o u t of 
p u t r s s c m e and d e c a r b o x y l a t e d A d o M e t . and s p e r m i n e f r o m s p e r m i d i n e 
and d e c a r b o x y l a t e d A d o M e t (Fig 4 ) In t h e s e r e a c t i o n s , t h e Ca-C« 
c a r b o n - c h a i n of methionine is i n c o r p o r a t e d in t h e p o l y a m m e e Only 
t h e m e t h y l t h i o m o i e t y of methionine is p r e s e r v e d m 5 ' - m e t h y l t h i o -
adenosine The l a t t e r compound may a l s o b e f o r m e d in t h e s y n t h e e i s of 
homoeenne lactone out of AdoMet(32) 
The n e x t s t e p s of t h i s p a t h w a y h a v e n o t all b e e n i d e n t i f i e d y e t . 
but it ie known t h a t t h e m e t h y l t h i o g r o u p of 5 ' - m e t h y l t h i o a d e n o s i n e 
is s a l v a g e d by c o n v e r s i o n of t h e m e t h y l t h i o n b o s e compound via 4 -
m e t h y l t h i o - 2 - o x o b u t y r a t e into methionine This r o u t e may be of p a r ­
t icular I m p o r t a n c e m c e l l e producing r e l a t i v e l y l a r g e a m o u n t s of 
p o l y a m m s s , such a s r a p i d l y dividing or malignant c e l l a T r a c e r 
e x p e r i m e n t s h a v e e s t a b l i e h e d t h a t t h e methionine s a l v a t i o n i n v o l v e s a 
m o d i f i c a t i o n m t h e n b o s s m o i e t y of t h e molecule t o f o r m t h e a -
a m m o b u t y r a t e p o r t i o n of methionine, r a t h e r t h a n a t r a n s f e r of t h e 
m e t h y l t h i o g r o u p t o an a c c e p t o r c o m p o u n d ( 3 3 - 3 5 ) The e n z y m e s i n v o l v e d 
m t h i s c o n v e r s i o n h a v e n o t b e e n fully c h a r a c t e r i z e d , t h e p a t h w a y 
a p p e a r s t o include p h o s p h o r y l a t i o n of 5 ' - m e t h y l t h i o a d e n o e i n e , r e m o v a l 
of t h e p h o e p h a t s t o f o r m an i n t e r m e d i a t e , and a u b e e q u e n t o x i d a t i o n 
and p r o d u c t i o n of f o r m a t e and 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e ( 3 5 - 3 7 ) In 
t h e f inal s t e p of t h e methionine s a l v a t i o n . 4 - m e t h y l t h i o - 2 - o x o b u t y -
r a t e le c o n v e r t e d into methionine by t r a n s a m i n a t i o n w i t h a s u i t a b l e 
amine donor. The r e l a t i v e a c t i v i t y o f t h i e r e a c t i o n ie high in 
c o m p a r i s o n w i t h t h e t r a n s a m i n a t i o n of t h e k e t o a c i d e of p h e n y l a l a ­
nine. leucine, l e o l e u c m e . and val ine (3Θ). Glutamine and a s p a r a g i n e 
mat be t h e p r e f e r r e d amine d o n o r e , b e c a u s e 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e 
g 
ie a g o o d s u b s t r a t e f o r b o t h g l u t a m i n a t r a n e a m i n a e e and a e p a r a g i n e 
t r a n e a m i n a e e (39.40). 
The r e l a t i v e i m p o r t a n c e s o f t h e d i f f e r e n t m e t a b o l i c p a t h w a y e 
s t a r t i n g f r o m A d o M e t a r s n o t c o m p l e t e l y u n d e r s t o o d . I t h a s b e e n 
s u g g e s t e d t h a t r e l a t i v e l y l a r g e a m o u n t s o f m e t h i o n i n e m a y b e u s e d In 
t h e s y n t h e s i s o f polyaminee and homoser lne lactone(6.41). 
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1.2.3 METHIONINE SULFOXIDE METABOLISM 
The ox ida t ion of methionine into methionine su l fox ide ( f r e e or 
in p r o t e i n ) hae b e e n d e s c r i b e d t o be accompl ished b y ( 4 2 . 4 3 ) : 1. f r e e 
r a d i c a l e . 2. H2O2. 3. enzymat ic o x i d a t i o n . The physiological impor -
tance of methionine su l fox ide f o r m a t i o n ie no t fully u n d e r e t o o d . It 
hae been s u g g e s t e d t h a t methionine in p r o t e i n e and p e p t i d e e can be a 
t a r g e t f o r rad ica le in v i v o , and subséquent ox ida t ion ie a e e o c i a t e d 
wi th loee of biochemical a c t i v i t y in a wide r a n g e of p r o t e i n s and 
p s p t i d e e ( 4 4 ) I n c r e a s e d l eve ls of methionine su l fox ide in p r o t e i n s 
may be involved in emphysema, rheumato id a r t h n t i e and c a t a r a c t , and 
may cauee a d e c r e a s e in enzyme a c t i v i t y in o lder an ima ls (43 ,44 ) 
Mammals a r e able t o absorb and metabol ize methionine su l fox ide . 
It can r e p l a c e methionine in t h e d i e t of t h e r a t ( 4 5 ) . Only f e w d a t a 
a r e avai lable about t h e metabol ic u t i l i za t ion of methionine s u l f -
o x i d e ( 4 6 , 4 7 ) It is not a s u b s t r a t e f o r methionine a d e n o s y l t r a n s -
f e r a e e nor f o r methionyl- tRNA e y n t h s t a e e t E C 6 1.1.10.], ne i ther d o e s 
methionine su l fox ide inhibit t h e s e г в а с і ю п ( 4 2 , 4 8 , 4 9 ) This indi­
c a t e s t h a t methionine s u l f o x i d e i t e s l f I B n o t i n v o l v e d in t h e 
t r a n e e u l f u r a t i o n p a t h w a y nor in p r o t e i n s y n t h e e i e . E v i d e n t l y , m e t h i o ­
nine e u l f o x i d e hae t o be r e d u c e d b e f o r e i t can r e p l a c e methiomns in 
t h e e s essential p r o c e s s e s 
T h r e e e n z y m a t i c р г о с е f o r t h e r e d u c t i o n or d e g r a d a t i o n of 
methionine s u l f o x i d e h a v e b e e n d e s c r i b e d : 1. r e d u c t i o n of methionine 
s u l f o x i d e In t h e p r e s e n c e of NAOH o r N A G P H ( 4 4 , 4 7 , 5 0 ) , 2 a c e t y l a t i o n 
and e x c r e t i o n into u r i n e ( 5 1 , 5 2 ) , 3. t r a n e a m m a t i o n into t h e s u l f o x i d e 
analogue of 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e and p o s e i b l y f u r t h e r d e g r a d a ­
t i o n v i a t h e t r a n s a m i n a t i o n p a t h w a y similar t o t h a t of methionine 
( e e e Fig. 5 and 1.2.4). The l a t t e r p r o c e e e ie e u g g e e t e d t o be of 
p a r t i c u l a r i m p o r t a n c e In methionine s u l f o x i d e c a t a b o l i s m ( 4 2 , 5 3 ) 
I 2.4 THE TRANSAMINATION PATHWAY 
1.2.4.1 METABOLISM OF 4-METHYLTHI0-2-0X0BUTYRATE ANO Э-METHYLTHIO-
PR0PI0NATE 
In 1 9 5 1 , R o s w e l l ( 5 4 ) d e m o n s t r a t e d t h a t methionine can b e t r a n e -
a m l n a t e d In t h e p r e s e n c e of r a t l i v e r h o m o g e n a t e e . Cannellakls and 
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Таг г(55) demonstrated for the f i r s t time that methionine can be 
catabollzed via Its keto acid into MT. The last ten уеаг . degrada­
tion of methionine via the transamination pathway, has particularly 
been studied by Benevenga and co-workere( reviewed in B). 
The f i r s t etep in the transamination pathway is the t r a n s ­
amination of methionine into 4-methylthio-2-oxobutyrate (Fig. 5). 
This keto acid can also bs formed via the polyamine biosynthesis (see 
1.2.2). 4-Methylthio-2-oxobutyrats lies at a metabolic branch point 
from which it may either bs catabolized via oxidative decarboxylation 
into 3-methylthioproplonate, or transammated back into methionine. 
The latter procese may bs catalyzed by several transammasesOB-
4-0.56). Enzymes involved In the traneammation of methionine into 4 -
methylthio-2-oxobutyrats are found in many tissuee of the r a t (liver. 
kidnsy. heart, brain, spleen, skeletal muscls and small intestines), 
among which liver and kidney have been r e p o r t e d to be the moet 
activs(57). 
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Fig. 5. The traneamination pathway. 
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B e s i d e s i m p l i c a t i o n s in methionine m e t a b o l i s m , 4 - m e t h y l t h i o - 2 -
o x o b u t y r a t e may a l e o p r o t e c t t h e b o d y by s c a v e n g i n g r a d i c a l s . In s o m e 
р а р г в ( 5 8 , 5 9 ) , 4 - m e t h y l t h i o - 2 - o x o b u t y r a t s h a s b e e n d e c r i b e d t o c a p -
t i r e hydroxyl radicals, resulting In ethylene production. 
In t h e d e g r a d a t i v s s e q u e n c e of methionine v i a t h e t r a n s a m i n a t i o n 
p a t h w a y , 4 - m s t h y l t h l o - 2 - o x o b u t y r a t e p r o b a b l y e n t e r s t h e m i t o c h o n d r i a 
by means of t h e p y r u v a t e c a r r i e r , a f t e r which 4 - m e t h y l t h i o - 2 - o x o -
b u t y r a t e can b e c o n v e r t e d into 3 - m s t h y l t h i o p r o p i o n a t e - C o A v i a o x i ­
d a t i v e d s c a r b o x y l a t i o n ( 7 , 5 3 , 6 0 - 6 4 ) . This r e a c t i o n is c a t a l y z e d by t h e 
b r a n c h e d - c h a m 2 - o x o acid d e h y d r o g e n a s e c o m p l e x and n o t by t h e c o m ­
p l e x e s p y r u v a t e d s h y d r o g e n a s s o r 2 - o x o g l u t a r a t e d e h y d r o g e n a e e ( 6 3 , 6 4 ) . 
1.2.4.2 METHANETHIOL METABOLISM 
Oral a d m i n i s t r a t i o n of methionine l e a d s t o MT f o r m a t i o n ( 6 5 - 6 8 ) . 
Although t h i s p r o c e e s has o f t e n b e e n h y p o t h e s i z e d t o p r o c e e d v i a t h e 
t r a n s a m i n a t i o n p a t h w a y C s e e r e v i e w s 5 - B , 1 2 ) , l i t t l e is known a b o u t t h e 
m e t a b o l i c s e q u e n c e leading t o MT f o r m a t i o n . S t e e l e and B e n e v e n g a ( 6 9 ) 
r e p o r t e d t h e f o r m a t i o n of MT f r o m 3 - m e t h y l t h i o p r o p i o n a t e in r a t l i v e r 
h o m o g e n a t e s . B e s i d e s MT. a l s o h y d r o g e n s u l f i d e , c a r b o n d i o x i d e and 
sulfate w e r e products of 3-methylthiopropionate catcbolism 
Table 2. Volatile sulfur compoinds involved in methanethiol 
metabolism. 
HaS Hyck-ogensulfids 
СНзЗ Methanethiol (MT) 
СНзЗСНэ Dimethyleulfide 
СНэЗЗСНэ Dimethyldisulfide 
N o t only t h e f o r m a t i o n of MT, b u t also i t s d i s p o s i t i o n and 
d e g r a d a t i o n is p o o r l y u n d e r s t o o d . This may a t l e a s t p a r t l y b e 
a s c r i b e d t o t h e g r e a t p r o b l e m s coming a c r o s s in m e a s u r i n g v o l a t i l e 
sulfur compounds a t low c o n c e n t r a t i o n e . I t has b e e n d e m o n s t r a t e d in 
r a t s t h a t i n t r a p e r l t o n e a l l y a d m i n i s t e r e d MT is l a r g e l y o x i d i z e d t o 
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su l fa te and carbondloxide(65,70,71). The sulfur atom of MT was 
r e c o v e r e d f o r 79% ae su l fa te In urine and the carbon atom fo r about 
40% as carbondioxide in the b rea th . In v i v o . MT may also be oxidized 
Into i te disulf ide dlmethyldieulf ids(1,72) or into mixsd d isu l f ides. 
e.g. with proteins (proteln-S-S-CH3K1.73). 
On the one hand MT may enzymatically be demethylated into 
hydrogen eulf lde(74). On the o ther hand th io l -S-methy l t rane fs raee is 
able t o methylate hydrogen sulf ide into MT(75). The eame enzyme can 
aleo methy late MT into dimethyleulf ide. a vo la t i le sulfur compound 
p resen t in the b rea th and blood of healthy eub jec ts and in e levated 
concent ra t ions m pat ien ta with l iver d iseaeB(66,67,76-78). Thiol-S-
me thy l t rans fe rass is p resen t in many t i ssues . The highest concen t ra -
t ion of th is enzyme wae found In the large bowel mucosa, indicating 
tha t t h io l -S -methy l t rans fe rase may play a ro le in the de tox i f i ca t ion 
of hycfr-ogensulfide and MT formed by the intestinal flora(75). 
1.2.5 THE QUANTITATIVE IMPORTANCE OF THE TRANSAMINATION VERSUS THE 
TRANSSULFURATION PATHWAY 
In l i t e ra tu re a discrepancy e x i s t s about the quant i ta t ive impor-
tance of the transaminat ion pathway in comparison with the t r anssu l -
fu ra t lon pathway. According t o L ivesey(7,64) . ths t rans-aminat ion 
pathway may be ths major degradat ive r o u t s of methionine in r a t s 
Bensvenga and co -works rs (79 ,e0) demonst ra ted tha t r a t s are able t o 
catabol ize methionine f o r 60-70%. and sheep f o r a t least 80%. via 
r o u t é e o ther than the t ranssu l fu ra t ion pathway, such as ths t ransami-
nat ion pathway. In a rev iew(8) , Benevenga claimed tha t the t r a n s -
amination pathway Is quant i ta t ive ly important in methionine degrada-
t ion and cannot be coneidered a pathway tha t o p e r a t e s only at high 
lévele of methionine. Finkeletem e t al.(17) demonst ra ted , however , 
t h a t r a t s are able t o catabol ize exceeeive amounte of methionine via 
the t raneeu l fu ra t ion pathway. They euggeeted tha t the traneamination 
pathway may be re levan t only at ex t remely high lévele of methionine. 
A recen t in v ivo 2H NMR spec t roscop i c s tudy in the rat(81) also 
p rov ided evidence tha t a f t e r methionine loading the bulk of meth io-
nine wae most l ikely degraded via the t raneeul fura t ion pathway. 
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L3 TOXIC PROPERTIES OF METHIONINE AND METHANETHIOL 
1.3.1 TOXICITY OF METHIONirC 
Many s t u d i e s on the t o x i c i t y of methionine have been p e r f o r m e d 
In animals consuming low p r o t e i n d i e t e supplemented with some amino 
acide (9.Θ2). In t h o s e animals, a marked g r o w t h euppreesion was 
already o b s e r v e d at a methionine Intake of four t o s ix t imes i t s 
requirement. The most not iceable t o x i c e f f e c t s in t h e r a t w e r e an 
enlarged darkened spleen. containing increased c o n c e n t r a t i o n s of 
i r o n , and an increase In weight of l iver and kldnsy. The Increase In 
splenic Iron was ascr ibed t o an e l e v a t e d d e s t r u c t i o n of e r y t h r o -
cytes(9,e3,84). 
In d i e t a r y e x c e s s , methionine is considered the most t o x i c amino 
acid when compared with o t h e r amino acids required f o r p r o t e i n 
eyntheeie(9.B2). Although the t o x i c p r o p e r t i e s of methionine have 
e x t e n s i v e l y been s t u d i e d , i t s biochemical mechanism is s t i l l unsol­
v e d . Hardwick e t аІ.( 5) o b s e r v e d t h a t methionine oral ly administered 
t o the guinea pig induced a p r o g r e s s i v e drop in hepat ic ATP. 
Administrat ion of adenoeme or ATP c o u n t e r a c t e d the t o x i c i t y of 
methionine. These findings s u g g e s t t h a t ATP deplet ion caused by the 
convers ion of methionine and ATP into AdoMet is a t l e a s t p a r t l y 
reeponelble f o r methionine t o x i c i t y . The t o x i c i t y of хс в і 
amounts of methionine may aleo be t h e r e s u l t of a built up of homo-
cy9telne(B6) (see also 1.2.1.2). 
Benevenga and c o - w o r k e r s ( e , 9 , 8 7 ) showed t h a t the t o x i c i t y of 
methionine may be r e l a t e d t o i t s degradat ion into MT via the 
transamination pathway (see aleo 1.2.4), They found t h a t coneumption 
of e x c e s s i v s amounts of methionine caused a g r e a t e r s u p p r e s s i o n in 
g r o w t h and more t ieeue damage than homocysteine. In t h e i r e x p e r i ­
ments, t h e t o x i c i t y of methionine resembled t h a t of S-methy l th io-
c y e t e m e . 3 - m e t h y l t h i o p r o p i o n a t e . and d i m e t h y l t h e t m . It was t h e r e ­
f o r e s u g g e e t e d t h a t the t o x i c i t y of methionine is r e l a t e d t o the 
presence of the methylthio group. 
1.3.2 TOXICITY OF METHATCTHIOL 
Oespite the p o o r knowledge of t h e biochemical pathways involved 
In MT metabollem. the t o x i c i t y of methionine is v e r y o f t e n ascr ibed 
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t o I ts degradation into ΜΤΟ,6-9,11.66.67,69.79.84,Θ7-101). 
In r e l a t i o n t o o t h e r vo lat i le sulfur compounds, MT ie as t o x i c 
as dimethyldleulf ide, about 10-fold lees t o x i c than hydrogen sul f ide, 
and about 10-fold more t o x i c than dimethyleulfide(102.103). Small 
amounts of MT can cause r e v e r s i b l e coma in t h e r a t (104). Two 
Industr ial accidents with MT intox icat ion have been r e p o r t e d 
(103,105). In one case an employee became unconscious f o r nine houre 
a f t e r inhalation of MT. but th is man r e c o v e r e d complete ly. In another 
caee a worker col lapsed Into coma a f t e r Inhalation of MT. Severe 
hemolyt ic anemia was o b s e r v e d and the coma p e r s i s t e d until his d e a t h , 
28 days af ter the accident. 
In v i t r o , low levels of MT s u p p r e s s e d mitochondrial r e s p i r a t i o n 
in l iver and brain c e l l s , probably due t o a r e a c t i o n with cytochrome 
с охігіаве( 4.106-10а). F u r t h e r m o r e , MT inhibits Na/K-ATPaae(109-111), 
muscle c r e a t i n e kinase(112), carbonic anhydraee(113), urea s y n -
thaee(114) and cata lase act iv i ty(84,110). The t o x i c i t y of MT may be 
r e l a t e d t o i t a chemical r e a c t i v i t y t o w a r d s s u l f h y d r y l groupe in 
proteine and towards enzyme bound metalad). 
1.4 THE ROLE OF METHIONINE AND METHANETHIOL IN THE PATHOGENESIS 
OF HEPATIC ENCEPHALOPATHY 
I 4 1 HEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy denotes a clinical d ieorder wherein 
hepat ic dysfunct ion causee changée in mental s t a t e (see fo r rev iews 
3.89,90,94.98,115.116) About 30% of pa t ien ts with c i r rhos is die in 
hepat ic comaOB) Despi te ex tene ive invest igat ion the exac t pa tho -
geneeie of hepat ic encephalopathy ie s t i l l obscure. It is even 
unclear whether the pathogeneeie of hepat ic encephalopathy due t o 
acute l iver fa i lure cor reeponde t o tha t seen in chronic l iver 
d isease. The cu r ren t view holde tha t potent ia l ly t ox i c compounds 
der ived f rom the in tes t ine are not adequately removed or metabo-
l ized. due t o the decreased l iver funct ion These compounde may 
accumulate and can have a d i rec t e f f e c t on the brain. Several 
compounde have been sugges ted t o be involved in the pathogeneeie of 
hepat ic encephalopathy: ammonia, methanethiol , f a t t y acids, phenols. 
t -ammobuty r lc acid and amino acid Imbalance. However, no single 
substance eeeme t o account f o r most cases of hepat ic encephalopathy. 
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Z l e v e and c o - w o r k e r s (104) f o u n d t h a t ammonia , MT, and f a t t y a d d s 
p o t e n t i a t e d e a c h o t h e r s t o x i c i t y . They t h e r e f o r e p o s t u l a t e d t h a t 
h e p a t i c e n c e p h a l o p a t h y may b e m e d i a t e d b y a s y n e r g i s t i c i n t e r a c t i o n 
b e t w e e n t h e s e compoLrde(104.114). 
1.4.2 METHIONINE ANO HEPATIC ENCEPHALOPATHY 
In many é t u d i é e i t h a s b e e n c l e a r l y d e m o n s t r a t e d t h a t in 
p a t i e n t s w i t h h e p a t i c e n c e p h a l o p a t h y due t o f u lm inan t a s w e l l a s 
c h r o n i c h e p a t i t i s , t h e i n c r e a s e in t h e s e r u m l e v e l o f m e t h i o n i n e 
s h o w e d t o b e o n e o f t h e m o s t p r o n o u n c e d when c o m p a r e d t o o t h e r amino 
a c i d s ( 3 . 9 2 . 9 6 , 9 7 . 1 1 7 - 1 2 1 ) . The I n c r e a s e In t h e l e v e l s o f m e t h i o n i n e 
is p r o b a b l y c a u e e d b y an I m p a i r e d c a t a b o l i s m in t h e d a m a g e d l i v e r and 
is n o t t h e r e e u l t o f i n c r e a s e d p r o t e i n d e g r a d a t i o n ( 9 2 . 1 1 7 , 1 2 2 ) . A 
d e l a y in t h e c l e a r a n c e o f p l a s m a m e t h i o n i n e in p a t i e n t s w i t h l i v e r 
damage w a s a l r e a d y o b s e r v e d in 1947 b y K inse l l e t a l . (123) Dai ly 
a d m i n i s t r a t i o n o f m e t h i o n i n e t o t h e s e p a t i e n t s r e s u l t e d in a h i g h e r 
e l e v a t i o n o f i t s p l a s m a I s v e l e when c o m p a r e d t o n o r m a l s u b j e c t s . This 
abno rma l m e t h i o n i n e r e t e n t i o n d i s a p p e a r e d when t h e h e p a t i c f u n c t i o n 
r e t u r n e d t o n o r m a l S e v e r a l i n v e s t i g a t o r s s h o w e d t h a t m o n i t o r i n g o f 
s e r u m m e t h i o n i n e l e v e l s can b e v e r y v a l u a b l e f o r j u d g i n g p r o g n o s i s 
and p r e d i c t i n g h e p a t i c e n c e p h a l o p a t h y in s s v s r s l i v e r d i s e a s e 
(92.96.97,117.123). 
M e t h i o n i n e a c c u m u l a t i o n In c i r r h o t i c s i s t h e r e s u l t o f an 
i m p a i r e d c a t a b o l i s m o f m e t h i o n i n e v i a t h e t r a n s s u l f u r a t i o n p a t h -
w a y ( 2 3 , 2 4 ) , m o e t l i ke l y c a u s e d b y a d e c r e a s e d a c t i v i t y o f m e t h i o n i n e 
a d e n o e y l t r a n e f e r a s e ( 2 3 - 2 5 ) . This w o u l d e x p l a i n t h e o b s e r v e d d e p l e t i o n 
o f t h e e e e e n t i a l c o m p o u n d A d o M e t in l i v e r d i e e a g e ( 2 3 , 1 2 4 . 1 2 5 ) . 
P h a r m a c o l o g i c a l a d m i n i s t r a t i o n o f A d o M e t m igh t he lp t o r e s t o r e t h e 
d e p l e t i o n o f A d o M e t and s t i m u l a t e t h e d e c r e a s e d l i v e r f u n c -
t ion(25,126). 
The c o m a t o g e n i c p r o p e r t i e e o f m e t h i o n i n e in t h e p r e s e n c e o f a 
d a m a g e d l i v e r h a v e b e e n o b s e r v e d in r a t s , d o g s , m o n k e y s and humans a s 
w e l l ( 3 . 9 3 , 9 5 . 1 2 7 - 1 2 9 ) . A c c o r d i n g t o S h i o t a e t a l . (129) and 
H i g a s h i ( 9 3 ) , t h r e e f a c t o r e a r e i n v o l v e d in t h e i n d u c t i o n o f r e v e r -
s i b l e c o m a : 1. l i v e r d a m a g e , 2. i n c r e a s e d ammonia l é v e l e . 3 . 
I n c r e a s e d m e t h i o n i n e l e v e l s . Coma d id n o t d e v e l o p in t h e i r animal 
m o d e l s , i f on l y t w o o u t o f t h e s e t h r e e f a c t o r e w e r e p r e s e n t . M e r i n o 
e t a l . ( 95 ) a l s o d e m o n s t r a t e d a c l e a r s y n e r g i s m b e t w e e n ammon ia , 
m e t h i o n i n e , and t h e p r e e e n c e o f a d e c r e a s e d l i v e r f u n c t i o n in d o g e 
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w i t h a p o r t a c a v a l ehunt. Phear e t al. ( 1 0 0 ) d e m o n s t r a t e d t h a t In 
c i r r h o t i c p a t i e n t e with a p r e v i o u s l y e n d u r e d h e p a t i c e n c e p h a l o p a t h y . 
o r a l a d m i n i s t r a t i o n of methionine induced n e u r o l o g i c a l d e t e r i o r a t i o n . 
Oral a n t i b i o t i c a p r e v e n t e d o r d e l a y e d t h e s e n e u r o l o g i c a l a b e r r a t i o n e . 
I n t r a v e n o u s l y a d m i n i s t e r e d methionine w i t h o u t o r a l a n t i b i o t i c s s h o w e d 
a d e l a y e d e x a c e r b a t i o n or no a f f e c t s a t all. They concluded t h a t o r a l 
methionine w a e m e t a b o l i z e d by t h e i n t e e t m a l f l o r a into a t o x i c 
a g e n t , p o s s i b l y MT, which w a s n o t r e m o v e d f r o m t h e blood c i r c u l a t i o n 
dus t o an impaired llvsr f inction. 
І.4.Э K/ETHAI^THIOL AND HEPATIC ENCEPHALOPATHY 
The t o x i c p r o p e r t i e s of methionine under normal condit ions a s 
well a s in t h e p r e s e n c e of a d e c r e a s e d l i v e r f u n c t i o n has o f t e n b e e n 
a t t r i b u t e d t o i t s d e g r a d a t i o n i n t o МТСэ I.3 2 and 1.4.2). H o w e v e r , 
l i t t l e is known a b o u t t h e c a t a b o l i s m of methionine leading t o 
f o r m a t i o n of MT ( a e e 1.2.4.2). F o r m a t i o n of MT may p r o c e e d via t h e 
t r a n s a m i n a t i o n p a t h w a y , but a leo v l a 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e f o r ­
med o u t of S ' - m e t h y l t h i o a d e n o e m e ( e e e 1.2.2). H o w e v e r , in p a t i e n t s 
w i t h l iver d l e e a s e it is g e n e r a l l y b e l i e v e d t h a t MT ie f o r m e d t h r o u g h 
d e g r a d a t i o n of methionine by t h e i n t e s t i n a l f l o r a i s e e r e v i e w s 3,116), 
although t h e r e ie hardly any evidence f o r thie aeeumption. 
The a s s o c i a t i o n t h a t MT may b e i n v o l v e d in t h e p a t h o g e n e s i s of 
h e p a t i c e n c e p h a l o p a t h y w a e f i r s t p u t f o r w a r d by D a v i d e o n e t a l . ( 1 3 0 ) , 
who n o t e d t h e s i m i l a r i t y of f e t o r h e p a t i c u e t o t h e odour of v o l a t i l e 
e u l f u r compounds. T h e r e u p o n , Chal lenger and Walshe(OB) i s o l a t e d l a r g s 
q u a n t i t i e s of MT and d l m e t h y l d l e u l f l d e f r o m t h e urine of a woman w i t h 
h e p a t i c e n c e p h a l o p a t h y and a s t r o n g f e t o r h e p a t i c u s , due t o m a s s i v e 
n e c r o s i s of t h e l i v e r . M o r s r e c e n t l y . I t w a s e e t a b h s h e d t h a t 
v o l a t i l e sulfur compounds a r e e l e v a t e d In t h e b r e a t h of p a t i e n t s with 
s e v e r e liver d i s e a s e ( 6 6 , 7 6 - 7 8 ) . 
Much a t t e n t i o n has b e e n paid t o t h e d e v e l o p m e n t of m e t h o d s f o r 
t h e m e a e u r e m e n t of MT in blood. Doizaki and Z i e v e d O D r e l e a s e d MT 
f r o m b l o o d by u e m g zinc and a c i d , and t h e y m e a s u r e d t h i s v o l a t i l s 
sulfur compound by using g a s c h r o m a t o g r a p h y . Thsir m e t h o d has b s s n 
u s e d by t h r e e d i f f e r e n t g r o u p e ( 1 3 1 - 1 3 3 ) . The r e l i a b i l i t y of t h i e 
m e t h o d rs a t l e a s t d o u b t f u l , b e c a u s e t h o s e g r o u p e r e p o r t e d v a l u e s of 
MT in humane which d i f f e r e d widely. 
By using new t e c h n i q u e s f o r t h e m e a s u m s n t o f v o l a t i l e sulfur 
c o m p o u n d s , Tangerman e t a l . ( 7 3 , 7 6 , 1 3 4 ) s h o w e d t h a t t h s zinc and acid 
1B 
method gave riss to unwanted side reactions, such as reduction of 
methionine into MT. They expressed the need for reinveetigating the 
role of MT in hepatic encephalopathy using b e t t e r methods for the 
meaeument of an хроеіг of the body to MT. 
L5 THE OBJECTIVES OF THE PRESENT INVESTIGATION 
The aim of the present etudy wae to obtain more insight into 
metabolism of methionine and methanethiol (MT) in r a t s and men under 
normal conditione ae well as in hepatic encephalopathy and some other 
pathological conditions. 
Chapter II deals with the toxicity of excessive amounts of 
methionine in normal r a t e and in r a t s with a decreased liver 
fuiction, induced by D-galactosamme. 
The degradation of methionine can proceed via two routes: the 
transeulfuration and the transamination pathway. In l i terature a 
contradiction exists about the quantitative importance of the t r a n s ­
amination versus the transsulfuration pathway Chapter 111 deals with 
the study on the existence and the quantitative importance of the 
transamination pathway In normal subjects. In the fasting s t a t e as 
well as a f t e r oral methionine loading The quantitative significance 
of the transamination pathway is also studied in three groups of 
patients with hypermethioninemia due to. 1 methionine adenoayltrans-
ferass deficiency (Chapter IV). 2. cystathionine synthase deficiency 
(Chapter V). 3. liver disease (Chapter VIII). 
In chapter VI attention is paid to the observed differences in 
methionine handling in the transamination pathway as well as in the 
transsulfuration pathway between premenopausal women and young men of 
comparable age. The differencee obeerved are associated with the low 
incidence of vascular diseaee in premenopausal women. 
The toxicity of methionine has often been suggested to be 
related to its degradation into MT. However, l ittle ie known about 
the biochemical mechamam resulting in formation and degradation of 
this metabolite. In Chapter VII Д. the formation of MT from 3 -
methylthioproplonate in hepatocytee of both human and r a t is de­
scribed. Chapter VII В deals with the metabohem of MT in whole 
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blood. 
MT has been s u g g e s t e d t o play a r o l e in the pathogenesis of 
hepat ic encephalopathy. However, the e x i s t i n g method f o r measuring an 
e x p o e u r e of the body t o MT p r o v e d t o be unreliable (Chapter VII В). 
New methode were developed (Chapter III. IV and VII A) and used t o 
r e - i n v e e t i g a t e the r o l e of MT in the pathogenesis of hepat ic 
encephalopathy in t w o animal modele (Chapter VIM A) ae well as in 
patiente with severe liver dieease (Chapter Vili B). 
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SUMMARY 
To s t u d y t h e t o x i c p r o p e r t i e s of methionine under t h e c o n d i t i o n s 
o f a l imited l i v e r f u n c t i o n , h e p a t i t i s w a s induced In r a t e by a 
s u b l e t h a l d o s e o f D - g a l a c t o s a m i n s . L i v e r injury w a s s t u d i e d by 
m e a e u r l n g t h e s e r u m a c t i v i t i e s of a s p a r t a t e and alanine 
a m i n o t r a n s f e r a s e . Methionine a p p e a r e d t o b e an e x c e l l e n t a n t i d o t e . 
when a d m i n i s t e r e d a t t h e s a m e t ims a s D - g a l a c t o s a m i n e . At a d o s e of 4 
g / k g b o d y w e i g h t , methionine g a v e an a l m o s t c o m p i s t e p r o t e c t i o n of 
t h e l i v e r a g a i n s t D - g a l a c t o s a m i n s induced h e p a t i t i s . H o w e v e r , when 
methionine w a s g i v e n 24 houre a f t e r O - g a l a c t o e a m i n e . methionine 
a p p e a r e d t o b e t o x i c . I t r e s u l t e d in an e x t r a i n c r e a s e in a s p a r t a t e 
and alanine a m i n o t r a n e f e r a s e and all r a t s died within 7 2 hours a f t e r 
D-galactosamine administration. 
INTRODUCTION 
Methionine is a s u l f u r - c o n t a i n i n g amino acid and e s s e n t i a l f o r 
p r o t e i n s y n t h e s i s , polyamine s y n t h e s i s and i t is a principal m e t h y l -
d o n o r [ 1 , 2 ] . In t h e t r a n s s u l f u r a t l o n p a t h w a y methionine is c o n v e r t e d 
i n t o c y s t e i n e , while v i a t h e t r a n s a m i n a t i o n p a t h w a y t h e m s t h y l - s u l f u r 
m o l s t y of methionine can b e c o n v e r t e d into m e t h a n e t h i o l (Fig. 1) 
[1.2.3.4]. 
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Although methionine. In e x c e s e l v e d i e t a r y amounts, le bel ieved 
t o be one of the moat t o x i c amino ac ide[5] , high c o n c e n t r a t i o n s of 
methionine showed t o be non t o x i c In pereons wi th a def ic iency in 
methionine a d e n o e y l t r a n e f e r a e e [ 2 . B ] . In healthy p e r s o n s . It le not 
known whether high levels of methionine are t o x i c or n o t . Methionine 
Is even used as an a n t i d o t e in acetaminophen poi9oning[7.8]. However, 
In the caee of an Impaired l iver f u n c t i o n , methionine is able t o 
Induce coma in r a t e [ 9 ] . dogs[10] and humans[11]. F u r t h e r m o r e . 
methionine may even be Involved In the pathogenesis of hepat ic 
sncsphalopathy[12,13]. Deeplte e x t e n s i v e etudiee[1,2], at p r e s e n t It 
is s t i l l unclear which metabol i te(e) of methionine is r e s p o n s i b l e f o r 
i t e t o x i c p r o p e r t y under the condit ione of impaired l iver funct ion. 
To s t u d y the t o x i c p r o p e r t i e s of methionine under the condit ion 
of a l imited l iver f u n c t i o n . methionine was administered t o r a t a , in 
which h e p a t i t i s was induced by D-galactosamme (O-GaIN). We p e r f o r ­
med two kinds of e x p e r i m e n t s . One group of r a t s was given methionine 
simultaneouely wi th D-GaIN and another group r e c e i v e d methionine 24 
hoLTS after D-GaIN administration 
MATERIALS AND METHODS 
Male Wietar r a t s of 250 g (rangs: 230-270 g) w e r e used in all 
exper imente Food and w a t e r were given a d libitum H e p a t i t i s was 
induced by a single i n t r a p e r i t o n e a l (ι p.) in ject ion of D-galactos-
amine-hydrochlonds (Msrck. Darmstadt , FRG) in a dose of 300-1300 
mg/kg body weight . All dosss of D-GaIN w e r s d i s s o l v e d in 0 5 ml 
water . L-methiomns (Bufa Chemie, Castr icum, The Netherlands) wae 
suspsndsd in 3.5 ml w a t e r and given in doeee of 1-4 g/kg body weight 
and administered i n t r a gaetr ica l ly (i.g ) via an o r o - g a e t r i c tube. 
In the f i r s t exper iment r a t s r e c e i v e d methionine within 10 
minutes a f t e r the D-GALN in ject ion. Methionine administrat ion was 
r e p e a t e d a f t e r 24. 4Θ and 72 houre. In the second e x p e r i m e n t r a t s 
r e c e i v e d methionine only 24 and 48 hours a f t e r D-GaIN in ject ion. 
Blood samples w e r e taken f rom the ta i l of the r a t wi thout 
anaesthesia. 
The l iver injury was studied by measuring in eerum the a c t i v i t y 
of a s p a r t a t e (ASAT) and alanine (ALAT) a m m o t r a n s f s r a s s s , according 
t o r o u t i n e l a b o r a t o r y methods ( M u l t i s t a t I I I, Inst rumentat ion 
L a b o r a t o r y . I j e e e l s t s m . The Netherlande). Addition of methionine t o 
serum did not interfere with the aminotraneferaee meaeurement. 
31 
RESULTS 
Fig. 2 e h o w a t h e a m i n o t r a n e f e r a e e a c t i v i t i e e ASAT and ALAT in 
e e r u m o f r a t a r e c e i v i n g d i f f e r e n t amounte of O-GalN. Normal amino­
t r a n e f e r a e e a c t i v i t i e e w e r e : ASAT 31 ±5 mU/ml, ALAT 21 ±2 mU/ml (mean 
±SD, n = 7 ) . ASAT and ALAT s h o w e d a d i e t i n c t ( п с г е а е with an 
i n o r e a e m g d o s e of D-GalN. Up t o a d o e e of 9 0 0 mg D-GalN/kg body 
w e i g h t t h e h e p a t o t o x i c e f f e c t e of 0-GalN a p p e a r e d t o b e r e v e r s i b l e . 
All r a t s d i e d within t h r e e d a y s a f t e r a d o s e of 1100 mg D-GalN/kg 
b o d y w e i g h t and within t w o d a y s a f t e r a d o e e of 1 3 0 0 mg D-GalN/kg 
body weight. 
ASAT |mU/ml) ALAT (mU/ml) 
Fig. 2. A m i n o t r a n e f e r a e e a c t i v i t i e s in e e r u m of r a t e a f t e r D-GalN 
a d m i m e t r a t l o n . The r a t e r e c e i v e d 3 0 0 ( • ) , 5 0 0 ( D ) , 7 0 0 ( A ) , 9 0 0 ( Δ ), 
1 1 0 0 ( · ) and 1 3 0 0 ( 0 ) mg 0-GalN/kg body w e i g h t i.p on day z e r o of t h e 
e x p e r i m e n t . Each point r e p r e e e n t s t h e mean a m i n o t r a n e f e r a e e a c t i v i t y 
in eerum of t h r e e r a t e . 
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Prior to the study of the effect of methionine in rate treated 
with D-GaIN, the ef fect of methionine administration alone wae 
studied. Two groupe of three healthy rate received methionine ι g 
for three days in a dally does of ^, and 4 g/kg body weight 
respectively. The behaviour of all rate remained normal and their 
aminotransferase activities In serum did not іпсг а Only the group 
of rats receiving 4g methionme/kg body weight showed a mean decrease 
of ЭВ g in their body weight after three days. Thus, administration 
of large doeee of methionine alone to rate during a limited period of 
time does not lead to any major toxic effect. 
A S A I (mU/ml) ALAT ImU/ml) 
-, , , t , , , 1 
1 2 3 1 2 3 day 
Fig. 3. Influence of simultaneous admimetration of methionine and D-
GalN on the aminotraneferaee activitiee in eerum of rate On day zero 
of the experiment the rats received 900 mg D-GalN/kg body weight 
(i.p ). Methionine was administered i.g. in the doeee of 0 g ( o ) , 1 g 
( Δ ) or 4 g(0)/kg body weight. Methionine administration was repeated 
each day. Each point represents the mean aminotransferase activity in 
serum of three rata. 
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To study the toxic properties of methionine, r a t e received a 
sublethal does of 9 0 0 mg D-GalN/kg body weight. In the f i r s t 
experiment methionine was administered eimultaneouely with the D-GaIN 
injection and In the second experiment methionine wae given 24 h our a 
after D-GaIN. 
Simultaneous administration of 900 mg D-GalN/kg body weight and 
Ig methiomne/kg body weight reeulted in much lower peak ASAT (mean 
1723 mU/ml) aid ALAT (mean 1491 mU/ml) levels than the peak ASAT 
(mean 3872 mU/ml) and ALAT (mean 4ΘΘΘ mU/ml) levels of r a t s t r e a t e d 
with D-GaIN alone (Fig. 3). Admimetration of 4g methionine/kg body 
weight reeulted in an almost a 100% protection of the liver against 
the toxicity of D-GaIN. In this experiment the mean peak level of 
ASAT wae 13B mU/ml aid of ALAT 64 mU/ml (Fig.3). 
In the second experiment methionine was administered 24 hours 
a f t e r the injection of 9 0 0 mg D-GalN/kg body weight. One group of 3 
r a t e received 1o methionine/kg body weight and another group of 3 
r a t s received 4g methionine/kg body weight. In this experiment 
methionine showed no protection at all against the hepatotoxicity of 
D-GAL. On the contrary, due to methionine admimetration four out of 
elx r a t s died within 24 hours a f t e r the f i r e t dose of methionine. The 
two r a t s (one out of each group), that were etili alive at that time 
had very high ASAT (6095 and 6120 mU/ml) and ALAT (7319 and 8568 
mU/ml) values. These valuee were in the eame range ae those of the 
r a t e that were given a поп-г г іЫ and lethal dose of D-GaIN alone 
(Fig. 2). In thie experiment all r a t s died within 72 hours after D-
GalN injection. 
DISCUSSION 
D-GaIN was used to induce liver injury in r a t s because of its 
dose/reeponee relationship and its rsvereibil ity. The hepatotoxicity 
of D-GaIN is attr ibuted to undylate trapping, which leads to a 
depression of uracil nuclsotide-dependent biosynthetic path-
ways[14]. The distinct doee/reeponee relationship between D-GaIN 
administration and ite hepatotoxicity in r a t e wae demonetrated in 
Fig. 2. 
Our results demonstrate a remarkable protection of the liver 
against the toxic e f f e c t e of D-GaIN by simultaneous administration of 
methionine. In particular, a does of 4g methionine/kg body weight 
3 4 
reeulted in an almost 100X protection aoainst the hepatotoxicity of 
D-GalN. However, when methionine was administered t o a r a t with an 
injured liver (24 hours a f t e r O-GaIN injection), the toxic propert iee 
of methionine became predominant and all rats died. 
Kroger e t af.[15] also studied the antidotal e f f e c t of 
methionine on D-GalN. They claimed a limitation of D-GalN-mduced 
liver injury by methionlns administration. However, their results 
were much less pronounced and difficult to I n t e r p r e t e , probably due 
to the much smaller doses of D-GalN (375 mg/kg body weight) and 
methionine (0.5 g/kg body weight) used. Moreover, thsy applied a 
different route of methionine administration d.p. versus i.g. in the 
present etudy). 
Toxic propert ies of methionine in r a t s , when given in the 
presence of liver injury, have been demonstrated previouely[9]. These 
r a t e , t r e a t e d with carbontetrachlonde, became comatogenic a f t e r 
administration of msthlomns (ι g ) and ammomumacetate (I.ρ ). A 
similar reeult was obtained in dogs with a portacaval shunt a f t e r 
ι g. feeding of methionine[10]. In cirrhotic patients, neurological 
deterioration can also be induced by oral methionine[11]. In 
contrast, intravenous administration of methionine wae without e f f e c t 
in these patients and an antibiotic (Chlortetracycline) wae able to 
prevent or delay the neurological deterioration a f t e r oral 
methionine. These findings indicate that methionine metabolism in the 
gut might lead to the formation of one or mors toxic compounds 
responsible for the clinical symptoms. Dus to the impaired liver 
function, such compounds would be removed insufficiently and might 
therefore lead to neurological deterioration 
The origin of the toxicity of methionine has often been ascribed 
to the formation of msthanethiol out of methionine[1.1D.11.12,16] 
However, we recently descrlbsd[6] a very high msthanethiol production 
in a man with a deficiency in methionine adsnoeyltransferass(EC 
2.5.1.6), the enzyme responsible for the formation of S-adenoeyl-
methionine out of methionine (Flg.1). Deepite the v e r y high msthane­
thiol production. this man showed no neurological abnormalitiee. 
Another explanation for the toxic propert ies of methionine may be a 
transient ATP depletion due to the ATP consuming conversion of an 
excess of methionine into S-adsnosylmethionme. In particular, par­
tially damaged hepatocytes. euch as those of r a t s 24 houre a f t e r 0 -
GalN injection, would be expected to euccumb mors readily to a drop 
η ATP. 
The molecular mechanism of the protection by methionine against 
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t h e h e p a t o t o x i c i t y of D-GaIN, when g i v e n e i m u l t a n e o u s l y . has not y e t 
b e e n e l u c i d a t e d . This phenomenon might b e r e l a t e d t o t h e e f f e c t of S -
a d e n o e y l m e t h i o n i n e a g a m e t t h e h e p a t o t o x i c i t y of D-GalN[17]. S -
A d e n o e y l m e t h i o n m e ie f o r m e d f r o m methionine by methionine 
a d e n o s y l t r a n s f e r a s e (Fig. 1). T h e r e f o r e , I n t a k e of l a r g e amounts of 
methionine m o s t likely r e s u l t s in an i n c r e a s e of S - a d e n o s y l m e t h l o m n s 
l e v e l s in t h e b o d y . A p a r t f r o m t h e p r o t e c t i o n by S -
a d e n o e y l m e t h i o n m e . m s t h i o m n s may also p r o t e c t t h e l iver a g a i n s t 
t o x i n s v i a o t h e r mechanisms: 1. Via t h e t r a n s s u l f u r a t i o n p a t h w a y 
methionine is c o n v e r t e d into c y s t e i n e (Fig.1) and f u r t h e r into 
g l u t a t h i o n e . A d m i n i s t r a t i o n of l a r g e a m o u n t s of methionine would 
t h e r e f o r e c o r r e c t or p r e v e n t t h e g l u t a t h i o n e d e p l e t i o n a s is t h s c a s e 
In e.g. a c e t a m i n o p h e n poisoning. 2. Similar t o g l u t a t h i o n e , 
methionine and i t s t r a n s a m i n a t i o n m e t a b o l i t e 2 - k e t o - 4 -
m e t h y l t h i o b u t y r a t e (Fig. 1) may play a r o l e in t h e cellular d s f e n s i v s 
mechanism a g a i n s t h y d r o g e n p e r o x i d e and lipid p e r o x i d e s [ 1 B . 1 9 , 2 0 ] . 
In conclusion, o r a l methionine a d m i n i s t r a t i o n p r o t e c t s t h s l iver 
a g a i n s t t h e h e p a t o t o x i c i t y of D-GaIN. H o w e v e r , o r a l methionine must 
b e a p p l i e d with c a r e , b e c a u s e it can t u r n into a t o x i n in c a s e t h e r e 
is a l imited l i v e r f u n c t i o n . This finding might account f o r t h e 
u n e x p l a i n e d f a i l u r e of methionine as an a n t i d o t e in soms p a t i e n t s 
a f t e r a c e t a m i n o p h e n p o i s o n i n o [ 7 ] . I n t r a v e n o u s i n s t e a d of o r a l 
administration of methionine may be an important a l t e r n a t i v e . 
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SLMMARY 
1 This study was designed to investigate the transami­
nation pathway of methionine in humans 
2 Evidence is provided that mclhancihiol and its 
metabolites are formed via transamination of mclhioninc 
Τ Gas-liquid chromatography was used to measure 
serum and urinary transamination metabolites of methio­
nine 2-keto-4-methylthiobutyrate 3-methylthiopropio-
nate and methanelhiol, and the metabolites of 
methancthiol, dimcthylsulphide, protein—S—S—CH, (a 
imxcd disulphide of blood proteins and methanethiol) and 
X—S—S—CH, (a mixed disulphide of methanethiol and 
another thiol with an unknown component X) 
4 Methionine and the transamination intermediates 
were measured in 10 normal subjects in six normal sub 
jects after L-methionme loading (0 1 g/kg body weight) 
and in a male patient with hepatic methionine adenosyl-
transferase (EC 2 5 16) deficiency 
4 In the patient with methionine adenosyltransferase 
deficiency at least 20% of methionine was degraded via 
transamination In normal subjects transamination of 
methionine did exist but was quantitatively not important 
in methionine catabohsm, not even after methionine load­
ing 
6 The results of this study might be of importance for 
future studies on the role of methanethiol in hepatic en­
cephalopathy 
Ke\ words: 2-keto-4-methylthiobutyraic, methanethiol, 
methionine, methionine adenosvltransferase deficiency, 
3-methy Ithiopropionate, transamination 
Abbreviations: AdoMel. 5-adenosylmethionine, DMS, 
dimcthvlsulphide, KMTB 2-keto-4-melhylthiobutyrate, 
Correspondence Dr A Tangcrman Dcparimem of Medicine 
Dmsion of Gaslroinlestinal and Liver Diseases University 
Hospital Nijmegen PO Box 9101 6500 HB Nijmegen The 
Netherlands 
MAT methionine adenosyltransferase (EC 2 5 16), MT 
methanethiol, MTP, 3-methylthiopropionate 
INTRODUCTION 
Large amounts of the essential amino acid methionine 
retard the growth of the rat [1-4] and may cause neuro­
logical deterioration in cirrhotic patients [5) It is 
suggested that this toxicity is caused by methanethiol 
(MT j , a methionine catabohte [6-8] MT induces a rever 
sible coma in rats at low dosage [9] MT may also be one 
of the endogenous factors responsible for hepatic en­
cephalopathy in man [5, 10, l l | The premise that MT 
effects the toxicity of methionine depends upon the 
assumption that MT is produced from methionine in sig 
nificant quantities 
Methionine can be degraded via two known pathwavs 
trans-sulphuration and transamination (big 1) Only the 
latter pathway includes MT as an intermediate In trans-
sulphuration [7, 12], methionine and adenosine 5-tri­
phosphate are first converted to Л-adenosylmcthionine 
(AdoMel) by the enzyme methionine adenosyltransferase 
(MAT, EC 2 4 1 6) AdoMet is an important methyl donor 
and yields S-adenosylhomocysteine m the process S-
Adenosvlhomocysteinc is metabolized to adenosine and 
homocysteine Homocysteine condenses with serine to 
form cystathionine, which is cleaved to cysteine and 
homosenne In the trans-sulphuration pathway the 
methyl-sulphur moiety is lost In contrast, transamination 
preserves the methyl-sulphur moiety of methionine [7 
13] This latter pathway leads to the formalion of MT 
During transamination (Fig 1), methionine is convened 
to 2-keio-4-methyllhiobutyrate (ΚΜΊΒ), which is decar-
boxylated to 3-inethyhhiopropionate (MTP) MT is 
formed from MTP 
The quantitative significance of the transamination 
pathwav has not been definitively determined In a recent 
review [14], Livescy suggested that, in vuro an excess of 
methionine can be degraded via transamination Expcn 
ments in vivo by Benevenga & Lgan [15] have shown that 
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Fig. 1. Catabolism of methionine 
in rat* and sheep 60-80% of methionine was not 
degraded via trans-sulphuration but via another degrada­
tion route In particular, they suggested that transamina­
tion might be of quantitative importance in these species 
In contrast, Finkelstein & Martin [16] found that rats 
could degrade exceedingly large amounts of methionine 
via trans-sulphuration alone In normal subjects, the con­
tribution of transamination to methionine catabolism is 
unknown We recently found [17) that in a patient with 
MAT deficiency, iransanunaiion might contribute at least 
2(1% to total methionine degradation 
In this study, we investigated the methionine transami­
nation pathway in humans through measurement of the 
transamination intermediates КМТВ, MTP and the 
resulting MT, and the metabolites of MT , dimcthylsul-
phide, protein—S—S—CH, (a mixed disulphide of blood 
proteins and MT) and X—S—S—CH, (a mixed disulphide 
of MT and another thiol with an unknown component X) 
The normal, methionme-loaded and MAT-deficient states 
were all examined for production of methionine transami­
nation products m serum, urine and breath 
METHODS 
Serum and urine samples of normal subjects 
Ten healthy volunteers (five males and five females), 
non-vegetanans and not taking any drugs or vitamins, col­
lected unne for 24 h There was no restriction to the diet 
Blood samples were withdrawn by venepuncture 
methionine-restncted breakfast and luncheon on the lest 
day (total content 14 mg of methionine in 2 g of protein, 
95 g of carbohydrate and 31 g of fat) Urine was collected 
before methionine loading and in two different portions 
(0-3 5 and 3 5-7 h) after methionine loading Breath and 
serum samples were obtained at regular intervals Methio­
nine was measured in serum by ion-exchange chromatog­
raphy (Biotronik LC 2000) 
Hepatic MAT-deficient patient 
An extensive report on this 31-year old male has been 
published by Gahl el al [18] We summarize some impor­
tant features The patient was examined medically 
because of an odd odour to his breath resembling fetor 
hcpaticus Methionine concentrations in plasma (0 7 
mmol/1) were about 25 times normal and in urine 
(282-658 /¿mol/dayj three to five times normal Mcthio-
mncsulphoxidc also appeared in urine (1721-2017 
/«nol/day) A liver biopsy showed a partial deficiency of 
hepatic MAT (about 10% of normall Cystathionine ¿I-
synthasc (EC 4 2 1 22) and y-cvstathionasc (cvsialhionmc 
y-lyase, EC 4 4 11) were near normal and no homocvsti-
nuna or cystathioninuna «as drice ted The hi pane, con 
centration of AdoMct (IS ^mol/ke wet »eight was 
somewhat reduced compared with normal subjects 
(35-70 /¿mol/kgl Apart from the hepatic MAT defici-
ency the patient appeared to be clinicall) normal and 
healthy 
Materials 
MT and dimethvbulphide (DMS) were obtained from 
Merck (Darmstad F G R >. КМТВ and dithiothreitol from 
Sigma Chemical Co 'St Louis MO U S A ' and methvl 
(3 methvlthioipropionale was from Aldnch vMilwaul.ee, 
Wl U b A ! MTP was synthesized from mcthyhV 
methylthio 'pi opionate 
Synthesis of M T P 
MethyH3-methylthio(propionate (10 g) was hydro-
lysed to MTP by refluxing for 4 h in 100 ml of 20% lw/v| 
NaOH solution The solution was refrigerated, acidified 
(pH 1 0) and extracted three times with ether The ether 
phases were pooled and re-extracted three times with 
NaOH (0 1 mol/1) The NaOH phases were pooled, acidi­
fied (pH 1 0) and again extracted three times with ether 
The ether phases were pooled and evaporated icsuliing 
in a colourless oil (3-mcthylthiopropionic acid) The 
lithium salt of MTP was prepared by treating the acid with 
equimolar amounts of LiOH The structure of MTP was 
confirmed by nuclear magnetic resonance, mass spec­
trometry and gas chromatographic analysis 
Methionine administration 
After an overnight fast, su volunteers (three males and 
three females) received an oral dose of L-methiomne (0 1 
g/kg body weight) at 09 00 hours They consumed a 
Gas chromatographic analyses 
MT, DMS, KMTB and MTP were measured using a 
Packard gas Chromatograph (type 429, Packard-Becker, 
Delft, The Netherlands), supplied with a flame photomet-
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nc detector (Packard, model 906) The injection port of 
the gas Chromatograph was supplied with a glass Imer 
(length 8 cm, outside diameter 6 mm) For further details 
and measurement of MT and DMS, sec [ 19] and [20] 
KMTB m urine was analysed by the gas chromatogra-
phic method of Favier & Caillât (21] In unne, KMTB 
remained stable for at least 5 h at 37°C, for at least 1 day 
at room temperature, for 4 days at 4°C and for at least 6 
months at - 20°C This result does not agree with that of 
Màrtensson [24], who reported that KMTB was less 
stable 
MTP in unne was measured using a modification of the 
method of Kaji et al [22] Unne samples (20-50 ml) were 
acidified (pH 1 0) and extracted three times with ether 
The ether phases were pooled and the ether was evapo-
rated at room temperature under a stream of nitrogen 
The residue was dissolved in 200 μ\ of HCl (0 1 mol/l) 
Samples (2-5 u\) were injected in the gas Chromatograph 
The glass column (length I 8 m 2 mm inner diameter) 
was packed with 10% (w/v) SP-1200/1% (w/v) Η,ΡΟ, on 
80/100 Chromosorb WAW (Supclco Ine PN, U S A ) 
The liner was filled with Chromosorb 101, mesh 60/80 
ι Chrompack The Netherlands) Column temperature 
0-1 min 150°C, 1-3 min nsc HVC/nun 3-8 mm rise 
2''C/min, 8-10 mm 180°C Detector and injector lem-
peraturc was 200°C The carrier gas was nitrogen at a 
flow rate of 30 ml/min 
DMS (breath 120 ml ) was measured as desenbed [20] 
Protein—S—S—CH, (serum), X-S—S—CH, (serum, 
unne) and 'indirect' KMTB (unne) were measured by 
conversion to MT Under neutral conditions only pro­
tein—S—S—CH, reacts with dithiothrcitol, resulting in 
the release of MT Al pH 10, both protem—S—S—CH, 
and X—S—S—CH, showed complete release of MT The 
values of MT at pH 10 must be corrected for protem— 
S - S - C H , , to obtain the value o f X - S - S - C H , 
At pH 12 5-13 0, all three compounds (pro-
te in-S-S-СНз, X - S - S - C H , and KMTB) gave 
complete release of MT Therefore the values of KMTB 
obtained by the indirect method of pH 12 5-13 0 were 
corrected for protem—S—S—CH 3 and X—S—S—СН3 
pH 7 
pH 10 
., - ™. dithiothreitol. „ 
protem—S—S—CH, • M T 
X - S - S - C H dithiothreitol 
CH,) Next, KMTB was measured 'indirectly' by conver­
sion to MT After the above procedure was performed for 
measurement of the mixed disulphides of MT, the remain­
ing mixture was flushed with nitrogen to remove traces of 
free MT, and left at room temperature for 10 mm in the 
opened vial The vial was again evacuated and 15 /il of 10 
mol/l NaOH was injected, bringing the pH to 12 5-13 0 
After vortexmg for 15 s and letting stand for 4 mm, 30 μΐ 
of 10 mol/l acetic acid was mjected and the released MT 
was assayed [19] The values for KMTB obtained by this 
indirect method corresponded to those obtained by the 
'direct' method of Favier & Caillât [21] 
X—S—S—CH, was identified as a mixed disulphide, by 
virtue of its reactivity towards dithiothreitol and of the 
production of appropriate amounts of CH,—CH,—S— 
S—CH, upon addition of a basic solution of ethanethiol 
CH,-CH,—S—S—CH, is formed through a thiol-disul-
phide exchange [23] 
C H , - C H ; - S - + X - S - S - C H 3 -
CH , - C H , - S - S - C H , + X - S 
The nature of the thiol X—SH is currently under studv 
Filtration experiments indicated that [he Λ/, of X—S—S— 
CH, is less than 1000 The filtration experiments were 
performed with an ultrafiltration cell, model 12, and using 
Diaflo ultrafilters YM2 with an M, cut-off of 1000 (Ami-
con Corp, Danvcrs, MA, U S A ) Preliminary expen-
ments have shown that 5-methylthiocysteine and 
N-acetyl-S-methylthiocysieine reacted similarly to X—S— 
S—CH, with respect to the release of MT by reaction with 
dithiothreitol at pH 10 0 Therefore X-SH might be 
cysteine or the ,\'-acclvl metabolite of cysteine Isolation 
and purification of X—S—S—CH, from urine might 
clarify the nature of X 
Creatinine 
Creatmme was measured by the picrate method 
Statistical analysis 
Statistical analysis was performed by using Student's 
r-tesl for paired results 
• MT 
, , , , , , , „ , . _ _ dithiothreitol „ 
pH 12 5-13 KMTB »MT 
Protein—S—S—CH 3 was measured as previously 
desenbed [19] The expenmental procedure for the 
measurement of X—S—S—CH, and of indirect' KMTB is 
as follows To 10-100 μί of a sample (unne or senim)ina 
closed evacuated 15 ml glass vial, was added 200 μ\ of 
dithiothreitol (10 mg/ml) m 0 1 mol/l Tns, pH 100 
After vortexmg for 10 s the mixture was left at room tem­
perature for 90 mm and 10 μί of 10 mol/l acetic acid was 
injected to release the MT mio the headspace The MT 
was sampled quantitatively and assayed as previously 
desenbed [19], yielding the concentration of the mixed 
disulphides of MT (protein—S—S—CHj and X—S—S— 
RESULTS 
Normal subjects 
The normal concentrations of methionine (serum), 
KMTB (urine), MTP (unne) and MT metabolites X - S — 
S—CH, (serum and unne), protein—S—S—CH, (serum) 
and DMS (breath) are given m Table 1 
Normal subjects loaded with methionine 
Fig 2 shows a rapid and significant ( Pi 0 001 ) increase 
m mean serum methionine concentrations due to methio­
nine loading in six normal subjects The peak was reached 
at approximately 1 h, by which tune methionine was 
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Table 1. Concentrations of methionine and its transamination metabolites in serum, urine and 
breath of 10 normal subjects and of a patient with MAT deficiency 
Abbreviation Cr, creatinine 
Methionine (μπτοΙ/Ι) 
KMTBImmol/molofCr) 
MTPImmol/molofCr) 
Protein—S-S-CH, (¿anol/l) 
X-S-S-CH,(/miol/l) 
X - S - S - C H , (mmol/mol of Cr) 
DMS(nmol/l) 
Source 
Serum 
Unnc 
Unne 
Serum 
Serum 
Unne 
Breath 
Normal subjects 
Mean 
26 
0 047 
0 022 
< 0 I 
0 37 
17 
0 34 
Range 
15-40 
0 024-0 075 
Tracc-0 080 
Trace 
0 20-0 46 
0 7-3 2 
0 16-0 61 
MAT-deficient 
716 
72 
20 
58 
16 1 
171 
59 
Fig. 2. Concentration of methionine ι mean ± SEM, H » fil in 
the serum of normal subjects after an oral dose ot 0 1 g of 
L-methiomne/kg body weight 
about 10-times normal Fig 3 presents the mean con­
centrations of KMTB, MTP and X—S-S—CH% in unne 
(N•=6) before and after methionine loading AU three 
compound* increased significantly (P^0 05) after methi­
onine loading The serum values of the mixed disulphides 
X—S—S-CH, and protem—S—S—CH, ( н - 6 ) also 
increased significantly *Р<0 02) after methionine mtakc 
(Fig 4) The concentrations of MT and DMS in breath 
(n = 6) after methionine intake are depicted in Fig 5 MT 
was easily detectable in the first hour of the experiment, 
but fell below the limits of detection (0 05 nmol/l) after 
2 h The mean DMS concentration in breath increased 
significantly (Z'íOOS) after methionine loading, peaking 
after 90 mm and remaining raised for at least 6 h 
MAT-deficient patient 
The serum concentration of methionine was raised 
20-3U-fold in this patient (Table 1) The concentrations 
of the transamination intermediates KMTB (urine), MTP 
(unne) and the MT metabolites X—S—S—CH, (serum 
and urine1, protein—S—S—CH, (serum) and DMS 
(breath) of the MAT-deficient patient were all greatly 
increased (about 100 timesl compared with normal sub-
jects The increase in the MT metabolites in this patient 
correlated well with the rise in the transamination inter-
mediates KMTB and MTP 
In Table 2 the excretion of methionine transamination 
metabolites KMTB, MTP and X - S - S - C H , in urine of 
normal subjects is compared with that of normal subjects 
loaded with methionine and with that of the MAT-defi-
cient patient The total excretion per hour of these three 
transamination metabolites in normal subjects after me-
thionine loading was about six times that in normal 
subjects before loadmg and in the MAT-deficient pa-
tient 141 tunes that m normal subjects before loadmg 
DISCUSSION 
Our results establish normal values for methionine trans-
amination products m man The concentration of KMTB 
in the urine of normal subjects measured here 147 /¿mol/ 
mol of creatinine, or 0 43 μιηοΙ/Ι) agrees well with that 
found by Manensson[24](0 181 ^mol/1, n = 5l, by Kaji el 
al [22] (100 /¿mol/mol of creatinine, /i™ 5) and by Favier 
& Caillât |21] t0 65 /jmol/l in children) The increase in 
urinary KMTB in the MAT-deficient patient ( 1 SO times 
normal. Table 1, also resembles that described b\ Favier 
& Caillât [21 in a patient with hypermethioninaemia (294 
/¿mol/l) Urinary MTP values have been previously 
reported only in a subject who ingested D-methtomne '25] 
MT is a ver) reactive compound and therefore difficult 
to detect in blood, breath and unne The zinc and acid 
method of McClain ei al [10] to liberate MT from whole 
blood, is very non-specific and yields several unwanted 
side-reactions [19, 26] Therefore, we developed new 
methods for determining MT by measunng the follow-
ing metabolites of MT DMS, protein—S—S—CH, and 
X - S - S - C H , 
The levels of MT metabolites in the MAT-deficient 
patient were shown to be extremely elevated (Table 1) 
Since the patient was clinically normal at the age of 31 
and did not show any signs of encephalopathy, these high 
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Fig. 3. Concentration of KMTB, MTP and X—S—S—CH, (mean±SFM ;i = 6) in the unne of 
nonnal subjects after an oral dose of 0 1 g of L-mcthionine/kg body weight Abbreviation С r, 
creatinine 
Fig. 4. Concentration of X—S—S—CH, (οι and protein— 
S—S—CH,(·) (meant SFM η = 6) in the serum of normal 
subjects after an oral dose of 0 1 g of L-mclhionme/kg 
body weight 
levels of MT may be considered non-toxic This conclu­
sion should prove important with respect to the role of 
MT in hepatic encephalopathy 
The MT metabolites X—S—S—CH, (serum and unne), 
protein—S—S—CH, (serum) and DMS (breath) all 
showed a significant increase after methionine ingestion 
The increase of DMS in breath after methionine loading 
(Fig 5) has been reported previously [27-29, It has been 
Fig. 5. Concentration of MT ( ·) and DMS (ol 
(mean ± SFM η — 6) in the breath of normal subjects alter 
an oral dose of 0 1 g of L-methionine/kg body weight 
shown thai melhylation of MT by thiol-S-methvltrans-
ferase results in the formation of DMS |30 | 
In normal subjects loaded with methionine and in the 
MAT-deficient patient, the increase in KMTB and MTP 
paralleled the increase in MT metabolites Studies m mm 
Table 2. Excretion of KMTB, MTP and X—S—S—CH, in urine of normal subjects, of normal 
subjects loaded with methionine (0.1 g of i-melhionine/kg body weight) and of a patient Kith 
MAT deficiency (mean ± SEM ) 
KMTB 
MTP 
X - S - S - C H , 
Normal 
subjects 
(>i-10) 
0 030 ± 0 004 
0O12±OO03 
0 71 ± 0 09 
Excretion (¿jmol/h) 
Nonnal subjects after methionine 
loading {n = 6) 
0-3 5 h 
after loading 
0 7 7 ± 0 1 4 
0 15 ± 0 0 8 
3 1 ± 0 9 
I W h 
afler loading 
1 3 ± 0 4 
0 14 ± 0 06 
4 2 ± 1 6 
MAT-deficieni 
patient 
4 25 
1 IB 
ιοί 
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H J Blometal 
have shown 113| that M T is formed from M T P These 
results indicate that in humans transamination of methio­
nine leads to the formation of M T and that an increase in 
transamination leads to an increase in M T production 
In general M T might also be formed from methionine 
by the intestinal flora However, it has been shown that 
the small intestine is able to absorb methionine very fast 
[31] This is also evident from } ig 2, which shows that 
oral methionine is quickly absorbed It seems therefore 
unlikely that oral methionine reaches the large intestine 
and that M T is produced from methionine by the intesti­
nal flora If small amounts of M T arc produced via this 
route, the relative contribution of the transamination 
pathway to M T production will become smaller 
Apart from transamination, K M T B may also be 
formed from mcthylthioadcnosinc. generated from 
AdoMet via polyamme synthesis or via direct cleavage [7] 
Formation of quantitatively important amounts of K M T B 
via these routes is highly unlikely in the MAT-dcficient 
patient, due lo his diminished AdoMet formation The 
huge increase in production of K M T B , M T P and M T in 
this patient must therefore be ascribed to an increase m 
methionine transamination In normal subjects K M T B 
formation from methvlthioadenosine cannot be ruled out 
However if this K M T B formation is of qujntnative 
importance, the relative contribution of methionine trans­
amination to K M T B production will decrease Measure­
ment of K M T B , M T P and M T metabolites in normal 
subjects represents a maximum estimate of the relative 
importance of methionine degradation via the transami­
nation pathway 
The patient with M A T deficiency showed a high accu­
mulation of methionine and a 1 OO-fold increase in trans­
amination metabolites in serum and unne However, even 
this level of methionine transamination was not sufficient 
to present hvpermethiomnaemia. indicating that the 
transamination pathway is not a major route in methio­
nine degradation It may be assumed that the amounts of 
the transamination metabolites X — S — S — C H , and pro­
t e i n — S - S — C H , m serum and of K M T B . M T P and 
X — S — S — C H , in urine can be used as an estimate of the 
relative importance of the transamination pathwav of 
methionine In the MAT-deficiem patient methyl and 
sulphur balance studies have shown [ 171 that at least 2 0 % 
of his methionine catabohsm occurred via the transamina­
tion pathway The low concentrations in serum and the 
low excretion in urme of the transamination metabolites 
in normal subjects compared with the MAT-deficient 
patient (Table 2) indicate that methionine transamination 
in humans exists, but is of little importance in the catabol-
ism of methionine Table 2 also shows that in normal sub­
jects after methionine loading, the quantitative 
importance of transamination in methionine catabohsm 
remains small, although a significant increase in methio­
nine transamination was observed 
Although methiomne levels in the sera of normal sub­
jects loaded with methionine are as high as in the M A T -
dcficienl patient, transamination in the MAT-deficient 
patient appeared to be much higher There are several 
possible explanations for this First, the trans-sulphura-
tion pathway m humans involves three different iso­
enzymes of hepatic M A I [32] In adults 3 % of the hepatic 
M A T activity originates from a fetal form with a low Km 
(high affinity) for methionine (3 /imol/l) and 6 % from an 
intermediate form with a λ'„ of 20 μιποΙ/Ι A n adult form 
with a high K m (650 ^mol/l) contributes 9 1 % to the total 
activity This latter form with the high Km is apparently 
lacking m the MAT-deficient patient ¡17] Secondly, the 
serum methiomne concentration in normal subjects after 
a methionine load is as high as in the MAT-deficient 
patient, but only for a short period of time (a few hours) 
Thirdly, transamination of methionine might be stimu-
lated in the MAT-deficient patient through induction of 
enzymes involved in the transamination pathway 
Using the data presented above, the relative contribu-
tions of transamination and trans-sulphuration in normal 
subjects and in the patient with M A T deficiency can be 
estimated In normal subjects with normal methionine 
concentrations transamination is very low and trans-sul-
phuration has a great reserve capacity A methionine load 
is mainlv catabohzed via trans-sulphuration and not wa 
transamination In the MAT-deficient patient trans-sul-
phuration is largely diminished due to lack of the high-A^ 
isoenzyme Therefore, saturation of trans-sulphuration is 
reached at low methionine levels As a result methionine 
Icscls increase and transamination becomes relativelv 
more important Equilibrium is reached when a further 
increase of methionine levels is prevented by catabohsm 
via transamination and excretion of methionine and meth-
lomnesulphoxide in urme 
The question of M T toxicitv can be addressed by 
examining patients wiih elevated M T levels Our MAT-
dcficicnt patient, for example, had no signs of endogenous 
intoxication [17, IS] despite extremely high M T levels 
Oaull et al |31 described four voung patients with partial 
M A T deficiency who also showed no signs of endogenous 
intoxication These fmdmgs are inconsistent with the 
suggestion of Benevcnga and co-workers [3, 13] that an 
increase in transamination might lead to M T intoxication 
However our results agree with those of studies on the 
difference in toxicity between D- and L-methionmc o-
Methiomne is metabolized for a much larger pan via 
K M T B [22. 25'than is ι-methionine and n-methionine is 
reported to be less toxic than the L-isomer 6] Walser et al 
[34] administered daily doses of 1 1-1 9 g of K M T B to 
patients for 15-18 days without any toxic signs Appar­
ently, the toxicity ol methionine can not be explained by 
degradation of methionine to M T via the transamination 
pathway It is intriguing to speculate that the catabohsm of 
methionine via transamination might protect patients with 
a deficiency in trans-sulphuration against very high levels 
of methionine 1 he toxic properties of large amounts of 
methiomne may be related to us conversion into AdoMet 
by M A T This would explain the lack of toxicity in M A T 
deficiency [18, 33] despite 30-fold increases in L-melhio-
mne itself 
The role of methionine transamination in other forms 
of hypermethiomnacmia, such as liver failure and homo-
cystinuna due to cystathionine synthase deficiency, is cur­
rently being investigated 
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Abstract 
We investigated sulfur and methyl group metabolism in • 
ЗІ-ут-old man with partial hepatic methionine adenosyltrans­
ferase (MAT) deficiency. The patient's cultured fibroblasts 
and erythrocytes had normal ΜΑ Γ activity. Hepatic S-adeno-
sylmethionine (SAM) was slightly decreased. This clinically 
normal individual lives with a 20-30-fold elevation of plasma 
methionine (0.72 mM). He excretes in his urine methionine 
and L-methionine-d-sulfoxide (2.7 mmol/d), a mixed disulfide 
of methanethiol and a thiol bound to an unidentified group X, 
which we abbreviate СНэ8-5Х (2.1 mmol/d), and smaller 
quantities of 4-methylthio-2-oxobutyrate and 3-methylthio-
propionate. His breath contains 17-fold normal concentrations 
of dimethylsulflde. He converts only 6-7 mmol/d of methio­
nine sulfur to inorganic sulfate. This abnormally low rate is due 
not to a decreased flux through the primarily defective enzyme, 
MAT, since SAM is produced at an essentially normal rate of 
18 mmol/d, but rather to a rate of homocysteine methylalion 
which is abnormally high in the face of the very elevated methi­
onine concentrations demonstrated in this patient. These find­
ings support the view that SAM (which is marginally low in 
this patient) is an important regulator that helps to determine 
the partitioning of homocysteine between degradation via cys­
tathionine and conservation by reformation of methionine. In 
addition, these studies demonstrate that the methionine trans­
amination pathway operates in the presence of an elevated 
body load of that amino add in human beings, but is not suffi­
cient to maintain methionine levels in a normal range. 
Introduction 
We investigated the sulfur and labile methyl group balances of 
a 31-yr-old man with a severe, yet incomplete, deficiency in 
the activity of hepatic methionine adenosyltransferase (MAT)' 
( 1 ). MAT catalyzes the conversion of methionine to S-adcno 
sylmethionine (SAM) (Fig 1 ) SAM is a precursor of spermi­
dine and spermine, and the obligatory methyl donor in numer­
ous methyl transfer reactions, forming creatine, phosphatidyl-
Addres correspondence and reprint requests to Dr Gahl, Building 10, 
Room 10N-318, National Institutes of Health, Bethesda, MD 20892 
Received for publication 21 May 1987 and in revised form I Sep­
tember 1987 
1 Abbreviations used in this paper MAT, methionine adenosyltrans­
ferase, SAM, S-adenosylmcthiomne 
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choline, methylated derivatives of DNA, RNA, proteins, and 
catechol amines, carnitine and other compounds (2) In each 
of these methyl transfers, SAM gives nse to S-adenosylhomo-
cysleine, which is then converted to homocysteine These arc 
necessary steps in the transsulfuration pathway responsible for 
most methionine degradation (3) SAM has also been shown 
by in vitro studies to inhibit the rale of formation ofN'-meth-
yltelrahydrofolate by methylenetelrahydrofolate reductase (4. 
5), to stimulate the activity of cystathionine /3-synthase (6), 
and to inactivate betaine-homocysteinc melhyltransfcrasc (7) 
Each of these effects, a pnon, endows SAM with the potential 
to function as an important regulator such that when SAM is 
raised, the partitioning of homocysteine would be less toward 
conservation by methylation to methionine, and more toward 
conversion to cystathionine for eventual degradation to inor­
ganic sulfate Although the possibility that the pathway is regu­
lated by the partitioning of homocysteine between these reac­
tions (8) has been studied in intact humans (2. 9, 10), in iso­
lated rat hepalocvtes (11, 12), and in model sjstems 
reconstituted from cell-free preparations from rats (13 14) 
and the topic has been reviewed by vanous authors (15-17), 
definitive evidence on the in vivo regulatory role of SAM is not 
available 
In our patient we have now investigated МЛI activity m 
nonhepatic tissues Such activity mav be normal in subjects 
with decreased hepatic ΜΑ Г activity (18) We also identified 
the compound responsible for the patient's unusual breath 
odor, as well as several sulfur-containing compounds, m addi­
tion to methionine, which were present in abnormally elevated 
amounts in his unne and tissues Further, we earned out stud­
ies that allowed us to estimate the fluxes of sulfur and of labile 
methyl groups in this patient These studies furnish strong new 
evidence that regulatory effects of SAM, previously demon­
strated in vitro only, do indeed help determine the extent to 
which homocysteine is conserved by the human body finally, 
the findings reported here also provide for the first time quan­
titative insight into the contribution to methionine degrada­
tion provided by transamination to 4-methylthio-2-oxobutyr-
ate (19) under conditions of elevated methionine 
Methods 
The patient 
This 31-yr-old man with ~- 7% of normal hepatic MAT aclivily has 
been described elsewhere ( I ) Ascertained by the unusual odor to his 
breath, he had plasma methionine levels of 0 7 mM (25 times normal) 
with 0 46 mM methionine sulfoxide (see below) Daily unnary excre­
tion of methionine was between 282 and 658 μιηοΙ. and steady-slate 
excretion of methionine sulfoxide was between 1,721 and 2,017 
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Figure 1 Methionine metabolism and related reactions 
/imol/d, both abnormally elevated The liver parenchyma contained 
25 9 nmol of soluble methionine and methionine sulfoxide/mg of 
protein This amounts to 5 S mmol of methionme/kg wet weight or 
16-80 times normal values (I) The hepatic SAM level was slightly 
decreased, 18 μπ\ο\ΙΥ.% wet weight, compared lo published normal 
values of 35-70 ^mol/kg (9) I he patient had normal physical and 
mental development, and liver histology was normal 
Materials 
Polyethylene glycol PEG-6000 was from Koch Chemicals (Colnbrook 
Bucks, UK), and from Sigma Chemical Co (St Louis MO), which 
also supplied indoxyl sulfate, ΛΓ-acetyl-L-mettuonine, methionine sulf­
oxide, and 4-methylth]0-2-oxobutyrate Dimethylsulfìde was from 
Merck & Co (Darmstadt, Federal Republic of Germany) Bio-Rad 
1 aboratones (Richmond, CA) supplied the resin AG 50W-8X 
100-200 mesh and Pierce Chemical Co (Rotkford, IL) supplied sulfo 
salicylic acid All reagents were of analytical grade 
Methods 
Clinical studies Clinical investigations were performed after written 
informed consent was obtained from the patient During the sulfur 
balance studies, the patient received a constant diet2 the methionine 
and cystine content of which was estimated by the use of published 
tables (20, 21) His body weight remained essentially unchanged dur-
ing these studies 24-h un ne collections were started and ended at β 
a m Unne specimens were refrigerated immediately after passage and 
pooled and frozen upon completion of each 24-h collection Blood 
samples for determination of amino acids were drawn in the morning 
with the patient in the fasted stale L-Methionine was made up in 
gelatin capsules containing 2S0 mg of the amino acid and administered 
four capsules at a time, once in the morning and once in the evening. 
Cell culture Normal skin fibroblasts (GM-3349A) and lung fibro-
blasls (IMR-90) from the Human Mutant Cell Repository (Camden 
NJ), and skin fibroblasts from the patient were grown to confluence m 
Eagle's minimum essential medium containing 10% fetal bovine 
serum (Gibco, Grand Island, NY), and harvested by trypsimzation 
2 The food composition of each meal of this daily diet is available 
upon request 
Enzvme assays MAT was assayed as described (22) For MAT 
measurement in erythrocytes, red blood cells were mixed with 2 vol of 
distilled water and centnfuged at 2 500 g for 10 mm For fibroblasts, 
cells were washed twice and suspended in 2 ml of 0 I M potassium 
phosphate pH 7 5 sonicated and centnfuged Supernatant fluids were 
assayed for MAT activity using a 120-imn incubation penod One unit 
of enzyme activity formed I nmol of SAM in 60 mm Protein was 
determined by the Bio-Rad protein assay 
Analyses of ammo acids creatinine creatine andcarnmne Amino 
acids were quanlitated using an LKB 4150 alpha ammo acid analyzer 
(LKB Biochrom Ltd Cambridge UK) Urine and hepanmzed 
plasma were dcproteinized with 5% sulfosahcyhc acid filtered through 
0 22 μπι Millipore membranes (Millipore Corp Bedford, MA), and 
stored at -гО'С рпог to analysis 
"Bound" methionine was taken as the total of methionine plus 
methionine sulfoxide in a sample of un ne which had been subjected to 
acid hydrolysis (23) minus the methionine plus methionine sulfoxide 
present in the same unne without acid hydrolysis (23) This quantity 
represents methionine liberated from ninhvdnn-negative forms (e g , 
A-acetylmethiomne) without being confounded by any reduction of 
methionine sulfoxide to methionine which may occur dunng the acid 
treatment (24) 
Creatinine plus creatine were assayed according to the Jaffe reac­
tion after treatment of unne with hot acid (25) Carnitine was mea­
sured as described (26) 
Periodate treatrntnt A sample of unne (5 ml) was titrated to pH 
6 85 with I NKOH ToaO 4S-ml aliquot at 0oC was added 0 75 ml of 
NaKV 0 25 M After 3 mm at 0oC the reaction was stopped by 
addition of 0 65 ml of ethylene glycol 2 5M and an aliquot was used 
for amino acid analysis l o a second ahquoi of (he pH 6 85 sample, 
authentic ι -sc π ne and ι -threonine (2 μ mol each m a total of 0 088 ml 
H30) were added рпог to treatment with penodate 
2-Hereapioelhanol treatnu ni A sample ol unne (5 ml) was titrated 
to pH 7 5 with 1 N KOH Io a 0 5 ml aliquot was added 0 5 ml of a 
1 10 (vol/vol) aqueous dilution of 2-mercjptoelhanol The solution 
was heated in a screw-cap tube al 100° for 60 mm l o a second aliquot 
of the pll 7 5 sample, authentic ι-methionine sulfone (550 nmol in 
0 055 ml of H2O) was added before treatment with 2-mcrcaptocthanol 
S\nthe\i\ and partial resolution of methionine \ulfn\tdc\ 1 -Methi­
onine was treated with Н
г
О; in acetic acid as described by Iselin (27) 
Under these conditions the oxidation has been reported to proceed 
with some enantio-specificitv producing a preponderance of the L-d-
diastereoisomer (28) The crude sulfoxide product was funher resoKed 
by use of the picrate salts (29) to yield preparations consisting approxi­
mately of either 90S- ι d- and 10^ 1-/-methionine sulfoxide or 10% 
L-d-, and 90% L-Z-mclhiomnc sulfoxide 
'Sulfur and sulfate determinations Unnary inorganic sulfate and 
sulfate esters were measured by the turbidomelnc method uf Lund-
quist et al (30), with minor modifications to increase recovery in the 
case of the sulfate esters Instead oí applying the unne to a column 
following the remo\al of inorganic sulfate with Bad; the sulfate-free 
unne (3 ml) was batch adsorbed in glass lubes with a 1 5-ml packed 
volume of AG 50W-X8 ion exchange resin After \ortcx-mixing twice, 
the liquid phase was removed and combined with two distilled water 
washings (3 ml) of the resin slurrv I he combined volume (8 ml) was 
hydrolyzed by boiling in a lOO'C water bath for 1 h and the sullalc 
content, representing hydrolyzed sulfate esters was assayed as for free 
inorganic sulfate Indoxyl sulfate 0-6μΓηο1 treated as above provided 
a standard curve for the assay I olal unnary sulfur was measured by 
oxidation using Benedict's solution (31 ) and measunng inorganic sul­
fate, as above 
Breath analysis Measured volumes of breath (100 and 250 ml) 
were collected in Tenax tubes and sulfur-containing compounds were 
analyzed by gas chromatography as previously desenbed (32, 33) 
4-MethyUhuy2 oxobutyrate assay Unnary 4-melhylthio-2-oxobu-
tyrate was measured directly by the gas chromatographic method of 
Favier and Caillât (34) 
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Analysis and identification of CHjS-SX The compound abbre­
viated CHjS-SX is the mixed disulfide of meihanethiol and a thiol 
bound to an unidentified group X It was originally identified only as a 
"base-labile methylthio" compound, and was measured by conversion 
to methanethiol To 10 μΙ ofunne in a closed evacuated 15-ml glass 
vial was added 100 μΐ of dithiothreiiol (10 mg/ml) in 0 1 M Tns-HCI, 
pH 100 After vorteung for 10 s, the mixture was left at room temper­
ature for 90 mm and 10 μΐ of 10 M acetic acid was injected to release 
the methanethiol into the headspace The methanethiol was sampled 
quantitatively and assayed as for serum (33). yielding the concentra­
tion of the base-labile methylthio compound 
4-Methylthio-2-oxobutyrate was also measured indirectly by con­
version to methanethiol After the above procedure was performed for 
measurement of CHjS-SX, the remaining mixture was flushed with 
nitrogen to remove traces of free methanethiol, and left at room tem­
perature for 10 min in the opened vial The vial was again evacuated 
and 10-15 μΐ of 10 M NaOH was injected, bringing the pH to 
12 5-13 0 After vortexing for 15 s and letting stand for 4 mm, 30μ1οΓ 
10 M acótic acid was injected and the released methanethiol was as-
sayed (33) The values for 4-methyIthio-2-oxobutyrate obtained by this 
indirect method corresponded to those obtained by the direct method 
4-Methylthio-2-oxobutyrate appeared stable for at least 4 d at 4°C in 
unne, whether tested by the direct or indirect method of analysis This 
finding contrasts with that of Martensson (35), who reported a marked 
decrease after 6 h at room temperature or 40C 
The 'base-labile methylthio" compound was identified as a mixed 
disulfide, CH3S-SX, by virtue of the production of appropriate 
amounts of CH3S-SCH2CHJ upon addition of a basic solution ofeth-
anethiol to the patient's unne (thiol-disulfide exchange) The chemical 
identity of the group, "X," is under investigation ( I angerman, A, and 
H J Blom manuscript in preparation) 
3-MeihvUhiopropionate This compound was synthesized as de-
scribed by Kaji et al (36), and measured in the unne by gas chromatog-
raphy (36) 
Results 
Nonhepatic MAT activity Extracts of the patient's erythro-
cytes and fibroblasts each displayed a normal MAT activity 
(Table I) 
Identification of the methionine oxidation product During 
chromatography of the patient's urine, an unknown ninhy-
dnn-reactive compound appeared in the area near which ser-
ine and threonine elute (Fig 2 a) Doth methionine sulfone 
and the two diaslereoisomers of [.-methionine sulfoxide (L-me-
thionine-/-suIfoxide and L-methionine-</-sulfoxide), elute 
close to this area, although the sulfoxides resolve from one 
another The compound proved insensitive to periodate treat-
ment (Fig 2 b) and, therefore, is neither threonine nor senne 
(Fig 2, с and d) The unknown was sensitive to 2-mercap-
I I I ! 
figure 2 Determination of chemical structure of methionine oxida­
tion product m the unne of MAT-deficient patient (a) Portion of 
amino acidogram of patient's untreated unne (40 μ!) Peak 1 con 
lai η s unknown compound and threonine Peak 2 represents sen ne 
(6) After penodale trealmcnt Threonine is gone from peak 1 senne 
from peak 2 (c) Same as a but with added sen ne and threonine (J) 
Same as с after penodate treatment (?) Same as a alter 2 mercap-
toethanol treatment Peak I containing unknown compound is di­
minished (ƒ ) Same as a but with added methionine sullonc which 
el ules with peak I (#) Same as ƒ after 2-mercaptoethanol treatment 
Methionine sulfone is relatively insensitive to 2-mercaptocthanol (/7) 
Same as a but with added i-methionine-ti-sulfoxide Note single 
peak (f) Same as a but with added L-methionine-Z-sulfoxide Two 
peaks indicate that unknown compound is not the ¿-/-diastcrco-
isomer 
Table I MAT Activity m Erythrocytes and Cultured Fibroblasts 
from a Panera with Hepatic ΜΑ Τ Deficiency 
Normal controls 
Pauent 
Erythrocytes 
unililml 
5 2,40 
44 
Fibfoblus 
unüiimg prolan 
0 51,125 
0 81 
Results ait means of multiple delenninations erythrocytes (3), fibro-
blasts (4) Erythrocyte controls were from two men aged 31 and 36 
yis. Fibroblast controls were from a human skin biopsy (first value) 
and from human fetal lung cells (second value) 
toethanol (Fig 2 f), suggesting it is a methionine sulfoxide 
rather than methionine sulfone (big 2, ƒ and?) Finally the 
unknown coeluted with authentic L-methionine-^-sulfoxide 
(Fig. 2 h), but separated from L-methionme-/-sulfoxide (Fig 2 
0 These results identified the unnary methionine oxidation 
product as L-methionme-d-sulfoxide 
Chromatography of the patient's plasma yielded an ammo 
acid profile in the area of interest identical to that for his unne 
Therefore, the likely origin of the unnary L-methionme-J-sulf-
oxide was the patient's plasma 
Sulfur balance studies in steady stale The patient, weigh-
ing 73 kg, selected a palatable diet, normal for him, and ad-
hered to the same menu for 7 d The diet was free of meat and, 
therefore, essentially devoid of creatine and creatinine and 
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veiy low in tf-methy1histidines (37) and carnitine (38) It con-
tained 3,014 calones, 87 7 g of protein, 11 2 mmol methio-
nine, 9 3 mg-atom cystine sulfur, and 3 6 mmol choline Dur-
ing the final 2 d of the diet, the patient collected his unne, 
which was analyzed for vanous su I fur-con taming compounds 
(Table II) Sulfur intake (20 S mg-atom) was roughly balanced 
by un nary excretion (22 I mg-atom) Of the total un nary sul-
fur, 65% was in the form of sulfate Free methionine (0 5 
mmol), "bound" methionine (0 5 mmol) and methionine 
sulfoxide (1 7 mmol) accounted for 12% of total sulfur excre-
tion 
Sulfur balance studies during merhtontne restriction and 
supplementation The patient was placed for 11 d on a diet 
with methionine lowered to 4 8 mmol/d Cystine was close to 
normal at 6 8 mg-atom sulfur/d, and the choline content was 
approximately 3 6 mmol/d For the last 5 d of this regimen, a 
supplement of L-methionine (13 4 mmol) brought the methio-
nine intake to 18 2 mmol Total unnary sulfate did not reflect 
the changes in methionine intake, falling only slightly dunng 
methionine restriction, from 14 0 to 10 4 mmol/d and barely 
returning to 13 6 mmol/d with methionine supplementation 
Plasma methionine and methionine sulfoxide concentrations 
did not fall substantially under methionine restriction but did 
increase marginally dunng supplementation (i ig Ì) Changes 
in urinary methionine and methionine sulloxidc mirrored 
somewhat the changes in plasma levels, starting at I 8 mmol/ 
Table ¡I Í nnan l· и ret ion oi Sulfur lomatntmi С ompounds 
bv \l4Tdefiiient Patient in Steadx State Sulfur Balance 
С ompound Daily unnar\ емтсмоп 
a Total sulfur 
b Inorganic sulfate 
Í Fslenfied sulfate 
d Total sulfate (b + О 
e ( alculalcd organic sulfur [a - d) 
f Methionine + methionine sulfoxide 
g Bound methionine* 
h 4-Meth\ Ithio-Z-oxobulyratc' 
i 3 Melhylthiopropionate 
j CH3S-SX 
к Dimethylsulfide 
/ Taunne l· cystine 
m Identified organic sulfur ( / + g 
+ h + i+y + λ + /) 
The patient received a fixed normal diet containing 11 2 mmol of 
methionine and 9 3 mg-atom of cystine sulfur daily for 7 d Values 
listed are for a 24-h unne collected on day 6 of the regimen On this 
da>, creatinine excretion was 14 3 mmol A second 24-h unne col­
lected on day 7 contained similar amounts of each sulfur compound 
if corrected for the creatinine recovery, which was 72% of that on 
day 6 and outside the range of creatinine excretions for collections 
made in the hospital (see Results) Note similanly between calcu­
lated and identified organic sulfur 
* Corrected for 85% recovery determined for acetylmethionine after 
extensive and hydrolysis 
* The degradation product, 4-methylthio-2-hydroxybutyrate (35). was 
not measured but is expected to be small, ι e, < 0 I mg*atom of S 
mjf aiorrt чі 9 
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Figure Î Unnarv excretion ol lolal sulfur and sulfate before and 
after the administration of supplemental I -methionine Each day is 
represented b\ two bars The left-hand bar represents dietar\ cvstme 
(hauhidn'ltanftU') plus methionine (opim reitangU') The nght-hand 
bar represents иппагл excretion of lolal sulfate (solid bar) and of 
nonsulfate sulfur (mm Iwri fu li hur) The patient received a hxed 
diet throughout the studv Starting on dav 7 the diet was supple­
mented with oral L-methionme (1 gram b ι d total 11 4 mmol) in 
capsule form Plasma melhionme plus methionine sulfoxide concen­
tration is plotted for each da\ of the studv 
d falling to 1 0 mmol/d on djys 6 and 7. and returning to I 9 
mmol/d bv da\ 11 (data not shown) These compounds never 
contributed > 101 of the total sulfur excretion lolal unnary 
sulfur 14 I mg-atom on the first day. fell only to 15 I mg-
atom during the penod of methionine restntlion anil reached 
only 19 4 mg-atom dunng methionine supplementation As a 
result, during the 6 d of methionine rcstnction the patient had 
a net negative sulfur balance of 27 8 mg-atom. whereas dunng 
the 5 d of methionine supplementation he had a net positive 
balance of 37 4 mg-alom 
Prodiiition ol ι mumme and other meth\taied metabolites 
Because decreased availability ol SAM might limn creatine 
svnthesis and consequenllv creatinine production we deter­
mined whether the MAI-deficient patient produced a normal 
amount of creatinine Several facts suggested thai he did His 
muscle mass appeared grossly normal He participated in ng-
orous long-dislance running Mis total body potassium (140 1 
g), determined in a whole-body counting chamber, revealed a 
lean body mass of 63 8 kg or 87% of total body weight (73 kg) 
Standards indicate that this should be reflected bv a total daily 
creatinine production of 14 7 mmol (39) In fact, four 24-h 
unne collections contained 13 9±0 4 mmolcreatinme Dunng 
the steady-state balance studies, unnary creatinine + crcatme 
excretion amounted to 14 3 mmol/d (Table 111), unnary lolal 
carnitine, 0 2 mmol/d. and methylhistidmes, 0 4 mmol/d 
Identification of volatile suljur compounds The patient's 
breath, analyzed by gas chromatography, revealed a dimethyl­
sulfide concentration of 5 86±0 11 nM (mean±SD, η = 5) 
Normal values (n = 20) are 0 34x0 03 nM (range, 0 13-0 65 
nM) (33) No methancthiol or dimcthyldisulñdc was detected 
in the breath 
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Table III Steady-State SA M hormaiion Methyl Balance 
and Methylneogenesis in a AfAT-deficient Patient 
Compound 
a 
ь 
с 
d 
e 
f 
g 
h 
I 
J 
к 
l 
m 
π 
0 
Ρ 
Я 
г 
Urinary creatinine + creatine 
Unnarv carnitine 
Unnary 3-mcthylhistidine + 1-methvlhistidine 
Other melhylated compounds in unne* 
Sarcosine from SAM* 
Spermidine and spermine 
Total SAM formauon (a + b + c + d+e+f) 
Methvls used for methylations (g - f )' 
Unnary methionine (free + bound) 
4- methionine sulfoxide 
Unnary 4-melhyllhio-2-oxobulyraie 
Unnary 3-methyllhiopropionale 
Unnary CH,S-SX 
Respiratory dimethylsulfide 
Total methyl utilization and loss (A + ι +j 
+ к τ / + m) 
Dietary methionine 
Adjusted dietary choline 
Total dietary labile methyls (o + p) 
Melhylneogcnesis (л - q) 
Melhyl moielies 
nieql24 h 
14 3 
0 2 
0 4 
0 8 
2 2 
0 5 
184 
179 
2 7 
0 1 
0 03 
2 1 
01 
22 9 
112 
2 9 
14 1 
8 8 
See legend to Table 11 
• Estimated from reference 2, Table 3 with adjustments 
* Estimated from reference 8 
' Estimated from reference 2, Table 4 No net consumption of labile 
methyls results from the reactions forming spermidine and spermine 
The methyls in question are recycled to methionine through meth-
ylthioadenosine and methylthionbose (50) 
Duplicate blood concentrations of dimelhylsulfide were 73 
and 96 nM (normal 3-6 nM (33)) No other volatile sulfur 
compounds were identified Dimcthylsulhde in the patient's 
unne, collected under conditions which did not ensure against 
losses due to volatilitv, was 400 nM (normal, 2 nM) Normal 
small amounts of methanethiol were also identified in the 
unne 
Methionine transamination melabolite\ m urine For eight 
24-h urines collected under different dietary regimens, the pa­
tient's mean±SD excretion of 4-melhyllhio-2-oxobutyrale was 
5 6+2 4 mmol/mol creatinine (normal 0 047±0 015, л = 10 
[Blom, H J , et a l , manuscript in preparation]) During steady 
state, the patient's daily output of 4-methyIthio-2-oxobulyratc 
amounted to 0 1 mmol (Table II, A) 
The patient's excretion of 3-methylthiopropionate under 
steady-state conditions was 2 0 mmol/mol creatinine (normal, 
0 022+0 024, л = 10 [Blom, Η J , et a l . manuscnpl in prepa­
ration]). amounting to 0 03 mmol/day (Table II, /) 
The "base-labile methylthio" compound, CHjS-SX, was 
present in six 24-h collections at 166+14 mmol/mol creatinine 
(normal, 1 7±0 7, л = 10 [Blom, Η J , et al, manuscnpl in 
preparation]) During methionine restnclion (days 6 and 7, 
Fig 3). the patient's value was 66 mmol/mol creatinine The 
total amount of CH3S-SX excreted dunng steady state was 2 1 
mmol/d (Table II,./) 
Discussion 
Our patient with hepatic MAT deficiency has been normal 
mentally and physically for at least three decades ( 1 ) Presum­
ably, this reflects the presence of some residual MAT activity 
in his liver ( 1 ) and the normal MAT activity in his nonhepatic 
tissues (Table I) The latter finding is similar to that reported 
for other patients with hepatic MAT deficiency (18,40), and is 
consistent with the occurrence of forms of MAT in exlrahe-
patic tissues under genetic control separate from that of the 
high K
m
 hepatic form 
A vanely ofsulfur-containing compounds are excreted by 
this patient in elevated quantities 
(a) Methionine and methionine sulfoxide, now identified as 
the L-methionme-J-sulfoxide diastereoisomer (Fig 2) At a 
plasma concentration of 460 μ M the latter accounted for 
— 1 7 mg-atom of the daily unnary sulfur excretion The pres­
ence of only one diastereoisomer suggests that the compound 
is formed en/ymatically by a reaction not previously desenbed 
in human beings 
(/;) Compounds denved via the methionine transamination 
pathway 
1 4-Methylthio-2-oxobutyrate, the immediate product of 
methionine transamination (41) Direct assay of unne gave a 
value of 0 1 mmol/d under steady-stale conditions This com­
pound has been similarly increased in other patients with hy-
pcrmethionincmia (34), and in normal subjects after ingestion 
of D-, but not L-methionme (42) The latter finding may be 
attnbuted to the fact that to enter the mainstream ol methio­
nine metabolism the D-isomer unlike the 1 -, must undergo 
cither oxidation by D-amino acid oxidase or transamination 
2 3-Mcthylthiopropionate the unnary excretion of which 
amounted to 0 03 mmol/d In rat tissues, this compound is 
formed by oxidative decarboxylation of 4-methylthio-2-oxo-
butyrale (43) It is increased also in normal humans after ad­
ministration of »methionine (36) 
3 Dimethylsulfide. the only volatile sulfur-containing 
compound increased in the breath of our patient, and account­
ing for the unusual brealh odor which was his presenting com­
plaint With a minute volume of expiration of 8 liters the 
patient's 17-fold normal le\el of expired dimethylsulfide (5 9 
nM) would result in a net loss of 0 14 mequivalent of methyl 
groups and 0 07 mg-atom of sulfur/d The unnary excretion of 
dimethylsulfide was small Dimethylsulfide increases in breath 
of normal humans after administration of D-, but not L-methi-
onine (44) It may denve its sulfur atom and one methyl group 
from 4-methvlthio-2-oxobutyrale, since methanethiol is a deg­
radation product of 3-methylthiopropionate in rats (45) The 
second methyl group would then come via a transmethylation 
reaction involving SAM, an hepatic enzyme that performs this 
methylalion has recently been desenbed (46) 
4 The mixed disulfide, CH3S-SX, quantitatively impor­
tant, with a unnary excretion of 2 I mmol/d To our knowl­
edge this compound has not been found before in humans or 
other mammals Although the identity of the -SX portion of 
the molecule remains to be established, preliminary findings 
indicate this moiety denves, directly or indirectly, from cys­
teine (Tangerman, A , and H J Blom, manuscnpl in prepara­
tion) The CH3S- moiety appears to denve from 4-methylthio-
2-oxobutyrate, or a metabolite thereof (45) 
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Total identified urinary sulfur in these organic compounds 
and in taurine and cystine (excreted in normal quantities by 
our patient) was 8.6 mmol (Table II, m). This value agreed well 
with the total urinary organic sulfur calculated as the differ­
ence between total sulfur and total sulfate (Table II, e). Thus 
the quantitatively important organic sulfur-containing com­
pounds in the patient's urine have been identified, although 
minor amounts of others may be present. For example, the 
action of lactate dehydrogenase would be expected to form an 
amount of 4-methylthio-2-hydroxybutyrale roughly commen­
surate with the amount of 4-methylthio-2-oxobutyrate (35). 
The hydroxy compound was not measured directly in the 
present experiments. 
The patient's excretion of sulfur-containing and methyl-
containing compounds was measured while he was on several 
constant dietary intakes. These determinations (Tables II and 
HI. and Fig. 3) were used to estimate the fluxes of sulfur and of 
labile methyl groups in the presence of a severe deficiency of 
hepatic MAT (Tables III and IV). Several unexpected and im­
portant points emerge from these tables: 
(a) The patient forms at least 14.9 mmol/d of SAM (Table III, 
sum of the measured quantities of the methylated excretory 
products creatinine, creatine, carnitine, and /V'-methylhisli-
Tabtc 11'. Sulfur Fluxes in MAT-tJcJicicnl Patii'tu 
in Steady-State Sulfur Balance 
Compound 
Dietary cystine 
Urinary cystine and taurine 
Urinary CHjS-SX* 
Sulfate from cysline (a h с) 
Dietary methionine 
Urinar) free and bound methionine and 
methionine sulfoxide, 2.7: 4-methylthio-2-
oxobulyratc and dimethylsulñde. 0.1; CH]S' 
SX. 2.1 
Respiratory dimethylsulñde 
Sulfate from methionine {e - ƒ - g) 
Homocysteine from transmethylation reactions 
Homocysteine recycled (/ - A) 
Adjusted dietary choline 
Minimum homocysteine recycled by Ns-
mcthyltetrahydrofolate (_/' - A')* 
9.3 
1.6 
2.1 
5.6 
11.2 
4.9 
0 1 
6.2 
17.9 
11.7 
2.9 
Set legend to Table II. 
* The - SX portion of this disulfide is presumed to derive from cys-
teine (Tangerman, Α., and H. J. Blom. manuscript in preparation). If 
it derived from methionine instead, the value of / would be even 
greater, i.e.. 10.9. 
* In making this calculation it is assumed that methyl moieties equiv­
alent to the "adjusted dietary choline" arc used for betaine-depen-
dent methylation of homocysteine. This is consistent with evidence 
from intact humans even under conditions in which SAM is presum­
ably not decreased (9). Thus, normally, there may well be sufficient 
bctaine-homocysteine methyltransferasc activity to utilize all avail­
able betaine, and any possible increase in the activity of this enzyme 
due to lower than normal SAM concentrations (7) has not been in­
voked. 
dines). To this can almost surely be added another 3.5 mmol 
estimated by indirect means (Table III, d + e + f), giving a 
total of 18.4 mmol/d. Thus, in spite of his proven defect in 
hepatic MAT, the patient is forming an amount of the product 
of this enzyme which is normal for young adult males on 
normal diets (2, 9). This normal flux is presumably achieved 
by the buildup of methionine (to 720 μΜ) which permits any 
residual activity of the high Ä'm hepatic form of MAT to func-
tion closer to its maximal velocity than is the case at a normal 
methionine concentration. In normal humans the hepatic me-
thionine concentration is well below half-saturation for the 
high A'm form of MAT (apparent A'm, 650 μΜ), the form that 
provides 91% of the maximal adult capacity to form SAM (47). 
Flux through the low K
m
 form(s) of MAT may also be in­
creased at the patient's increased methionine concentration, 
although current uncertainties as to the kinetic constants of 
these isoenzymes in humans prevent accurate estimation of 
the magnitude of this effect. 
(ft) In spite of the fact that a normal amount of methionine 
passes through the primary block at MAT, the patient converts 
an abnormally low proportion of methionine sulfur to sulfate. 
In steady state with a normal daily methionine intake of 11.2 
mmol, he spilled 4.9 mmol of methionine, methionine sulfox­
ide, 4-melhyHhio-2-oxobulyrate, 3-melhylthiopropionale, di-
methylsulfidc. and CHjS-SX into the urine, leaving only 6.2 
mmol of methionine sulfur to be converted to sulfate (Table 
IV. /ι). His total urinary sulfate contributed only 65% of the 
total urinary sulfur (normal. 80.1 + 5.3%). In addition, when 
given an abnormally high intake of methionine, the patient 
failed to convert the added sulfur virtually quantitatively to 
sulfate, as a normal subject would. In 5 d of methionine sup­
plementation (Fig. 3). urinary sulfate increased by a total of 
10.5 mmol while methionine intake increased by 68.5 mmol; 
thus only 15% of added methionine sulfur was converted to 
sulfate. Contributing to this lack of response by the patient is 
the damping effect of his large body load of methionine. Given 
a plasma volume of 3.5 liters with 720 μΜ methionine, this 
compartment would contain 2.5 mmol of methionine. A 
1,200-g liver with 5.5 mmol of methionine/kg wet weight 
would contain 6.6 mmol. If plasma and liver have methionine 
concentrations representative of extracellular fluid (18.3 liters) 
and intracellular fluid (25.6 liters), respectively, the patient's 
total body methionine would approximate 154 mmol. There­
fore, variations in methionine intake would only slightly per­
turb the concentration ol'lhis amino acid in his bodily fluids. 
The patient does convert the bulk of his cyst(e)inc sulfur to 
sulfate. Of 9.3 mg-atom cystine sulfur taken in. 1.6 mg-atom 
are excreted as taurine plus cystine (Table IV, /)). The only 
abnormal excretory compound in this patient which may de­
rive (in part) from cysteine is the mixed disulfide, CH3S-SX. If 
the -SX portion of this compound is formed from cysteine 
(Tangerman, Α., and H. J. Blom, manuscript in preparation), 
the 2.1 mg-atom of sulfur excreted daily during steady-slate 
balance in the -SX portion ofCHjS-SX (Table IV, c) should be 
subtracted from the cysteine sulfur available for conversion to 
sulfate. Daily formation ofsulfate from cysteine would then be 
5.6 mg-atom plus the amount of cysteine formed from methio­
nine. 
(c) In spite of his high body-load of methionine, the patient 
conserves a sizable amount of this amino acid by N!-methyl-
tetrahydrofolate-dependcnt methylation of homocysteine. Of 
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the 18 4 mmol of SAM fonned daily, virtually all (17 9 mmol) 
is utilized in transmethylation reactions (Table III, A) Thus 
17 9 mmol of homocysteine must anse from S-adenosylho-
mocysteine Approximately 6 2 mmol of this homocysteine is 
metabolized to sulfate (Table IV, A), leaving II 7 to be methy­
lated back to methionine (Table IV j) Betaine ansing from 
dietary choline contnbutcs at most 2 9 meq of the methyl 
groups needed for this recycling of homocysteine leaving the 
remainder to be donated by N'-mcthyltetrahydrofolate Thus, 
methyl groups are being formed by ncogenesis at a rate of at 
least 8 8 mmol/d (Table IV, /) The same value is obtained if 
one calculates the methylneogenesis as the amount by which 
methyl utilization and loss exceed the total dietary intake of 
labile methyls (Table III r) Whereas this rale of homocvsleine 
recycling due to new formation of methyls might be regarded 
as normal, or high normal for a normal young adult male on a 
normal methionine intake with a normal methionine body 
load (2), it is excessively high for the same subject ingesting 
excess methionine (9) A normal person would dispose of the 
excess methionine by increasing his rale of SAM formation, 
using the SAM to methylate glycine to sarcosine and oxidizing 
the methyl group of sarcosine, meanwhile the increased ho­
mocysteine formed from SAM would be metabolized quickly 
and quantitatively to sulfate with minimal recycling of homo­
cysteine to methionine (9) This sequence avoids the conser­
vation of methionine in the presence of excess methionine 
which is a sinking feature of our patient Three mechanisms 
may contnbute to our patient's abnormal methionine conser­
vation First since his MAT is probablv operating near satura­
tion with respect to methionine any further increment in me­
thionine may only marginally increase the (lux through MAI 
to produce added amounts of SAM Second although methio­
nine is elevated in this patient, SAM is not Thus the decrease 
in the rale of formation of N'-methyltetrahvdrofolate by SAM 
inhibition of melhylenetetrahydrofoUte reductase (4) ex­
pected to occur in a normal subject when methionine concen­
trations are increased, does not occur in this patient and he 
continues to have ample amounts of N'-melhyltetrahydrofo-
late available for homocysteine methylation Third the ex­
pected stimulation of cystathionine ^-synthase activity by in­
creased SAM (6), which may normally divert a greater portion 
of available homocysteine toward cystathionine, would not 
lake place in this patient The latter two effects achieve con­
tinued methionine conservation in the face ol extreme methio­
nine (but not SAM) excess ' 
(d) Finally the present studies help define the role in humans 
of the methionine transamination pathway described by 
Benevenga and colleagues (19, 41 43) The contnbution of 
this pathway to methionine catabolism in our patient may be 
taken as the sum of the amounts or4-methylthio-2-oxobutyr-
ate and its metabolic products, 3-methylthiopropionate di-
methylsulfide and the CHjS-moicly of CHjS-SX Since this 
3 In this interpreiauon, it is implied thai the concentration of SAM is 
noi so low as to produce a functionally significant decrease in ihe 
activity of N'-methylleirahydrofolate homocysteine methyltransfer-
ase The latter enzyme depends for its activilv upon SAM (48 49) 
Billings el al (12) have reponed evidence however suggesting this 
enzyme attains maximal activity at a concentration of SAM somewhat 
below that in normal liver whereas a higher than normal concentra­
tion of SAM is required to inhibit methylenetetrahydrofolate reduc 
tase 
3M Gahietal 
approximates 2 3 mg-atom sulfur/d (Table II), the nel amount 
of methionine undergoing conversion to 4-melhylthio-2-oxo-
butyrate is al least 20% (2 3/11 2 X 100%) of the dietary in­
take * This rate is attained under conditions of abnormal me­
thionine accumulation due to the pnmary block at MAT The 
transamination pathway is clearly inadequate to prevent this 
accumulation ' 
We note that our conclusions may not pertain in their 
entirety to patients with isolated hypermethiomncmia due to 
abnormalities other than that of hepatic MAT (1), or to pa­
tients with a complete MAT dehtiency, who may be more 
senously affccled both chemically and clinically 
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ABSTRACT 
Methionine ie supposed to be degraded via two known r o u t e s : the 
t ranseu l fura t ion and the transamination pathway. In par t icu lar , 
pa t i en ts with hypermethlonmemia due t o a de fec t in the t ranseu l fu ra -
t ion pathway, may catabol ize signi f icant amounts of methionine via 
the transamination pathway. In th is s tudy the re la t i ve amount of 
methionine degraded via the transaminat ion pathway in 17 pa t ien ts 
wi th homozygous homocyst lnuna. due t o cystath ionine synthase d e f i -
c iency. was compared wi th 23 normal sub jec t s , and with a pat ient with 
hypermethlonmemia due t o a def iciency In methionine adsnosy l t rane-
f e raee . The homocyet inuna pat lente and the normal eubjects were 
s tud ied In the fas t i ng s t a t e as well as a f t e r methionine loading (0 1 
g / k g body weight) It is concluded tha t in cystathionine synthase 
def ic ient pa t ien ts ths transaminat ion pathway is not quant i ta t ive ly 
important in methionine degradat ion desp i te e levated methionine 
leve ls . Thie is in c o n t r a s t to the pat ient with methionine adenosyl -
t r ane fe raee def ic iency, who catabol izes a t least 20% of his d ie ta ry 
methionine via the transamination pathway 
INTRODUCTION 
The essent ia l sul fur-contain ing ammo acid methionine and i t s 
metabol i tes are involved in severa l metabolic pathways, among which 
p ro te in eynthes is , polyamine synthes is and many t ransmethy lat ion 
rsact ions(1.2) Catabolism of methionine is supposed t o proceed via 
the t ranesu l fura t ion pathway and ths transaminat ion pathway (Fig 1) 
The t ranesu l fura t ion pathway, which ie general ly considered ae the 
major r ou te of methionine degradat ion, is in i t ia ted by the convers ion 
of methionine into S-adenoeylmethionine by methionine adenosy l t rans-
f e r a s e . Methy l t rane fe ra t ion by S-adenoeylmethione yielde S-adenoeyl-
homocysteme. and the l a t t e r ie hydro lyzed t o homocysteine. Homo-
cys te ine may be e i ther catabol ized by the pyndox ine dependent enzyme 
cystath ion ine synthase Into cystath ionine or re -me thy la ted t o methio-
nine In ths t ranesu l fu ra t ion pathway cystath ionine is in tu rn 
converted Into cysteine and 2-ketobutyrate 
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TRANSAMINATION TRANSSULFURATION 
CHjSCHjCHyCH-COOH 
KETO ЛСІО^ METHIONINE ν 
CHJSCHJCHJ-C-C-OH 
О о 
4-»eTHYLTHIO-î-OXOBUTYRATE 
CHjSCH^HjCOOH 
Э-METHYLTHIOPROPIONATE 
CKjSH 
METHANETHIOL 
DIMETHYLSULFOe ( CHjSCHj) 
MT MIXED DISULFIDES 
SULFATE 
METHIONINE-
^ADENOSYL-
.TRANSFEBASE 
S-ADENOSYLMETHIONNE 
S ADENOSYL HOMOCYSTEINE 
- HOMOCYSTEINE 
- SERINE 
CYSTATHIONINE 
-KETOeUTYRATE 
FIG. 1. Catabolism of 
transamination pathway. 
msthionins via the t r a n s e u l f u r a t i o n and the 
Evidence is p r o v i d e d f o r the e x i s t e n c e of the transaminat ion 
pathway in r a t . sheep and humans(3-10). In thie pathway methionine is 
t ransammated t o 4 - m B t h y l t h i o - 2 - o x o b u t y r a t e Oxidative d e c a r b o x y l a ­
t ion of the l a t t e r compound yields 3 - m s t h y l t h i o p r o p i o n a t e ( 3 - 6 ) and 
methanethiol(MT) is formed f r o m 3-methy l th iopropionate(3,7-10). 
Recently, we showed that the sum of the c o n c e n t r a t i o n s of 4 -
m e t h y l t h i o - 2 - o x o b u t y r a t e + MT mixed d isul f ides, c o n s i s t i n g of p r o -
tem-S-S-CHa and X-S-S-СНэ (X y e t unknown), can be used as a r e l a t i v e 
e s t i m a t e f o r the amount of methionine degraded via t h e transaminat ion 
pathway(7.e,1Q). It was d e m o n s t r a t e d d O ) , t h a t the q u a n t i t a t i v e 
signif icance of th is pathway in methionine catabol ism is only of 
minor importance in normal humane However, in hypermethionmemic 
p a t i e n t s with a d e f e c t in the t r a n s e u l f u r a t i o n pathway, as t h e r e are 
p a t i e n t s with methionine a d e n o s y l t r a n s f e r a s e d e f i c i e n c y , c y s t a t h i o ­
nine s y n t h a s e d e f i c i e n c y , and with impaired l iver f u n c t i o n d ) , 
catabolism of methionine via the transaminat ion pathway can bs 
quant i ta t ive ly i m p o r t a n t . In a p a t i e n t with a def ic iency in hepat ic 
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methionine a d e n o e y l t r a n s f e r a e e , w e r e c e n t l y e s t i m a t e d t h a t a t l e a s t 
20% of t h e daily i n t a k e of methionine w a s d e g r a d e d v i a t h e t r a n e -
a m m a t i o n p a t h w a y ( 7 ) . In p a t i e n t e w i t h h o m o z y g o u s h o m o c y a t i n u n a t h e 
a c t i v i t y of c y s t a t h i o n i n e s y n t h a s e 19 s t r o n g l y r e d u c e d or e v e n 
a b s e n t . This r e s u l t s In accumulation of m s t h i o m n s and h o m o c y s t e i n e 
in b l o o d and t i s s u s s ( 1 , 1 1 ) . H o m o c y s t e i n e is c o n s i d e r e d t o be an 
a r t e r i o B c l e r o t i c a g e n t and in h o m o c y e t i n u n c p a t i e n t e p r e m a t u r e 
a r t e r i o s c l e r o s i s and t h r o m b o e m b o l i c e v e n t s a r e t h e m o e t l i f e t h r e a t ­
ening complications(1,11). In t h s s s p a t i e n t e a d e g r a d a t i o n of a 
e u b e t a n t i a l amount of methionine v i a t h e t r a n s a m i n a t i o n p a t h w a y may 
contribute t o control homocyateinemia 
To s t u d y t h e q u a n t i t a t i v e i m p o r t a n c e of t r a n s a m i n a t i o n p a t h w a y 
in p a t i e n t e with c y e t a t h i o n i n e e y n t h a e e d e f i c i e n c y , w e m e a s u r e d t h e 
c o n c e n t r a t i o n e of methionine (in s e r u m ) , and t h e t r a n e a m m a t i o n 
m e t a b o l i t e s 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e and MT m i x e d disulf idee (in 
s e r u m and u r i n e ) in t h e f a s t i n g e t a t e a e well a s a f t e r o r a l 
methionine loading In p a r t i c u l a r , a t t e n t i o n w a s paid t o a c y s t a t h i o ­
nine e y n t h a e e d e f i c i e n t p a t i e n t , who did n o t h a v e any m e a s u r a b l e 
r e s i d u a l c y s t a t h i o n i n e s y n t h a s e a c t i v i t y and did n o t r e e p o n d t o 
p y n d o x i n e t r e a t m e n t . The c y e t a t h i o n i n e e y n t h a e e d e f i c i e n t p a t i e n t s 
a r e c o m p a r e d w i t h a well d o c u m e n t e d f ? ) p a t i e n t d e f i c i e n t in h e p a t i c 
methionine a d e n o e y l t r a n e f e r a e e 
MATERIALS AND METHODS 
MT w a s o b t a i n e d f r o m M e r c k ( D a r m s t a d t . F R G.). D i t h i o t h r e i t o l 
and 4 - m e t h y l t h i o - 2 - o x o b u t y r a t B came f r o m Sigma ( S t . L o u i s , USA) and L-
methionine f r o m Bufa Chemie ( C a e t r i c u m , The N e t h e r l a n d s ) Chemicals 
w e r e of analytical PLrity, іліе otherwiee epecified 
Control e u b j e c t s 
M e t h i o n i n e and t r a n s a m i n a t i o n m e t a b o l i t e s w e r e m e a s u r e d in t w o 
g r o u p e of h e a l t h y e u b j e c t s , viz: 10 women a g e d 21 t o 4 6 y e a r s ( 3 0 1 
1 0 . mean ± SD) and 13 men a g e d 15 t o 5 4 y e a r s (31 ± 12. mean ± SD). 
T h e s e t w o g r o u p e did n o t d i f f e r s i g n i f i c a n t l y In t h e mean a g e The 
s u b j e c t s did n o t t a k e any d r u g s o r v i t a m i n s u p p l e m e n t s A f t e r an 
o v e r n i g h t f a s t , an o r a l d o s e of 0.1 g L - m e t h i o n i n e / k g b o d y w e i g h t w a s 
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administered at 9.00 a.m. During the t e s t the subjects stayed in the 
metabolic ward and used a methionme-poor breakfast and luncheon with 
a total content of 14 mg methionine In 2 g of proteinsC12), 95 g of 
carbohydrates and 31 g fate. Informed consent was obtained from all 
volunteers after the protocol had been approved by the Hospital's 
Ethical Committee. Blood was sampled immediately before and 1,2.4.6 
and 8 hours after methionine loading. Two urine samples were 
obtained, one was taken juet before methionine loading and the other 
consisted of urine collected from 0 to θ hours after methionine 
loading. 
Patients with cyetathionine eynthase deficiency 
Serum and urine samples, which have also been used for another 
studyCH). were available of 17 patients suffering of homozygous 
homocyetinuria due to cystathionine synthase deficiency. The trans­
amination metabolites were measured in samples of patients in the 
fasting state as well as after oral administration of 0.1 g methio-
nine/kg body weight. Their clinical and biochemical characteristics 
have been published extensively eleewheredD. Stored fasting serum 
samples were available from 7 patients before and 13 after the s t a r t 
of the therapy with pyndoxme. After-methionme-load serum samples 
were available from 13 patiente before and 14 patients af tsr the 
s tar t of pyndoxme therapy. Fasting urine samples had been stored 
from 8 patients before pyndoxme therapy and 9 on pyndoxme. Af ter-
load urine samples were available from 4 patients before and from 10 
after the start of the pyndoxme therapy. 
In the group of 17 homocystlnurlcs the msan age of the 8 female 
patients did not differ significantly from the mean age of the 9 male 
patients (34 ±15 versus 25 ±8 years, mean ±S.D.). The mean age of the 
female patients did not differ significantly from that of the 10 
control women (30 ±10), nor did that of the male patients from that 
of the 13 control men (31 ±12). 
In eleven patients pyridoxine as the sole therapy did normalize 
the abnormalities of the sulfur amino acids in the fasting s t a t e , 4 
patients responded only partially and one patient has not been 
treated until now. One male patient showed to be non-responsive to 
pyridoxins treatment and fibroblasts cultures from his skin did not 
show any residual cystathionine eynthase activity. 
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Amino acid analysis 
Methionine was meaeured by ion-exchange chromatography with 
gamma-amino-butyrlc acid as an internal standard (LC 2000 ammo acid 
analyser, Biotronlk Wissenschaftliche Gerate, Munich, FRG). Serum was 
deproteimzed within 10 mm a f t e r sampling by addition of equal 
volumee of 12.5% eulphosalicylic acid. The deproteimzed serum was 
stored at -20°C and analyzed within two months. 
Gas chromatooraphlc analysis 
MT and 4-methylthio-2-oxobutyrate were meaeured using a Packard 
gae Chromatograph, t y p e 429 (Packard-Becker, Oelft, The Netherlands). 
supplied with a sulfur specific flame photometric detector (Packard, 
model 906). For further details and measurement of MT eee ref. 
10.13.14. 
Analysis of the transamination mstabolitee 
Venous blood samples were obtained as described above but the 
eamples were not deproteimzed The serum and urine samples were 
s t o r e d at -20 0 C until analyeie. At this temperature the transamina­
tion metabolites, measured as described below, proved to remain 
stable In serum and urine for at least 2.5 years. These transamina­
tion metabolites consisted of 4-mBthylthlo-2-oxobutyrats (serum and 
urine) and the MT mixed disulfides: protsin-S-S-CH3 (serum) and X-S-
5-СНэ( гит and urine). Ae described previously(7,8,10). all these 
three transamination metabolites were shown to release MT by dithio-
threitol under conditione of different pH. The eum of the concentra-
tione of 4-methylthio-2-oxobutyrate + MT mixed dieulfidee represents 
a relative measure of the amount of methionine degraded via the 
transamination pathway(7,10). The experimental procedure for the 
meaeurement of the transamination metabolites 4-methylthio-2-oxobuty-
r a t e and MT mixed disulfides has been described beforedO). It should 
be noted that 3-methylthlopropionate. the third metabolite involved 
in the transamination pathway(4-10). ie quantitatively of minor 
importa-ice(7.B.10) and was not measu-sd in this study. 
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S t a t i s t i c a l analyses w e r e p e r f o r m e d by using Wllcoxon'e t w o 
sample t e s t . Mean values iSEM are given. 
RESULTS 
Control subjects 
Fast ing. The mean f a s t i n g levels of methionine and the t r a n s ­
amination metabohtee of c o n t r o l s u b j e c t s are given in Table 1. The 
mean f a e t l n g level of the transamination metabol i tes in serum did not 
d i f f e r e igni f icant ly between women (0.69 ±0 09 цтоІ/ І ) and men (0.4 
±0.03 umol/l) nor did t h a t in urine (1.2 ±0.1 v e r s u s 1.2 ±0.1 
mmol/mol creatinine). 
Methionine loading. Methionine loading r e s u l t e d in an increase 
of the c o n c e n t r a t i o n s of methionine (serumKFig. 2) and of the t r a n s ­
amination m e t a b o l i t e s (both serum and urine) in all c o n t r o l s u b j e c t s 
(Fig. 3-5). The mean lévele of the transamination metabol i tes in 
serum of women (Fig. 3) were higher than those in men (Fig. 4), but 
thie was s t a t i s t i ca l l y e igmficant (P <0 05) only a t 2 hours a f t e r 
loading. The mean level of the transaminat ion metabol i tes in urine of 
women (1 .Э ±4.6 mmol/mol creat in ine) was also s igni f icant ly highsr 
(P <0.02) than t h a t of men (5.4 ±0 9 mmol/mol creat imneKFig 5). 
Patients before pvridoxine treatment 
Fasting. The mean f a s t i n g methionine c o n c e n t r a t i o n in serum of 
t h e cystath ion ine eynthaee def ic ient p a t i e n t s was s igni f icant ly 
higher (P <0.001) than t h a t of c o n t r o l s u b j e c t s (Table 1). The mean 
level of the transaminat ion m e t a b o l i t e s in serum of the p a t i e n t s did 
not d i f f e r e igni f icant ly f rom t h a t of the c o n t r o l group However, in 
urine the mean level waa e igni f icant ly lower (P <0 02) than t h a t of 
control e ib jecte (Table 1). 
Methionine loading. A f t e r loading the mean c o n c e n t r a t i o n s of 
methionine in the p a t i e n t e w e r e higher than t h o s e of c o n t r o l s (Fig. 
2). but th is d i f f e r e n c e wae only e igmficant (P <0 05) a t θ houre 
after loading. 
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FIG. 2. 
The concentrations of methionine (mean ±SEM) before and a f t e r oral 
administration of L-methionine (0.1 g/kg body weight) in serum of 
control s u b j e c t s ( ^ ) ( n = 2 3 ) , and in serum of cystathionine synthase 
deficient patients before( · )(n=17) and on ( • )(n=16) pyndoxme 
therapy. 
FIG. 3. 
The concentrations of the transamination metabolites (mean ±SEM) 
before and a f t e r oral administration of L-methionins (0.1 g/kg body 
weight) in serum of control women( φ )(n=10), and in serum of female 
cystathionine synthase deficient patients before( · )(n=B) and on( • ) 
(η=θ) pyndoxme therapy 
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FIG. 4. 
The c o n c e n t r a t i o n s of the transamination metabol i tes (mean ±SEM) 
b e f o r e and a f t e r oral administrat ion of L-methionine (0 1g/ka body 
weight) in serum of c o n t r o l men( •)(n=13), and in serum of male 
cystath ionine s y n t h a s s def ic ient p a t i e n t s b e f o r e ( · Xn=7) and on( • ) 
(n=6) pyridoxins therapy. 
S 
φ 
control men 
control women 
HCmen - pyndoxire 
| HOonen - pyricbxine 
j HCmen • pyndoxine 
Ι НСыолеп » pyndoxine 
FIG. 5. 
The c o n c e n t r a t i o n s o f t h e t r a n s a m i n a t i o n m e t a b o l i t e s ( m e a n ±SEM) 
a f t e r o r a l a d m i n i s t r a t i o n o f L - m e t h i o n i n e (0.1 g / k g b o d y w e i g h t ) in 
u r i n e o f 13 c o n t r o l m e n . 10 c o n t r o l w o m e n . 3 male and 1 f e m a l e 
c y s t a t h i o n i n e s y n t h a s e d e f i c i e n t p a t i e n t s b e f o r e , and in 6 m a l e and 4 
female p a t i e n t s on p y n d o x i n e t h e r a p y (HC=homocystinuric). 
6 5 
Due t o loading the leve ls of t h e t ransamina t ion m e t a b o l i t e s 
i n c r e a e e d in all t e s t e d p a t i e n t e (Fig. 3 - 5 ) . The mean a f t e r - l o a d 
v a l u e e In serum of fema le homocyet inur ice did no t d i f f e r s i g n i f i -
c a n t l y f r o m t h o s e o f male p a t i e n t s , th is in c o n t r a s t with t h e 
o b s e r v e d d i f f e r e n c e b e t w e e n con t ro l women and men. The mean l eve ls in 
s e r u m of female and male p a t i e n t e did not d i f f e r s igni f icant ly f r o m 
t h o s e o f c o n t r o l women and con t ro l men. r e e p e c t i v e l y , e x c e p t f o r 1 
hour a f t e r loading. At t h a t t ime t h e mean l é v e l e in female and In 
male p a t i e n t e w e r e s igni f icant ly lower than t h o s e In c o n t r o l women (P 
<0.1) and control men (P <0.05), respectivi ly. 
Only a f e w a f t e r - l o a d urine samples of th is group of p a t i e n t s 
w e r e avai lab le; t h e c o n c e n t r a t i o n s of t h e t raneaminat ion m e t a b o l i t e s 
(1 woman. 3.1 mmol/mol c r e a t i n i n e ; 3 men, mean: 5 .2 ±0 .3 mmol/mol 
c r e a t i n i n e ) wens in t h e eame r a n g e as t h o e e m e a s u r e d in c o n t r o l 
eubjects (Fig. 5). 
Table 1. 
The f a s t i n g c o n c e n t r a t i o n s of methionine (serum) and t h e t r a n s -
aminat ion m e t a b o l i t e s (serum and ur ineHmean ±SEM) of c o n t r o l s u b -
J e c t e and cys ta th ion ine s y n t h a s e de f ic ien t p a t i e n t s b e f o r e and on 
pyridoxins therapy. 
a: the values in brackets rspreeent the obeervsd rangs. 
b: t h e va lues in p a r e n t h s a e e r e p r e s e n t t h e number of p e r e o n e s tud ied . 
METHIONINE TRANSAMINATION METABOLITES 
Normal humans 
P a t i e n t s b e f o r e 
p y r i d o x i n s t h e r a p y 
eerum 
(umol / l ) 
29 ±2 
[16 t o 4 7 ] · 
(N=23)b 
107 * 2 9 
[ 3 4 t o 5 4 9 ] 
(N=17) 
serum 
(umol / l ) 
0 . 5 7 ± 0 . 0 5 
[ 0 . 3 2 t o 1.20] 
(N=23) 
0 . 6 9 ±0.13 
[ 0 . 3 0 t o 1.15] 
(N=7) 
urine 
(mmol/mol 
c rea t in ine ) 
1.2 ±0.1 
[0 .7 t o 
(N=23) 
2.1] 
0 .6 ±0.1 
[0 .2 t o 1.0] 
(Ν=β) 
P a t i e n t s on 
p y r i d o x i n s t h e r a p y 
7 7 ± 3 3 
[15 t o 5 6 8 ] 
(N=16) 
0 . 6 8 ± 0 . 0 8 
[ 0 . 4 1 t o 1.40] 
(N=12) 
1.5 ± 0 . 2 
[ 0 . 7 t o 2.1] 
(N=9) 
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Patienta on pyridoxine treatment 
Faeting. The mean fasting methionine level In serum of the 
cyetathionine synthase deficient patients on pyridoxins treatment was 
significantly higher (P <0.01) than that of control subjecte, but 
significantly lower (P <0.01) than that of the eame patiente off 
pyridoxine treatment (Table 1). 
The mean fasting concentration of the transamination metabolites 
in ssrum of the patients did not differ eignificantly from that of 
control eubjecte nor from that of patients off pyridoxine treatment 
(Table 1). In urine the mean level of the transamination metabolites 
did not differ eignificantly from that of control subjects but was 
significantly higher (P <0.02) than that of patients off pyridoxine 
treatment (Table 1). 
Methionine loading. The mean concentrations of methionine in the 
patiente on pyridoxine were highsr than those of control eubjects 
from 2 to θ hours a f t e r loading (Fig. 2). but this difference was 
only elgnlflcant (P <0.02) at В hours a f t e r loading. No significant 
diffsrencee were observed between patients on and off pyridoxine 
therapy. 
Due to loading the concentrations of the transamination metabo­
lites increased in all t e s t e d patiente (Flg. 3-5). In contrast to the 
reeulte obtained with normal subjects, no significant différences in 
the concentrations of these metabolites in serum were observed 
between female and male patients. Significant differences were 
observed neither between female patients nor between male patients on 
and off pyridoxins therapy (Fig. 3.4). 
The mean levels of the transamination metabolites in serum of 
female and male patients did not differ significantly from those in 
control women and control men. reepectivi ly. except for 1 hour a f ter 
loading in females ( Ρ <0.05) and for 2 hours a f t e r loading in males 
(P <0.05). 
In urine the mean level of the transamination metabolites was 
significantly (P <0.05) higher in female patients (16.3 ±5.9 mmol/mol 
creatinine) than in male patiente (Э.1 ±0.6 mmol/mol creatinine)(Fig. 
5). Significant differencee were not observed between female patients 
and control women nor between male patients and control men. 
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Out of t h e g r o u p of 17 p a t i e n t s with h o m o z y g o u s h o m o c y s t l n u r l a 
only 1 p r o v e d t o b e p y r i d o x i n s n o n - r e s p o n s i v e and w i t h o u t any 
c y s t a t h i o n i n e s y n t h a s e a c t i v i t y in f i b r o b l a s t c u l t u r e s . The d a t a o f 
t h i s male p a t i e n t a r e c o m p a r e d w i t h t h o e e of 13 male c o n t r o l s u b j e c t s 
and a male p a t i e n t w i t h methionine a d e n o s y l t r a n s f e r a s s d e f i c i e n c y , 
who w a s r e c e n t l y s t u d i e d e x t e n s l v e l y ( 7 ) The r e e u l t s in Table 2 show 
t h a t t h e methionine c o n c e n t r a t i o n e In t h i e h o m o c y s t i n u n a p a t i e n t a r e 
a t l e a s t in t h e s a m e r a n g e of t h e methionine a d e n o e y l t r a n s f e r a s e 
d e f i c i e n t p a t i e n t . H o w e v e r , his t r a n s a m i n a t i o n m e t a b o l i t e s a r e only 
s l i g h t l y e l e v a t e d In c o m p a r l e o n w i t h n o r m a l s , and c o n e i d e r a b l y l o w e r 
when c o m p a r e d t o t h e p a t i e n t w i t h methionine a d e n o e y l t r a n s f e r a s e 
deficiency. 
Table 2. 
The c o n c e n t r a t i o n s of methionine ( s e r u m ) and t h e t r a n e a m m a t i o n 
m e t a b o l i t e s ( s e r u m and u n n s X m e a n ±SEM) in 13 male c o n t r o l s u b j e c t s , 
in a mals methionine a d s n o s y l t r a n s f e r a a e d e f i c i e n t p a t i e n t , and in a 
male c y e t a t h i o n i n e s y n t h a s e d e f i c i e n t p a t i e n t w i t h no r e s i d u a l c y s t a ­
thionine e y n t h a s e a c t i v i t y and n o n - r e s p o n s i v e t o p y r i d o x i n s t h e r a p y . 
METHIONINE 
e e r u m 
(umol/l) 
TRANSAMINATION METABOLITES 
s e r u m 
(umol/l) 
urine 
(mmol/mol 
c r e a t ) 
Male c o n t r o l e u b j e c t s 
(N=13) 
31 ±3 0 6 9 ±0 0 9 1 2 ±0 1 
Cystathionine synthase 
deficient patient 
+ p y r l d o x l n e 
+ p y r i d o x l n e 
and folic acid 
6 5 5 
9 7 4 
2.5 
4.1 
+ p y r i d o x i n e and fol ic 
acid and methionine 
r e e t r l c t l o n 
4 6 7 1.0 1 5 
M e t h i o n i n e a d e n o e y l ­
t r a n s f e r a s e deficient 
p a t i e n t 
7 2 0 21.9 1Θ0 2 
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DISCUSSION 
The r e e u l t e d e m o n e t r a t e t h a t In t h e f a s t i n g á t a t e t h e mean 
c o n c e n t r a t i o n of methionine in eerum of t h e c y s t a t h i o n i n e s y n t h a e e 
de f ic ien t p a t i e n t s o f f pyr idox ins t r e a t m e n t ie four t imee I n c r e a s e d 
when c o m p a r e d t o c o n t r o l s u b j e c t s . In p a r t i c u l a r , t h e male p a t i e n t 
with no res idual cys ta th ion ine s y n t h a e e a c t i v i t y ehowsd a 18 fo ld 
e l e v a t i o n of methionine. flecently(7). we d e m o n s t r a t e d t h a t In a 
p a t i e n t wi th hypermeth ionmemia (Table 2) due t o methionine a d s n o s y l -
t r a r \ s f e r a e e def ic iency t h e c o n c e n t r a t i o n s of t h e t ransamina t ion 
m e t a b o l i t e s w e r e about 100 t imes higher in serum and urine than in 
cont ro l e u b j e c t s . If d e g r a d a t i o n v ia t h e t raneaminat ion p a t h w a y is 
con t ro l l ed mere ly by t h e methionine c o n c e n t r a t i o n , it may be e x p e c t e d 
t h a t the c o n c e n t r a t i o n s of t h e t ransaminat ion m e t a b o l i t e s a r s e l e v a -
t e d In p a t i e n t s wi th hypermeth ionmemia due t o c y s t a t h i o n i n e s y n t h a s e 
def ic iency . H o w e v e r , the r e e u l t e f r o m t h e p r e s e n t s t u d y c lea r ly 
d e m o n e t r a t e t h a t in t h e f a e t m g s t a t e t h e mean c o n c e n t r a t m n e of t h e 
t raneaminat ion m e t a b o l i t e s in c y s t a t h i o n i n e s y n t h a s e de f i c i en t 
p a t i e n t s o f f p y n d o x i n e t h e r a p y w e r e not i n c r e a s e d in serum and 
ur ine , but e v e n d e c r e a e e d in urine when c o m p a r e d t o c o n t r o l s u b j e c t s 
On pyr idox ins t h e r a p y t h e cys ta th ion ine s y n t h a s e de f i c i en t p a t i e n t s 
have c o n c e n t r a t i o n s of t h e t ransaminat ion m e t a b o l i t e s in serum and 
urlns in t h e r a n g e of normal c o n t r o l s , d e s p i t e e l e v a t e d methionine 
l eve ls . Even t h e p a t i e n t with no res idual cys ta th ion ine s y n t h a s e 
a c t i v i t y showed only a m o d e r a t e e l e v a t i o n of t h e t ransamina t ion 
m e t a b o l i t e s in s p i t e of v e r y high methionine c o n c e n t r a t i o n e In 
compar ison wi th t h e methionine a d e n o s y l t r a n s f e r a s e de f i c i en t p a t i e n t . 
t h e s e e l e v a t i o n s of t ransaminat ion m e t a b o l i t e s a r e not s u b s t a n t i a l 
Based upon t h e care fu l l y conducted balance e tudy on t h e methionine 
a d e n o s y l t r a n s f e r a s e de f ic ien t p a t i s n t ( 7 ) . d e m o n e t r a t i n g t h a t a t l e a s t 
20% of hie d i e t a r y methionine was d e g r a d e d v ia t h e t r a n s a m i n a t i o n 
p a t h w a y , i t can be e e t a b l i e h e d t h a t methionine d e g r a d a t i o n v ia t h e 
t ransaminat ion p a t h w a y ie v e r y l imited in p a t i e n t s with c y s t a t h i o n i n e 
s y n t h a e e de f ic iency . Thie conclusion holds t r u e e v e n in c o m p l e t e 
cys ta th ion ine s y n t h a e e d e f i c i e n c y , d e s p i t e methionine l e v e l s higher 
than in t h e p a t i e n t wi th methionine a d e n o e y l t r a n a f e r a e e de f ic iency 
The o b s e r v e d d i f f e r e n c e s in t h e ut i l i za t ion of t h e t r a n e -
amination p a t h w a y of methionine b e t w e e n normal humans, a p a t i e n t wi th 
a def ic iency o f methionine a d e n o s y l t r a n e f e r a s s and p a t i e n t s with a 
def ic iency in c y s t a t h i o n i n e s y n t h a s e may lead t o t h e h y p o t h e s i s t h a t 
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at high methionine levels the transamination of this amino acid 
becomes significant with the proviso that thie route Is inhibited by 
high levels of SAM and/or homocysteine. In the patient with methio­
nine adenoeyltransferase deficiency the transamination is increaeed 
because of high methionine and decreaeed SAM and/or low homocysteine 
І І (7). In cystathionine synthase deficiency despite high methio­
nine lévele the transamination ιβ not Increased. This might be due to 
elevated SAM(15) and/or homocysteine levels as present In such 
patients. A regulation by SAM may proceed via the interaction of SAM 
with pyridoxlne(16). This Interaction wae described to be responsible 
for an inhibition of pyrldoxme requiring enzymee(16). as there are 
enzymes involved in the traneamination of amino acide(17). Further, 
it has been deecrlbed that homocysteine reacte epontaneouely with 
pyndoxal 5'-phosphats leading to a complex, which is rather stable 
and devoid of coenzyme activity(ie,19). In this way increased lévele 
of homocysteine showed to be able to inhibit many pyridoxins 
dependent Bnzymes(18,19) and may therefore also inhibit the degrada-
tion of methionine via the traneamination pathway. 
In a recent etudy(20). no differences were observed in the 
fasting concentrations of the transamination metabolites between con-
trol women and men, whereae after methionine loading women showed a 
significant higher transamination rate than men. In the present study 
such a difference could not be demonstrated between female and male 
homocystlnurlc patiente before nor on pyridoxins treatment. 
Summarizing, cyetathionine synthase deficient patients with or 
without pyndoxine treatment do not show elevated concentrations of 
the methionine metabolites formed via the traneamination pathway In 
serum and urine. This In sharp contrast to a patient with hyper-
methlonmemia due to methionine adenoeyltransfsrase deficiency Appa-
rent ly. cyetathionine eynthase deficient patients fail to utilize the 
traneamination pathway to reduce hypermethionlnemia and homocysti-
ixria. 
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Abstract. Catabolism of methionine is supposed to 
proceed via two known pathways transsulphuration 
and transamination In 10 premenopausal women and 
13 young men we measured methionine the transsul­
phuration metabolite homocysteine and the transami­
nation metabolites 4-methylthio-2-oxo-bulryate and 
mcthanelhiol mixed disulphides in the fasting state as 
well as after oral administration ofO 1 g L-methionine 
kg ' body weight Both in the fasting state and after 
methionine loading the concentrations of homocys­
teine in serum were significantly lower in premenopau­
sal women than in voung men Since there is evidence 
that even a moderate homocysteinaemia may be a risk 
l a u o r in the development of vascular disease the low 
homocysteine levels could be an additional factor 
contributing to the lower incidence of vascular disease 
in premenopausal women After oral methionine these 
women showed significantly higher concentrations 
both in serum and urine ofthe transamination metabo­
lites than the group of men This higher methionine 
transamination in premenopausal women may contri 
bute to keeping the homocysteine levels low and may 
therefore have an impact on the protection of these 
women against vascular disease 
Keywords. Methionine metabolism homocysteine 
methanethiol transamination, transsulphuration 
arteriosclerosis 
Introduction 
In patients with homocystmuria premature arterios­
clerosis and thromboembolic events are the most life-
threatening complications [I 2] Furthermore homo­
cysteine is considered to be an arteriosclerotic agent 
even in much lower concentrations than present in 
homozygotes for homocystmuria [3-8] In our report 
Correspondence Dr A Tangerman Department ol Medicine 
Division üfGastrointeslinal and I iver Diseases University Hospital 
Nijmegen PO Box 9101 6500 HB Nijmegen The Nelhirlands 
concerning significantly lower homocysteine accumu-
lation in premenopausal women than in young men, 
we suggested a unique efficiency of methionine metab-
olism as a protection against vascular disease in 
premenopausal women [9) 
Methionine is involved in several metabolic path-
ways Methionine and its metabolites are essential, not 
only in protein synthesis, but also in polyamine 
synthesis and in many transmethylation reactions 
[I 10] The transsulphuration pathway (Fig 1) is 
generally considered to be the major route of methio-
nine catabolism In this pathway, methionine is con-
verted into S-adenosylmethionine by methionine ade-
nosyltransferase During the transmethylation. S-
adenosylmelhionine is converted into S-adenosylho-
mocysteme which in turn is hydrolised to homocys-
teine Methionine can be either preserved by remethy-
lauon of homocysteine or catabolired via 
transsulphuration of homocysteine [I 10,11] In the 
latter pathway homocysteine combines with serine to 
form cystathionine This reaction is catalysed by the 
pyndoxine-dependent enzyme cystathionine synthase 
(EC 4 2 I 22) Cystathionine is in turn cleaved into 
cysteine and 2-ketobutyrate 
Benevenga [12] provided evidence concerning the 
existence of an alternative methionine degradation via 
the transamination pathway (Fig 1) in rats and sheep 
According to Livesey [13], in the event of excess intake 
it is more plausible that methionine is calabolized via 
the transamination pa'hway rather than via the trans-
sulphuration pathway The latter pathway is consi-
dered to have a more anabolic nature In humans, 
however, the existence ofthe transamination pathway 
remained to be defined [I 10-15], let alone its signifi-
cance determined In recent reports [16 18]. we pre-
sented proof of the occurrence of the transamination 
pathway in humans In this pathway methionine is 
transammated to 4-methylthio-2-oxobutyrate which 
is converted by an oxidative decarboxylation to 3-
meth)lthiopropionate [13-15], from which metha-
nethiol (MT) is formed [17 19] Methanethiol is a 
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volatile reactive compound and therefore difficult to 
measure in serum and urine Nevertheless, we recently 
succeeded in measuring mixed disulphides of MT in 
serum and urine as a reflection of the formation of MT 
mino [16-I8| 
In this study, evidence is provided of a 
difference between premenopausal women and young 
men in methionine metabolism via the transamination 
pathway In these two groups of humans we measured 
methionine, the transsulphurdtion metabolite homo­
cysteine and the transamination metabolites 4-meth-
ylthio-2-oxobutyrate and the MT mixed disulphides. 
both in the fasting state and after methionine loading 
Patients and methods 
Methanethiol was obtained from Merck(Darmstadt. 
FRG), Dithiothreitol L-homocystine and 4-methyl-
thio-2-oxobutyrate came from Sigma (St Louis MO. 
U S A ) , and L-methionine from Bufa Chemie Chemi­
cals were of analytical purity, unless otherwise speci­
fied 
Subjects 
The amino acids and transamination metabolites were 
measured in two groups of age-matched healthy 
volunteers 10 women aged 21-46 years (30±IO, 
mean± SD) <ind 13 men aged 15 54 years (31 + 12, 
mean + SD) The subjects did not take any drugs or 
vitamin supplements After an overnight fast, an oral 
dose of 0 I g L-methionine kg"1 body weight was 
administered at 09 00 h During the test, the subjects 
stayed in the metabolic ward and consumed a methio-
nine-poor breakfast and luncheon, with a total content 
of 14 mg methionine in 2 g of protein [20]. 95 g of 
carbohydrates and 31 g fats Blood was sampled 
immediately before and 1 2 4,6 and 8 h after methio­
nine loading Two urine samples were obtained, one 
was taken just before methionine loading and the other 
consisted of urine collected 0-8 h after methionine 
loading 
Informed consent was obtained from all volunteers 
after the protocol had been approved by the hospital's 
Ethical Committee 
Ammo acid anali ш 
Methionine, homocystme and homocysteine-cysteine 
mixed disulphide were measured by ion-exchange 
chromatography (LC 2000 ammo acid analyser, Bio-
tronik Wissenschaftliche Geräte. Munich, FRG) 
Serum was deproteinized within 10 mm of sampling by 
the addition of equal volumes of 12 5% sulphosalicylic 
acid Gamma-amino-butync acid was used as an 
external standard The deproteinized serum was stored 
at —20 С and analvsed within 2 months The total 
amount of circulating non-protein-bound homocys­
teine in a serum sample was calculated as twice the 
concentration of homocystme (homocysteine homo­
cysteine) plus the concentration of homocysteine-
cysteine mixed disulphide. in micromoles per litre 
Cai Í hromatogntpluc anali sis 
Methanethiol and 4-methyl!hio-2-oxobutyrate were 
measured using a Packard gas Chromatograph type 
429 (Packard-Becker. Delft, The Netherlands), sup-
plied with a sulphur-specific flame-photometric detec-
tor (Packard, model 906) For further details and 
measurement of M I sec [21 221 
Anahsis of ι he transamination metabolites 
The venous blood samples were obtained as described 
above, but the samples were not deproteinized The 
serum and urine samples were stored at - 20 С until 
analysis At this temperature the amount of the 
transamination metabolites measured as described 
below was found to remain stable for at least 2 years 
These transamination metabolites consisted of 4-
mcthylthio-2-oxobutyrate and the MT mixed disul­
phides protein—S—S—CHj (only in serum) and 
X—S—S—CH ι As desenbed previously ( 16]. all three 
transamination metabolites released MT under certain 
conditions At pH 12 5 all three compounds released 
MT within 4 mm 
The experimental procedure for the measurement of 
the transamination metabolites 4-methylthio-2-oxo-
butyrate and MT mixed disulphides is as follows 200 
¿tlofdithiothreiloHlOmgml ' J m O l m o l l 'TnsipH 
12 8) were added to 50-200 μΐ of a sample (urine or 
serum) in a closed evacuated 15-ml glass vial After 
stirnng for 10 s, the mixture was left at room 
temperature for 4 minutes, then 30 μΙ of 10 mol 
I " ' acetic acid were injected to release the MT into the 
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heudspace Mcthaneihiol was sampled quantitatively 
and assayed as previously described [21.22]. yielding 
the sum of the concentrations of the transamination 
metabolites 4-methyllhio-2-oxo bulyrate. protcm-
S—S—CH, and X—S—S—CH, Recently, we 
reported [16] that X—S—S—CH^ is quantitatively an 
important metabolite of the transamination pathway 
The nature of group X is currently under study The 
sum of the concentrations of 4-methylthio-2-oxobu-
tyrate + MT mixed disulphides represents u relative 
measure of the amount of methionine degraded via the 
transamination pathway It should be noted that 3-
methylthioproptonate. the third metabolite that has 
been desenbed [12-17] to be involved in the transami-
nation pathway, is quantitatively of minor importance 
[16] and was not measured by this method [16.17] 
Statistical analysis was performed using Wilcoxon's 
two sample test Mean values± SEM are given 
Results 
Figure 2 shows the concentrations of methionine in 
serum. Fig 3 the concentrations of homocysteine in 
serum. Fig. 4 the concentrations of the transamination 
metabolites in serum, and Fig. S the concentrations of 
the transamination metabolites in urine of premeno-
pausal women and young men. in the fasting state and 
after methionine loading 
The individual fasting methionine levels in 10 pre-
menopausal women ranged from 16 to 38 /¿mol I ' and 
in 13 young men from 16 to 47 μιποΙ I ' The mean 
fasting serum methionine level in women (26 + 2 /jmol 
I ' 1 ) did not show a statistically significant difference 
from that in men (31 ± 3 μπιοΙ I ' ) . nor did the mean 
serum levels at 1.2.4.6 and 8 h after methionine loading 
in women differ significantly from those in men 
Figure 3. Homocysteine concentrations (homocysteine -cysteine 
mixed disulphidc plus twice homocysnne) in serum (mean ± SEM) of 
10 prcmenopdusjl women (*) and 13 young men (A) before and 
I 2.4 6 and 8 h after an oral dose of 0 I g L methionine kg ' body 
weight 
The fasting homocysteine concentrations in serum 
of women ranged from below the detection limit ( < 0· 1 
д т о і I" ' ) to 2 6 μπιοΙ I " ' , and in men from I 1 to 6 0 
μπιοΙ I '. The mean fasting level of homocysteine in 
women (I 0 ± 0 3 μπιοΙ I" 1) was significantly lower 
( P < 0 0 0 1 ) than the mean level in men (3 6 + 04μιπο1 
1 ') Also after methionine loading the mean homocys­
teine levels in serum of women were significantly lower 
( P < 0 0 l . I h after loading, P < 0 0 0 1 . 2 8 h after 
loading) than those in the serum of men 
Figure 2. Methionine concentrations (mean * SEM) in serum of 10 
premenopausal women (•) and 11 young men ( A I before and I 2.4 6 
and H h after an oral dose of 0 1 g L-methionme kg ' bod> weight 
4 S 
Time ( h ) 
Figure 4. The concentrations of the transammalion metabolites (4-
meihylthio-2-oxobutvrate plus MT mixed disulphides) m serum 
(mean^SEM) of 10 premenopausal women (•) and 13 young men 
(A), before and 1.2.4.6 and 8 h after an oral dose of 0 I g L-
methionine kg ' body weight 
76 
H J BLOM ETAL 
Men women 
ligure 5 The «.onLentrjlions (mejn + Si-Ml ol the Irjnsdmmjlion 
mt.tabo)ites (4 methvlthio 2 oiohulyrjte plus MT mixed ііічиі 
phiiies) in urine оГ 10 premenupausdl %omi.n hilnrc <•) and alur 
IB) jnd 11 ytiun^mcn bcfurL IB) and al t u 19) an oraldiiM. ol I) I g 
L mtlhioninL kg ' body weight One urine sampk was LOlkLUd just 
Ы.Гоге ind the other between I) h ind H h iflLf muhionmi. lo iding 
In women the individual fasting levels ol the 
transamination metabolites m serum ranged Irom 0 15 
lo I 20 pmol 1 ' and in urine from 0 7 to 2 I mmol 
mol 'creatinine In men these levels ranged from 0 12 
to 0 78 μπιοΙ I ' in serum and Irom 0 7 to 2 0 mmol 
mol ' creatinine in urine The mean lasting concentra­
tion of the transamination metabolites in serum of 
women (0 69 + 0 09 μπιοί I ') did not differ signifi­
cantly from that in men (0 4 8 + 0 01 μπιοί 1 ') neither 
did the mean concentration in tasting urine (I 2 + 0 1 
vs I 2+.0 lmmolmol 'creatinine) After methionine 
loading the mean concentrations ol the transamina­
tion metabolites in scrum of women were higher than 
those of men This difference was statistically signifi­
cant ( P < 0 05) 2 h alter methionine loading Further­
more the mean level of the transamination metabo­
lites in the urine of women (18 1 + 4 6 mmol mol ' 
creatinine) was signihcamly higher ( P < 0 02) than the 
mean level in urine of men ( 5 4 + 0 9 mmol mol ' 
creatinine) after methionine loading 
Discussion 
The mean levels of circulating non protein bound 
homocysteine in the serum of premenopausal women 
were signihcamly lower than those of men both in the 
lading state and at I 8 h after methionine loading 
Obviously premenopausal women are better pro­
tected against homocysteine accumulation than men 
of comparable age This finding is in agreement with 
our earlier published data [9] on fasting and after-
methiomnc load peak levels of homocystine and 
homocysteine cysteine mixed disulphides in pre- and 
postmenopausal women and young and older men 
postmenopausal women did not differ significantly 
from men of comparable ages Recent studies have 
demonstrated that about 75% of the total amount of 
homocysteine in blood of normal subjects is bound to 
plasma proteins [21 25] The method of amino acids 
analyses used by us previously did not include the 
determination of this protein bound homocysteine 
However our data on sex differences in levels of non­
protein bound homocysteine are in agreement *ith 
those on total homocysteine concentrations, as pub­
lished by Kang el al [24] They presented data on total 
homocysteine levels in the fasting state of a large group 
of young men and women In their study females aged 
between 30 years and 50 years showed lower total 
homocysteine levels than males of comparable ages 
and there was a significant correlation between age and 
total homocysteine concentrations in females but not 
in males suggesting an influence of menopause on the 
plasma homocysteine levels 
This study showed that the mean concentrations of 
the transamination metabolites in serum and urine 
after methionine loading are higher in premenopausal 
women than in young men This indicates that in 
premenopausal women a higher amount of the excess 
methionine intake is degraded via the transamination 
pathway compared with that degraded in young men 
Rased upon this finding it can be speculated that a 
higher transamination rate in premenopausal women 
accounts at least partly for the lower homocysteine 
concentrations when compared with young men 
Apart from being lormed via the transamination 
pathway 4 methyllhio-2 oxobutyrate may also be 
lormed Irom 5 S-methylthioadenosine, which may 
itself be formed during polyamine synthesis or possibly 
by direct cleavage of S-adenosylmethionine [26] 
Furthermore it should be mentioned that degradation 
of methionine by the intestinal ñora might lead to the 
production of mcthanethiol However the small intes-
tine is able to absorb methionine quickly (27) This is 
also evident from Fig 2 which shows that oral 
methionine is quickly absorbed Therefore it seems 
unlikely that oral methionine reaches the large intes 
tine and that MT is produced from oral methionine by 
the intestinal flora The importance of each of these 
alternative routes of methionine calabolism into tran 
samination metabolites in humans is unknown How 
ever, in case these hypothetical routes are of quantita-
tive significance they will contribute to methionine 
degradation independent of the transsulphuration 
pathway 
One might argue that MT from which MT mixed 
disulphides are formed, may also be formed through S-
adenosylmethionme-depcndent transmethylation of 
thiols However we have recently demonstrated that 
an increase in the levels of MT mixed disulphides is 
paralleled by an increase in the levels of 4-methyllhio-
2-oxobulyraie in normal humans after oral methionine 
administration as well as in a patient with a deficiency 
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in methionine adenosyltransferase [16.17] These 
results suggested that formation of MT mixed disul-
phides mainly proceeds via 4-methylthio-2-oxobutyr-
ate 
In patients with homocysteinaemia, accelerated 
arteriosclerosis and thromboembolisms are the most 
life-threatening complications [1 2] The hypothesis 
that high homocystein levels are a risk factor in the 
development of premature arteriosclerosis is sup­
ported by various experimental studies fn ι uro 
addition of homocysteine or homocystine to the 
medium of human endothelial cell cultures caused cell 
injury, which is considered to initiate the development 
of arteriosclerosis [28-30] In animals, chronic homo­
cysteinaemia has been shown to produce endothelial 
damage and arteriosclerosis [29,31 34] In these exper­
iments. a linear relationship was found between the 
homocystein concentration and the induced damage of 
the endothelial cells Based upon these findings it has 
been hypothesized that even moderate homocysteinae­
mia in humans is a nsk factor for arteriosclerosis [4 6-
8,34] Heterozygotes for homocystmura are character­
ized by mild homocysteinaemia In an attempt to 
establish the incidence of heart attacks and strokes in a 
group of such earners. Mudd el al. [35] analysed 
questionnaires from a large group of families with one 
or more homozygous homocystmuna patients ftascd 
upon these rather anecdotic data they estimated that 
no more than S% of heterozygotes might have a heart 
attack by the age of SO. and a relative nsk of such event 
higher than three-fold in earners was improbable 
Furthermore, no marked difference in the probability 
to develop a stroke was detected when compared with 
their control group However Swift & Morrell [36] 
stated, on the strength of the same data, that there are 
indications that substantial excess risk of cardiovascu­
lar disease or stroke might be associated with heterozy­
gosity for the homocystmuna gene Recently, we 
established that heterozygosity for cystathionine syn­
thase deficiency is indeed associated with premature 
occlusive cerebral and peripheral arterial disease [3] 
Even in normal persons the slight but significant 
differences in homocysteine levels between (a) preme­
nopausal women and (b) men and postmenopausal 
women could contnbule to the reduced proneness of 
premenopausal women to develop arteriosclerotic 
lesions [5.9 37] 
In general, methionine degradation is only depicted 
via the transsulphuration pathway However, Bene-
venga [12] provided evidence for the existence of an 
alternative degradation of methionine via the transa­
mination pathway Such a transsulphuration-indepen-
dent methionine degradation can be of great signifi­
cance for patients with impaired degradation via the 
transsulphuration pathway, as was recently described 
for a patient with a deficiency of methionine adenosyl­
transferase [16] In this patient, we demonstrated that 
at least 20% of his dietary methionine was catabohzed 
via the transamination pathway Benevenga & Egan 
[38] suggested that in rats and sheep 60-80% of 
methionine is not catabohzed via the transsulphu­
ration pathway but via alternative routes Conversely 
according to Finkelstemjc Martin [I I], the capacity of 
the transsulphuration pathway in rats can adapt to 
large amounts of dietary methionine In-iao NMR 
studies in rats [39] also suggested that the transsulphu­
ration pathway is the major route for the degradation 
of excess methionine in rats 
The quantitative significance of the transamination 
pathway in normal humans remains to be explored It 
is intriguing that the outcome of this investigation 
demonstrates a unique handling of methionine in 
premenopausal women, namely a relatively high 
degradation rate via the transamination pathway This 
may contribute to maintaining homocystein concen­
trations at minimal levels and to reducing the cardio­
vascular risk in premenopausal women 
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METHANETHIOU AND DINETHYLSULFIDE FORMATION FROM 3-METHYLTHIOPROPIO-
NATE IN HUMAN AND RAT HEPATOCYTES 
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Biochimica et Biophysica Acta, in press 
B2 
Biochimici a Biophysicu Acta, 00 (1988) BBA] 2359 
Elsevier 
Methanethiol and dimethylsulfide formation from 3-methylthiopropionate 
in human and rat hepatocytes 
Henk J. Blom, Jacintha P.A.M, van den Elzen, Sing Hiem Yap 
and Albert Tangerman 
Diinsion of Goslrotnlatmol and Uver Diseases, University Hospital Nijmegen, Nijmegen (The Setherlands) 
(Received 16 May 1988) 
Key words Methionine, Transamination, 3-Melhylthiopropionatc, Methanethiol Dimethyl sulfide 
This study was designed to investigate the metabolism of methanethiol, and the involvement of methanethiol 
and its metabolites in the transamination pathway of methionine. Gaseous methanethiol, methanethiol-mixed 
disulfides and dimethylsulfide were formed from 3-methylthiopropionBte, a metabolite in the transamination 
pathway of methionine, during incubation with human and rat hepatocytes. An increase of the 3-methyl-
thiopropionate concentration resulted in an increased formation of the products, up to a substrate 
concentration of 4.4 mM. Higher substrate levels resulted in a decreased methanethiol formation, probably 
due to poisoning of the system. However, in human hepatocytes the formation of dimethylsulfide increased 
up to a 3-inethylthioproptonate concentration of 12.5 mM. The formation of methanethiol, dimethylsulfide 
and methanethiol-mixed disulfides from 3-methylthiopropionate in hepatocytes of both human and rat 
support the hypothesis that methanethiol can be formed from methionine via the transamination pathway. 
Introduction 
Methanethiol (MT) has often been suggested as 
one of the endogenous factors involved in the 
pathogenesis of hepatic encephalopathy This as-
sociation is based upon the work of Challenger 
and Walshe [1], who isolated MT from the unne 
of a patient with massive hepatic necrosis and 
strong fetor hepaucus. The authors suggested that 
MT was derived from methionine Oral methionine 
is able to induce neurological delenorauon in 
Abbrevutions MT, methanethiol, 
MTP, 3>iiiethy1thiopropionaie 
DMS, dimethylsuinde, 
Correspondence A Tangerman, Department of Medicine, Di-
vision of Gaslromtestinal and Liver Diseases, University 
Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The 
NetherUndí 
cirrhotic patients [2,3] and coma in rats [4] and 
dogs [S] with limited liver function The toxicity of 
methionine has often been ascribed to formation 
of MT from methionine (Refs 1, 2, 5, reviews 
Refs 6-9). 
Our interest m the formation of MT from 
methionine was stimulated by a recent study [10] 
concerning a man with a partial deficiency of 
hepatic methionine adenosyltransferase (EC 
2 S 1 6), the first enzyme in the transsulfuration 
pathway of methionine (Fig 1) In this patient we 
showed that, despite a 35-fold increase m 
methionine (serum), a 100-fold increase m MTP 
(unne) and MT-imxed disulfides (serum and unne) 
and a 15-fold increase m DMS (breath), the pa-
tient was clinically normal and healthy An in-
crease in MT and DMS levels without clinica] 
side-effects has also been observed in normal sub-
jects after oral methionine administration [11-13] 
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Fig 1 Catabolism of methionine via the iran&aminauon and 
the transsulfuration pathways 
These observations seem to contradict the theory 
of methionine toxicity through MT formation 
In most texts, methionine degradation is de­
picted to occur only via the transsulfuration path­
way (Fig 1) However, MT is not formed via this 
pathway, because in this pathway the melhylthio 
moiety is lost 25 years ago, Canellakis and Tarver 
[14] reported the formation of MT from 
methionine in rat liver mitochondria, probably via 
4-methyllhio-2-oxobutyrate The authors reported 
that MT became bound to protein probably in a 
disulfide linkage Recently, Benevenga and col­
leagues (reviewed in Ref 6) have suggested that 
MT is formed via the methionine transamination 
pathway The first step in this pathway is the 
formation of 4-melhyllhio-2-oxobutyrate by the 
transamination of methionine [6,8] The oxidative 
decarboxylation of 4-meLbylthio-
2-oxobutyrate to 3-methylthiopropionate (MTP) 
has been well characterized [6,15-18] However, 
little is known about the next steps in the trans­
amination pathway of methionine, viz, the con­
version of MTP into MT and the catabolism of 
this compound (see for reviews Refs 6,7-9,18,19) 
This is probably due to difficulties encountered in 
measuring volatile sulfur compounds Recently, 
we have developed reliable methods for measuring 
volatile sulfur compounds [20,21], and MT-mixed 
disulfides (protem-S-S-CH^ and X-S-S-CH3) m 
body fluids [13] In the present study we describe 
the formation of the volatile compounds MT and 
dmiethylsulfide (DMS), and of MT-mued dis­
ulfides by both human and rat hepalocytes from 
MTP 
Expen mental 
Materials 
MT and DMS were obtained from Merck Di-
thiothreitol, collagenase type I, bovine serum al­
bumin, Tes and Hepes came from Sigma 
Methyl(3-methylthio)prooionate was from Al-
dnch William's medium E and fetal calf serum 
were from Flow Laboratories Dexamethasone 
disodium phosphate (Oradexon*) was from 
Organon, The Netherlands Chemicals, unless 
otherwise specified, were of analytical punly 
Methods 
Synthesis of MTP Methyl(3-methylthio)pro-
pionate (1 0 g) was hydrolyzed to MTP by reflux-
ing for 4 h in 100 ml 20% NaOH The solution 
was then acidified (pH 1) and extracted three 
times with diethyl ether The diethyl ether phases 
were pooled and re-extracted three limes with 0 1 
M NaOH The 0 1 M NaOH phases were pooled, 
acidified (pH 1) and again extracted three tunes 
with diethyl ether The diethyl ether phases were 
pooled and the ether was evaporated, resulting m 
a colourless oil (3-methylthiopropionic acid) The 
lithium salt of MTP was prepared by treating the 
acid with equimolar amounts of LiOH The struc­
ture of MTP was confirmed by nuclear magnetic 
resonance (a (ppm) [CDCI3] 21 [3H, s, СЯ3-5], 
2 7 [4H, m, 8-СЯ2-СЯгСООН], 9 8 [IH, s, 
СООЯ]), mass spectrometry (m/z 120 [M+], 103 
[ M * - O H ] , 75 [ЛГ-СООН]) and gas chro­
matographic analysis According to gas chromato­
graphic analysis, the punty of MTP was > 98% 
Isolation of rat hepalocytes Male Wistar rats 
(180-200 g) were used Food and water were given 
ad libitum The animals were anesthesized by an 
intraperitoneal injection of 0 2 ml sodium pento­
barbital (60 mg/ml) Hepalocytes were isolated 
according lo the method of Seglen [22] with the 
following modifications The liver was perfused 
with a Ca^-free Hepes buffer (pH 7 6) for 20 
84 
min followed by a Hepes buffer (pH 7 6) contain­
ing 005% (w/\) collagenase and 10 mM CaCl2 
for 10 min The perfusion rate was 40 ml/mm 
The cells were pelleted and resuspended m Wil­
liam's medium E and incubated at 37° С for 30 
mm After filtration and centnfugation, the 
hepatocyles were resuspended in William's 
medium E supplemented with 10% (v/v) fetal calf 
serum, 2 mM L-glutamine, 20 mU/ml porcine 
insulin, SO nM dexamethasone 2 5 Mg/ml fungi­
zone, 50 Mg/ml tetracycline and 100 /ig/ml 
vancomycine, and diluted to a density of 10 10' 
viable cells/ml The viability of hepatocyles was 
at least 95% before and 86% after the experiment, 
as estimated by the Trypan blue assay Micro­
scopic studies showed that the punty of the 
hepatocyles was greater than 98% 
holanon of human hepatocyles Post mortem 
human liver tissue was obtained from a kidney 
donor Hepatocyles were isolated as described 
previously [23], with some modifications EGTA 
was omitted in the Ca2*- and Mg2*free Hepes 
buffer After the perfusion the cell suspension was 
pelleted, resuspended and incubated at 37° С for 
30 mm After filtration and centnfugation, the 
hepatocyles were resuspended as described for rat 
hepatocyles The viability of the hepatocyles was 
at least 68% before and 61% after the expenmenl, 
as determined by the Trypan blue exclusion test 
The punty of the hepatocyles was greater lhan 
98%, as was eslimaled by microscopic experi­
ments 
Incubation procedure All incubation expen-
ments were performed in duplicate After addition 
of 100 μΐ of a neutralized aqueous MTP solution 
in a 15 ml glass vial containing 1 ml of the 
hepatocyte suspension (10 10' viable cells) and 2 
ml William's medium E (pH 7 8), the glass vial 
was sealed by means of a septum and gently 
shaken at 37° С A sample of the head space of 
the vial was withdrawn at regular intervals with 
gas-tight syringes, concentrated onto Tenax trap 
tubes and analyzed for volatile sulfur compounds 
by means of gas chromatography The volume of 
the sample of the head space vaned from 100 μΙ to 
12 ml, dependmg on the concentrations of the 
volatile sulfur compounds The concentrations of 
MT and DMS, as depicted m Figs 2a, 2c, 3a and 
3c, represent the sum of concentrations as de­
termined in the separate head space samples After 
sampling of the head space, the vial was flushed 
with air for a few seconds and a liquid sample 
(200 μΐ) was taken out of the incubation mixture 
The vial was sealed again by means of a septum 
and the incubation was continued The liquid 
sample was cooled on ice and the hepatocyles 
were pelleted by centnfugation The supernatant 
was frozen and stored at -80° С until analysis 
The MT-mixed disulfides, which were measured in 
this supernatant, were shown to be stable at 
- 80 ° С for at least 2 years 
Gar chromatographic analysis Gaseous MT and 
DMS were measured as described previously 
[20,21] The MT-mixed disulfides were measured 
by conversion to MT by means of dithiothreitol, 
as descnbed recently [10,13] MTP was measured 
by a modified method of K.aji et al [13,24] 
Results 
Up to a concentration of 0 125 mM MTP gase­
ous MT and DMS were not formed in detectable 
amounts (less than 5 nM) by rat hepatocyles (Fig 
2) However, MT-mixed disulfides were delected 
after 20 nun when the mcubation was earned out 
with 0 125 mM MTP Increasing amounts of MT, 
MT-mixed disulfides and DMS were recovered 
with increasing substrate concentrations up to 4 4 
mM MTP A higher substrate concentration (12 5 
mM) resulted m a decrease m the formation of all 
three products 
As demonstrated m Fig 3, mcubation of MTP 
with human hepatocyles also results in the forma­
tion of gaseous MT, MT-mixed disulfides and 
DMS MT and DMS were not formed in detecta­
ble amounts up to a concentration of 0 125 mM 
MTP, while the formation of MT-mixed disulfides 
was already measurable at a concentration of 0 044 
mM MTP after 15 mm An increase m substrate 
concentration resulted in an elevated formation of 
MT, MT-mixed disulfides and DMS Maximum 
production of MT and MT-mixed disulfides was 
observed at 4 4 mM MTP A higher concentration 
of MTP (12 5 mM) resulted in decreased MT 
formation In contrast to MT, DMS formation 
süll increased, when the substrate concentration 
was increased from 4 4 mM (o 12 5 mM MTP 
Θ5 
Blanks contained no hepatocytes or hepato­
cytes boded for 2-4 min MT, MT-rmxed dis­
ulfides or DMS were not formed m detectable 
amounts under these conditions However, when 
the incubation was performed without MTP, small 
amounts of MT mixed disulfides were delected 
(maximal 1 07 μΜ ш human hepatocytes and 0 80 
μ M in rat hepatocytes) Corrections were made for 
the endogenous formation of MT-nuxed dis­
ulfides This formation of small amounts of MT is 
probably due to the degradation of methionine 
present in the incubation mixture 
Discussion 
The results clearly demonstrate that MT, MT-
mixed disulfides and DMS are products of MTP 
calabolism in human and rat hepatocytes To our 
knowledge the formation of MT-nuxed disulfides 
and DMS from MTP has not been described 
before The formation of MT from MTP has been 
reported once before in rat liver homogenates [25] 
Although our gas chromatographic system is quite 
capable of measuring H 2 S [20 21 J, this compound 
was not detected during incubation of MTP with 
human or rat hepatocytes Steele and Benevenga 
[25] reported formation of H 2 S from MTP on 
incubation of MTP with rat liver homogenates at 
low pH (6 3) However when they used the same 
pH as we used m our hepatocyte studies (pH 7 8), 
they did not detect H 2 S 
Increasing amounts of MT and DMS were 
formed when the mcubation was earned out with 
increasing substrate concentrations A maximal 
MT formation was obtained at 4 4 mM MTP The 
conversion of MTP to MT did not show satura­
tion kinetics On the contrary, MT formation was 
markedly decreased when the substrate con-
Fig 2 Formation of methanethiol (MT) MT mixed disulfides 
and dunethylsulfide (DMS) from 3 methylthiopropionate in 
rat hepatocytes The formation of gaseous MT (a) MT muted 
disulfides (b) and gaseous DMS (c) from 3 methyl 
thiopropionate ш rat hepatocytes was measured as desenbed in 
the Experimental secuon When necessary corrections were 
made for endogenous formation of MT mixed disulfides Each 
point represents the mean of duplicate expenments 3 Methyl 
thiopropionate concentrations used (mM) о 0 044 A 0125 
л 0 44 • 1 25 О, 4 4 and · 12 5 mM 
86 
Time (mm) 
Fig 3 Formation of methanelhio],MT-iTiixed disulfides and dimelhylsulfide from 3-methyllhiopropionate in human hepatocytes The 
formation of gaseous MT (a). MT-mixed disulfides (b) and gaseous DMS (c) from 3-methvlthiopropionate in human hepatocytes was 
measured as descnbed in the Expenmenul section When necessary, corrections were made for endogenous formation of MT-mixed 
disulfides Each point represents the mean of duplicate expenments S-Melhylthiopropionate concoilrauons used (mM) о 0044, л, 
0 125. Δ. 0 44, •, 1 25. α 4 4 and · , 12 S mM 
cenlration was increased from 4 4 to 12.5 mM, 
both in the human and in the rat hepatocyte 
system. This phenomenon can be explained by 
assuming that at high substrale concentrations the 
incubation system was inactivated by MTP or one 
of its metabolites. Although MT is a well-known 
toxin, MT itself is probably not responsible for 
the inactivation, because MT formation was 
markedly decreased at 12.5 mM MTP The ob­
served decrease m MT formation is in agreement 
with results of Steele and Benevenga [25], who 
reported a decreased product formation at levels 
B7 
of MTP > 10 mM 
Theoretically, DMS can be formed from MTP 
via two different pathways an MT-dependem or 
an MT-independenl route In the MT-dependent 
route MT is methylated to DMS by thiol-S-meth-
yltransferase, an enzyme present in liver and many 
other organs [26] The existence of an MT-inde-
pendent route m humans has been suggested by 
Kaji et al [11] They observed that after adminis-
tration of methionine to human subjects, the in-
crease of DMS m breath was not parallelled by an 
increase of MT An MT-mdependent route can 
proceed via methylation of MTP on the S-alom. 
This reaction results in the formation of dimethyl-
/}-propiothetm and DMS can easily be formed 
from this compound [27] This pathway is well 
known in algae and various species of plankton 
[27] The existence of this MT-independent DMS-
producmg pathway in humans could explain our 
observation that in the human hepatocyte system 
at a substrate concentration of 12 5 mM the for-
mation of DMS mcreased while MT formation 
was markedly decreased 
In this paper we demonstrate that, in human 
hepatocytes, the formation of DMS is not totally 
dependent on MT and might proceed additionally 
via dimethyl-ß-propiothelin Evidence is provided 
that the volatile sulfur compounds, MT and DMS, 
and the MT-mixed disulfides are formed at least 
m part via the degradation of MTP in both human 
and rat hepatocytes This supports the hypothesis 
that MT is formed from methionine via the trans-
amination pathway In future studies the measure-
ment of MT, DMS, and MT-mixed disulfides will 
be used to investigate the methionine transamina-
tion pathway more extensively. 
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CHAPTER П В 
Methanethiol metabolism in whote blood 
HENK J. BLOM and ALBERT TANGERMAN 
NIJMEGEN, THE NETHERIANDS 
The metabolism of methanethiol In whole blood has been described. Incubation 
of carbon 14-labeled or sulfur 35-labeled gaseous methanethiol resulted In 
complete trapping of methanethiol by whole blood within 30 minutes. After 
trapping, both labels were found to be equally distributed over plasma and 
erythrocytes. Eighty to ninety percent of both labels could be extracted from 
erythrocytes Incubated In saline solution. The chemical properties ol t h e u C and 
"S labels In saline solution differed completely. The "C label was not precipi­
tated by BaClj, was moderately volatile, and could be extracted by ether 
(pH 1). In contrast, the "S label was precipitated by BaCI,, was not volatile, and 
was not extracted by ether. It Is concluded that the central carbon-sulfur bond 
of methanethiol Is split by Incubation with whole blood. Plasma components 
are not Involved In this process. Most likely, methanethiol becomes largely ox­
idized by erythrocytes to formic acid and sulfite or sulfate. Only 10% of meth­
anethiol became (Irmly bound to erythrocytes. One to two percent was trans­
formed to protein—S — S — CH, and 1% to dimethyl sulfide by the enzyme thiol 
methyltransferase. (J LAS CLIN MED 1986111:600-10) 
I ethanethiol has been suggested lo be one of the endogenous factors responsible for he­patic encephalopathy ' ' The association of 
methanethiol with hepatic encephalopathy is based on 
the work of Challenger and Walshe.' who isolated meth­
anethiol as a mercaptide from the unne of a patient with 
massive hepatic necrosis and a strong fetor hepaticus 
Methanethiol is an extremely toxic compound For ex­
ample, small amounts cause reversible coma in rats ' 
Little is known about the metabolism of methanethiol 
We have recently shown that in humans, methanethiol 
is formed via the transamination pathway of methio­
nine ' Methanethiol has also been suggested to be 
formed in the intestinal tract.2 Concerning the degra­
dation of methanethiol, it was shown that in rats the 
major part of intrapentoneally injected methanethiol 
was oxidized to carbon dioxide and sulfate ' 1 0 In a 
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Liver Diseases, University Hospital Nijmegen 
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previous article" we showed that methanethiol, when 
added to whole blood, became completely trapped by 
erythrocytes. At that time we suggested that metha-
nethiol was bound to hemoglobin Doizaki and Zievc6 
believed that methanethiol formed a covalent disulfide 
bond with blood proteins. They applied a zinc and acid 
method to reduce these disulfide bonds and to release 
methanethiol from whole blood The results obtained 
with this zinc-acid method have contributed to the hy-
pothesis that methanethiol might be involved in the 
pathogenesis of hepatic encephalopathy '^ The repro-
ducibility of this zinc-acid method is at least disputable, 
because three groups reported very different values of 
methanethiol in humans * " In our hands, the zinc-acid 
method was uniformly unsuccessful " Using improved 
methods for measuring mercaptans," 12 we found in 
blood or serum an infinite release of methanethiol after 
zinc-acid treatment, and the released amount of meth-
anethiol was independent of the amount of methanethiol 
added to blood It would appear that a senous meth-
odologie problem exists somewhere in (his area To 
tackle this problem, we synthesized labeled methane-
An editorial relevant to this article appears on 
p. 595 of this issue of the JOURNAL 
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thiol (carbon 14 or sulfur 35) and followed the labels 
after incubation of me thane thiol with whole blood. 
METHODS 
Labetod metharwthlol. Labeled methanettiiol was syn­
thesized by a modified method of Canellakis and Tar ver l0 
"S-methanethiol was prepared by using "S-thiourea (Amer-
sham) and "C-methanethio! was prepared by using '*C-
methyl iodide (Amcrsham) In a IS ml glass vial, thiourea 
(76 mg 1 mmol) was dissolved m 3 ml ethanol, and the vial 
was closed by septum Methyl iodide (213 mg. I 5 mmol) 
was injected and the reaction mixture was shaken for S min­
utes at 70° С After the mixture was cooled, ptene acid 
(Boom, Mcppel, The Netherlands) (344 mg, I mmol) was 
added The vial was closed again by septum and the mixture 
was heated for 5 minutes at 75° С Cooling resulted in 
yellow crystals (220 mg 5-methylthiourea picrate) Recrys-
lallization from water ( 100 mg in 12 ml water, 80° C) resulted 
in fine crystals with a melting point of 223° С (literature 
221° C") 
S-meth>lthiourea picrate (12 mg) and 5 mg dithiolhreitol 
(Sigma Chemical Co , St Louis) were put in a vial and the 
vial was evacuated Methanethiol was liberated from (he pi­
crate by heating with I ml 4N NaOH (20 minutes at 40° C) 
After the mixture was cooled. 1 5 ml 5N HCl was injected, 
releasing the labeled methanethiol as a gas in the hcadspace 
of the vial " The labeled methanethiol was analyzed by gas 
chromatography " 
The escape of radioactive methanethiol into the air was 
[»evented by two wash bottles The first bottle contained isatm 
(Boom) dissolved in concentrated sulfuric acid (10 mg/100 
ml), and the second bottle contained 4N NaOH 
Radioactivity was counted by two methods, both giving 
the same results ( I ) Methanethiol was added as a gas lo a 
closed vial containing IN NaOH After the methanethiol was 
trapped. 1 ml of this solution was dissolved in 13 ml scin­
tillation liquid (Aqualuma Plus. Lumac, Schaesberg, The 
Netherlands), (2) Methanethiol was directlv dissolved in the 
scintillation liquid by passing the gas through the liquid 
Radioactivity was measured by liquid scintillation counting 
(PW 4700, Philips. Eindhoven, The Netherlands) 
Isotachophoretll. Isotachophoresis is an electrophoretic 
technique separating ions according to their net mobilities in 
an electric field At the start of a separation, a sample is 
introduced between two electrolytes (referred to as the leading 
and terminating electrolytes) having ions of different mobil­
ities During the electrophoresis, the sample ions having a 
mobility between that of the leading and terminating electro­
lytes remain between these electrolytes and separate into 
zones These zones remain adjacent to each other in order of 
their net mobilities 
The isotachophoretic experiments were performed with the 
isotachophoresis equipment developed by bveracrts et al и 
The separation compartment consisted of polytetrafluoroe-
thylene narrow-bore tubing with a length of 25 cm (inside 
diameter 0 2 mm, outside diameter 0 4 mm) The direct con­
stant electneal driving current (25 μΑ) was obtained from a 
modified Brandenburg (Thornton Heath, England) high-
T o b l · I. Incubation of M C or ^ - l a b e l e d 
methanethiol with whole blood Distribution of 
radioactivity between erythrocytes and plasma 
Efythrocyt« Ptasma 
'C label 43% 57% 
:BS label 42% 58% 
voltage power supply The voltages vaned between 2 and 8 
kV Serum or physiologic salt samples were diluted 11 times 
and injected directly (I to 10 μΐ) with a Microhte synnge 
(Hamilton Medical Ine , Reno, Nev ) The leading electro­
lyte consisted of histidine-CI (0 01 mol/L. pH 6 01) and 
0 2% hydroxyethyl cellulose (Pol у scie nee s Ine , Wamngton, 
Pa ) The tenmnaiing electrolyte contained 2-(<V-morphoIino) 
ethane sulfonic acid (Sigma) and histiduie (0 01 mol/L. pH 
6 01) All chemicals were of analytic grade Separated zones 
were detected by measuring the electneal conductivity and 
measuring the UV absorption at 254 nm Physicochemical 
data were taken from reference 16 
Gas chromatographic analy·*·· Methanethiol, di­
methyl sulfide, and dimethyl disulfide (Merck, Darmstadt, 
West Germany) were measured with a gas Chromatograph 
(type 429, Packard-Becker, Delft, The Netherlands) supplied 
with a flame photometric detector (model 906, Packard) 
The injection port of the gas Chromatograph was supplied 
with a glass liner (length 8 cm, outside diameter 6 mm) The 
liner was filled with Tenax GC, a porous polymer based on 
2,6-diphenyl-p-phcnyleiK oxide, 80 to 100 mesh (Chrom-
pack, Middelburg, The Netherlands) The column (2m x 4 
mm) was packed with 20% SE-30 on Chromosorb P. 60 to 
80 mesh (Chrompack) Procedures were earned out as pre­
viously desenbed " " 
Protein — S — S — CH, was measured as methanethiol 
through release of methanethiol by means of dithiothreitol " 
Incubation •xpvrfmwitt. Blood samples were withdrawn 
by venipuncture and collected in vials containing heparin 
Only fresh blood samples were used In a 15 ml glass vial 
closed by septum, "C- or "S-labe led methanethiol was added 
to 2 ml blood as a gas at room temperature (concentration 
range studied 4 to 40 nmol methanethiol per milliliter blood) 
In some experiments an erythrocyte-saline solution mixture 
( I I ) was used instead of whole blood The incubation lasted 
for 30 minutes at 37° С After incubation, the headspacc of 
the vial was analyzed and the blood samples were cooled on 
ice Further experiments with the samples were earned out 
at 4° С 
Extraction of erythrocytes by saline solution was performed 
by removing plasma from erythrocytes by centnfugation 
Next, saline solution was added to erythrocytes (1 1 ) and die 
mixture was shaken smoothly for 2 minutes The erythrocytes 
were centnfuged off and the mixture was again shaken with 
saline solution This procedure was repeated four times The 
amount of label extracted was estimated in the plasma and 
saline solution fractions by liquid scintillation counting 
The serum obtained after incubation was filtered over filters 
with a molecular weight cutoff of 1000 (Diaflo ultrafilters 
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T a b l e II. Incubation of " С or »S-labeled 
mettianethiol wltti whole blood Distribution of 
the radioactivity after extraction of the 
etythrocytes with saline solution 
ІіуІІтк ylw Ptotma -f юНп· 
solution 
'C label 9% 9 1 % 
"S label 15% 85% 
YM2 and Ultrañlitration cell model 12. Amicon Соф . Dan­
ven. Mass ) The amount of label in the concentrale and 
filtrate was measured 
After incubation of labeled methanethiol with whole blood 
and with an erythrocyte-saline solution mixture (I I). some 
chemical propenies of the "C and "S labels were investigated 
in scrum and saline solution The presence of "S labeled 
sulfite or sulfate was tested by adding BaCl, Barium sulfile 
and banum tulfale are insoluble in aqueous solutions and will 
precipitate The volatility of the labels was investigated by 
evaporation of the solutions by flushing with nitrogen Acid­
ification of the solutions to pH 1 and extraction with elher 
was pcrfonned to test for the presence of the "C label in 
weak acids, namely, in fomnc acid 
The membranes of erythrocytes weie isolated according to 
a slightly modified method of Pazmifto and Wemshilboum " 
The membranes were suspended in 0 I mol/L Tns HCl (pH 
7 4) The concentnlions of the erythrocyte membranes and 
the cytosolic fraction were kept the same as their respective 
concentrations in whole blood In a IS ml glass vial I ml 
erythrocyte membranes or cytosolic fraction and 0 I ml I 25 
mmol/L 5-adenosyl-L-methionine (Sigma) was added The 
vial was closed by septum and 15 nmol methanethiol was 
added as a gas After incubation (30 minutes at 37° C) the 
amount of dimethyl sulfide was estimated in the headspace 
of the vial 
RESULTS 
Addition of gaseous methanethiol to whole blood or 
to an erythrocyte -saline solution mixture (1 1 ) resulted 
in a complete trapping of methanethiol within 30 min­
utes (concentration range studied 4 to 40 nmol meth­
anethiol per milliliter blood) After that time no residual 
gaseous methanethiol was detectable Only the addition 
of very high concentrations of methanethiol leads to 
the detection of some unbound "free" methanethiol For 
example, after incubation of 2 μιηοΐ methanethiol per 
milliliter whole blood, about 20 nmol methanethiol 
(1%) was recovered as free methanethiol in the head-
space above the blood In all experiments, the incu­
bation time was 30 minutes Pilot studies showed that 
most of the methanethiol (>90%) was trapped by blood 
within 10 minutes 
Earlier results of our group" have shown that the 
addition of gaseous methanethiol to plasma or serum 
alone gave a 100% binding of methanethiol to proteins, 
via a disulfide linkage 
Protein — S H + CH,SH-> Protein — S — S — СН
Э 
After incubation of methanethiol with whole blood, 
only 1% to 2% of methanethiol reacted with proteins 
to protein — S — S — CH, Therefore, plasma or se­
rum proteins are not important in the trapping of meth­
anethiol by whole blood Obviously, uptake and pro­
cessing of methanethiol by erythrocytes is faster than 
binding of methanethiol to plasma proteins To study 
this process in more detail, we incubated whole blood 
with "C- or "S-labeled methanethiol After incubation. 
the "C and "S labels were almost equally distnbuted 
over the plasma and erythrocytes (Table I) Similar 
results were obtained when plasma was replaced by 
saline solution Both labels could be extracted almost 
completely from erythrocytes by saline solution (Table 
II) Only about 10% remained to be bound to eryth­
rocytes 
After the incubation of '"C- or "S-labeled methan­
ethiol with whole blood, the erythrocytes were centn-
fuged off and the plasma was passed through filters 
with a molecular weight cutoff of 1000 The concen­
tration of "C in the filtrate amounted to 87% of that in 
the original plasma, and the concentration of "S in the 
filtrate amounted to 78% of that in the original plasma 
These results show that after incubation of methanethiol 
with whole blood, at least 80% of the products m plasma 
have a molecular weight of less than 1000 and are 
therefore not bound to proteins These results and those 
obtained by the extraction experiments show that 
during incubation, most of the methanethiol reacts with 
erythrocytes, resulting in products that are excreted in 
plasma Only about 10% of methanethiol became hmnly 
bound to erythrocytes 
The chemical properties of (he l 4C and "S labels were 
investigated after incubation of labeled methanethiol 
with blood or with an erythrocyte-saline solution mix­
ture (1 1 ) The "C label was not precipitated by BaCl,, 
was moderately volatile, and could be extracted with 
ether after acidification of saline solution to pH 1 Con­
versely, the " S label was precipitated by BaCl,. was 
not volatile, and could not be extracted with ether 
The results clearly show that 80% to 90% of meth­
anethiol. when incubated with whole blood, reacts with 
erythrocytes, resulting in products in which the carbon-
sulfur bond of methanethiol has been cleaved These 
results can best be explained by assuming that the sulfur 
atom of methanethiol is oxidized to sulfite or sulfate 
and the carbon atom of methanethiol to formic acid 
This oxidation of methanethiol can proceed via two 
routes (Fig 1 ) Isotachophoretic expenments show that 
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after incubation of methanethiol with whole blood or 
with an erythrocyte-salme solution mixture (1 1), 1 % 
of methanethiol was recovered as methanesulfonate 
( C H J S O J H ) Incubation of methanesulfonate with 
whole blood showed no decrease in the concentration 
of methanesulfonate, indicating that methanesulfonate 
is not metabolized by whole blood After incubation 
with whole blood, the carbon-sulfur bond of methane­
sulfonate is still intact, whereas the carbon-sulfur bond 
of methanethiol has been cleaved These findings favor 
pathway A (Fig 1) 
The incubation of methanethiol with whole blood 
also resulted in the formation of small amounts of di­
methyl sulfide (0 5% to 1%) Experiments done with 
methanethiol and erythrocyte membranes and with the 
soluble erythrocyte lysates showed that dimethyl sulfide 
was formed only during incubation of methanethiol with 
the membrane fraction 
The oxidation j f methanethiol might also lead to the 
formation of dimethyl disulfide However, during the 
incubation experiments done with methanethiol and 
whole blood, dimethyl disulfide was not formed in de­
tectable amounts ( < 0 1 % of the amount of methane­
thiol added to blood) 
DISCUSSION 
The toxin methanethiol is a very reactive compound 
and is difficult to detect in body fluids and breath 
Recently we developed simple and reliable methods for 
the determination of methanethiol " '' Using these 
methods, we found that methanethiol was completely 
trapped by whole blood, erythrocytes, or plasma after 
incubation The almost complete absorption of meth­
anethiol by whole blood was at that time explained by 
proposing that methanethiol binds to hemoglobin ' ' Do-
izaki and Zieve* and Mardini et al " assumed a binding 
of methanethiol in whole blood to proteins via mixed 
disulfides The results in this article clearly show that 
this is not the case The incubation of methanethiol 
with whole blood resulted in an oxidation of metha­
nethiol by the erythrocytes During the oxidation, the 
central carbon-sulfur bond of methanethiol is split up 
Most likely, the carbon atom is oxidized to formic acid 
and the sulfur atom to sulfite or sulfate The oxidation 
may proceed via two routes (Fig I ) Pathway В yields 
methanesulfonate as an intermediate in this process 
Tne latter compound was detected by means of iso-
tachophoresis, indicating that pathway В is operative 
to some degree However, the incubation of methane­
sulfonate with whole blood showed that this compound 
was not metabolized by blood Therefore, pathway A 
is probably the preferred oxidation route of methane­
thiol in erythrocytes 
Our in vitro findings regarding oxidation of metha-
route A rout« В 
CHjSH 
(methanethiol ) 
HOCH2SH CHjSOH 
I i C H J S O J H 
CHjO HjS ι 
1 1 C H J S O J H 
HCOOH HJSJOJ I 
I ' l 
* CHjO so3 2-
Τ ι ι 
i HCOOH so.2-
s o 4
2 
Fig I. Possible oxidation routes of methanethiol in whole blood 
nethiol by erythrocytes agree well with in vivo exper­
iments in rats,'' '" which showed a rapid oxidation of 
methanethiol into carbon dioxide and sulfate after in­
traperitoneal administration The liver most likely plays 
a role, but blood also might have played an important 
role in the in vivo oxidation of methanethiol From the 
experimental setup, it was not possible to differentiate 
between these two possibilities From the results pre­
sented in this article, we might argue that in addition 
to the role played by the liver, blood plays dn important 
role in the in vivo oxidation of methanethiol The 
oxidation in blood is most likely earned out by 
hemoglobin " x In analogy, it is known that hemoglobin 
is able to oxidize hydrogen sulfide :< Hemoglobin is 
available in large quantities, and we are inclined to 
speculate that hemoglobin might play an important role 
in biotransformation of certain toxins 
As shown above, the greater proportion of metha­
nethiol is oxidized into formic acid and sulfite or sulfate 
during incubation with blood Only a very small frac­
tion of about 10% became bound to erythrocytes, and 
about 1 % was methylated to dimethyl sulfide Two thiol 
methylating enzymes in the erythrocytes have been de­
scribed : 2 The thiol methyltransferase is membrane as­
sociated and preferentially catalyzes sulfur methylation 
of aliphatic thiols The other enzyme, thiopunne meth­
yltransferase, is a cytoplasmic enzyme that preferen­
tially catalyzes the thiol methylation of aromatic thiols 
The results showed that methanethiol is methylated to 
dimethyl sulfide in the erythrocyte membrane There­
fore, the methylation is probably catalyzed by thiol 
methyltransferase 
Methanethiol has often been suggested to be involved 
in the pathogenesis of hepatic encephalopathy ' ' Most 
of the data in support of this hypothesis' * ' have been 
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generated with the zinc and acid reducing method de­
veloped by Doizaki and Zieve.' It was assumed that 
methanethiol, added to blood, became bound to blood 
proteins, and that this bound methanethiol could be 
released by using zinc and acid Recovenes of up to 
80% of methanethiol added to blood have been claimed 
by using the zinc and acid method As previously de­
scribed," we found no recovery of any methanethiol 
added to whole blood by using the zinc and acid 
method However, by using improved techniques for 
measuring methanethiol, we found a gradual and infi­
nite release of methanethiol, and this amount of meth­
anethiol was independent of the amount of methanethiol 
added to blood 
The results described in this article refute the sup­
position that methanethiol added to blood can be re­
covered as methanethiol More than 80% of methane­
thiol added to whole blood was oxidized, resulting in 
a splitting of the central carbon-sulfur bond of metha­
nethiol This carbon-sulfur bond cannot be restored by 
using zinc and acid, which means that methanethiol 
added to blood can never quantitatively be recovered 
as methanethiol. The liberation of methanethiol from 
blood by zinc and acid is most likely caused by de­
composition of methylthio compounds, inasmuch as 
there are methionine (free or in protein) and methylthio 
compounds formed via the methylthiolation path­
way u 2 4 We must conclude that most results in literature 
about the role of methanethiol in hepatic encephalop­
athy are based on a wrong method Therefore, the role 
of methanethiol in hepatic encephalopathy must be rein­
vestigated by using new techniques for measuring an 
exposition to methanethiol. 
We thank A A G Lenuncns (University οΓ Technology, Ein­
dhoven, The Nelheriands) for performing the isolachophomic tu-
penments 
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ABSTRACT 
The m e t a b o l i e m of m s t h a n e t h i o l (MT) w a e s t u d i e d in r a t s 
A d m l n i e t r a t i o n of a n o n - c o m a t o g e n i c d o s e of MT v i a t h e i n s p i r e d air 
or v i a i n j e c t i o n into t h e c a e c u m , r e s u l t e d in an e l e v a t i o n of t h e 
c o n c e n t r a t i o n s of MT mixed d i e u l f i d e e In s e r u m ( p r o t e i n - S - S - С Н э and 
X - S - S - С Н э , X y e t unknown) and in ur ine ( X - S - S - С Н э ) The c o n c e n t r a ­
t i o n s of MT m i x e d d i s u l f i d e e p r o v e d t o b e a r e l a t i v e m e a s u r e f o r an 
e x p o s u r e t o MT The v o l a t i l e e u l f u r compounde MT, d i m s t h y l s u l f i d e , 
and d i m e t h y l d i e u l f i d e in t h e air e x p i r e d by r a t e e x p o e e d t o a n o n -
comatogenic dose of MT via the caecum w e r e aleo e l e v a t e d 
The c o n c e n t r a t i o n s of MT m i x e d d i s u l f i d e s and ammonia w e r e 
m e a s u r e d in r a t s w i t h a c u t e h e p a t i c e n c e p h a l o p a t h y (HE) due t o l iver 
Ischemia, and in d o g s s u f f e r i n g f r o m HE due t o chronic l i v e r d i s e a s e 
In b o t h t h e e e g r o u p e of animals a l a r g e and s i g n i f i c a n t i n c r e a s e in 
ammonia w a e m e a s u r e d H o w e v e r , t h e mean l e v e l s of MT mixed d i s u l f i d e s 
in r a t s w i t h HE a s well a s in d o g s with HE w e r e n o t d i f f e r e n t f r o m 
t h e mean normal l e v e l of t h e e e animals In conclusion, w e can s a y 
t h a t In t h e e e animal models of l i v e r f a i l u r e t h e r o l s o f MT in t h e 
p a t h o g e n e e i e of HE is minor if n o t i n s i g n i f i c a n t , e v e n in c a s e HE ie 
mediated through a synergist ic interaction of MT and ammonia 
INTRODUCTION 
Abnormal m e t a b o l i s m a n d / o r i n c r e a s e d c o n c e n t r a t i o n s of e g 
ammonia, m e t h a n e t h i o l ( M T ) , f a t t y a c i d e , and ΐ - a m i n o b u t y r i c acid h a v e 
b e e n s u g g e s t e d t o b e involved in t h e biochemical mechamem of h e p a t i c 
e n c e p h a l o p a t h y (HE) D e s p i t e many e f f o r t s , t h e impl icat ions of t h e e e 
changée in the pathogenesis of HE are still obscured,2) 
M o r s than t h i r t y y e a r e a g o . Chal lenger and W a l s h e O ) s u g g e s t e d a 
poasib le r o l e of MT in HE They l e o l a t e d MT f rom t h e urine of a woman 
with г h e p a t i c n e c r o s i s and a s t r o n g f e t o r h e p a t i c u s MT is an 
e x t r e m e l y t o x i c compound, and a s y n e r g i s t i c i n t e r a c t i o n of MT with 
ammonia and f a t t y a c i d s in inducing coma hae b e e n d e m o n s t r a t e d ( 4 ) 
V o l a t i l e sulfur compounds w e r e found t o b s e l e v a t e d in t h e b r e a t h of 
p a t i e n t s with s e v e r e l iver d i s e a s e ( 3 , 5 - 7 ) Doizaki and 2 і е ( ) 
d e v e l o p e d a m e t h o d f o r m e a s u r i n g MT in b l o o d , b a s e d upon a q u a n t i t a ­
t i v e r e c o v e r y of t h i s m s r c a p t a n f r o m b l o o d by using zinc and a d d 
Applying t h i s zinc and acid m e t h o d , t h r e e d i f f e r e n t g r o u p s ( 9 - 1 1 ) 
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s h o w e d t h a t t h s b l o o d l e v e l s of MT w e r e e l e v a t e d in p a t i e n t s with HE. 
H o w e v e r , t h e r e l i a b i l i t y o f t h i s zinc and acid m e t h o d is a t l e a s t 
d o u b t f u l , b e c a u s e t h e s e t h r e e g r o u p e r e p o r t e d v e r y d i f f e r e n t v a l u e s 
o f MT in normal humane and a l e o in p a t i e n t e w i t h HE. When w e a p p l i e d 
t h i s m e t h o d . i t w a s u n v a r y i n g l y u n e u c c e s s f u l ( 1 2 ) . In a r e c e n t 
р а р г ( І З ) , w e s h o w e d t h a t m o r e t h a n 8 0 % of MT. when a d d e d t o b l o o d . 
b e c a m e o x i d i z e d by e r y t h r o c y t e e . r e s u l t i n g in a s p l i t t i n g of t h e 
c e n t r a l c a r b o n - s u l f u r bond. T h e s e r e s u l t s d e m o n s t r a t e d t h a t MT a d d e d 
t o b l o o d can n e v e r b e q u a n t i t a t i v e l y r e c o v e r e d a s MT. It w a s 
t h e r e f o r e concluded t h a t t h e r o l e of MT in HE should b e r e i n v e s t i ­
g a t e d by using nsw m e t h o d e f o r m e a s u r i n g an e x p o s u r e t o MT. 
R e c e n t l y ( 1 4 ) , w e h a v e d e s c r i b e d new m e t h o d e f o r m e a s u r i n g mixed 
d i s u l f i d e s of MT in s e r u m and urine of humans. Oral methionine 
a d m i n i e t r a t i o n r e e u l t e d in an i n c r e a s e in MT m i x e d d i s u l f i d e s c a u s e d 
by an endogenous e x p o s L r e t o MT. 
In t h i s p a p e r we d e m o n e t r a t e t h a t an e x p o s u r e of r a t s t o MT (via 
inhalat ion o r i n j e c t i o n into t h e caecum) r e s u l t s in an i n c r e a s e in 
t h e l e v e l s o f MT m i x e d d i s u l f i d e s . M e a s u r e m e n t of MT mixed disulf ides 
is u s e d t o d e t e r m i n e t h e r o l e of MT in HE in t w o animal modele of 
l i v e r f a i l u r e : in d o g s s u f f e r i n g f r o m HE due t o chronic l i v e r 
d y s f u n c t i o n , and in r a t e w i t h HE due t o fulminant h e p a t i c f a i l u r e 
induced by l i v e r iechemia. Plasma ammonia w a s a l s o m e a s u r e d in t h e s e 
animale t o i n v e s t i g a t e t h e p o s s i b i l i t y of t h s s u g g e s t e d s y n e r g i s m 
b e t w e e n ammonia and methanethiol(4). 
MATERIALS ANO METHODS 
MT. d l m e t h y l e u l f i d e . and d i m e t h y l d i e u l f i d e w e r e o b t a i n e d f r o m 
M e r c k ( D a r m s t a d t . FRG). D i t h i o t h r e i t o l came f r o m Sigma ( S t . Louie. 
USA). Chemicals w e r e of a n a l y t i c a l p u r i t y , u n l e s s o t h e r w i s e s p e c i ­
fied. 
Analyees 
Ammonia w a s m e a s u r e d in EOTA-plasma f r o m d o g s and r a t s , using a 
c o m m e r c i a l l y a v a i l a b l e e n z y m a t i c m e t h o d ( M o n o t e s t , B o e h r i n g s r . M a n n ­
heim, FRG). C r e a t i n i n e w a e a n a l y z e d by a e t a n d a r d l a b o r a t o r y t e c h ­
nique. S u l f a t e w a e m e a s u r e d u e m g t h e m e t h o d o f Lundquiet e t al.(15). 
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The MT mixed disulfides in serum (protsm-S-S-CHs and X-S-S-СНз) 
and in urine (X-S-S-СНз) were measured by conversion to MT by means 
of dlthlothreitol as described before(14.). The composition of MT 
mixed disulfides has been discussed elsewhere(14). The released 
gassous MT was measured using a Packard gas Chromatograph, t y p e 429 
(Packard-Becker, Delft. The Netherlande), supplied with a eulfur-
spscific flams photometric detector (Packard, model 906). Further 
details with reference to meaeurement and trapping of MT. dimethyl-
eulflde, and dimethyldisulfide on Тепах trap tubes have been descri­
bed bsfors(7,12.16). 
Experiments with rats 
In all experimente male Wistar r a t e were used The r a t e had f r e e 
access to food and water. The experiments in the r a t s followed the 
National Research Council's criteria for the care and use of 
laboratory animals in research. 
EXPOSLTS to MT 
Group A. Eight r a t e (251 ±5 o. mean ±SD) were cannulated in the 
aorta via the femoral a r t e r y . Three days a f t e r the operation the r a t s 
were separately put in large gas-tight metabolic cages. After ssven 
days the r a t s were exposed to a non-comatose concentration of MT (30 
umol/l air) via the inspired air. After 150 mm. the exposure to MT 
was stopped by replacing the MT containing air of the metabolic cage 
by fresh air. Blood samples (0.5 ml) were obtained via the cannula 
juet before and at 15, 45, 105, 195, 315 and 1440 mm a f t e r the s t a r t 
of the MT exposure. After blood-sampling the cannula was fluehed with 
0.5 ml salins. The ealine contained heparin (5 mg/ml) to prevent 
obstruction of the cannula. Urine was collected in 24-hour portions. 
Control urine eamplee were obtained the day before the MT exposure. 
Group B. Six r a t e (233 ±5 g. mean ±SD). which were cannulated in 
the aorta ae described above, were expoeed to gaseous MT via the 
caecum. On the day of the experiment the animals were anesthesized by 
intraperitoneal sodium pentobarbital (60 mg/kg body weight). After 
laparotomy. MT (48 umol/rat) wae injected into the upper caecum as a 
gas via a very thin needle (outside diameter of 0.4 mm). Leakage of 
gaeeoue MT out of the caecum was negligible, ae could easily be 
determined by smell. Blood samples (0.7 ml) were taken via the 
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cannula just prior to and at 2, 10 and 30 min after MT Injection. 
After sampling, the cannula was flushed with 0 5 ml ealine containing 
5 mg heparin/ml 
Group C. Five ra ts (273 ±13 a. mean ±SD) were anestheeized by 
intraperitoneal pentobarbital. An endotracheal tube wae placed and 
the rat received artificial respiration via a pressure-cycled respir-
ator. After laparotomy, MT wae injected in the caecum in a concentra-
tion of 16 umol/rat. The air expired by the rat was led through Tenax 
trap tubes(14) during 0 5 to 2 mm Control trap tubes, which were 
placed after the trap tubes, showed negligible break-through of the 
volatile sulfur compounds from the trap tubes The trap tubes were 
replaced with freeh duplicates within seconde, without lose of 
expired air. The volatile eulfur compounds MT, dimethylsulfide, and 
dlmethyldieulfide present in the air expired by the rat were all 
captured onto the Tsnax trap tubas After trapping, the tubes were 
etored at -196°C intil analyees(14.15). 
Liver ischemia 
Group 0. In six ra ts (220-230 g) acute liver ischemia was 
induced by the following method On the f i rs t day a blood sample (2 
ml) was taken and a portocaval shunt was made according to Lee and 
Fischer(17) under ether anaesthesia. A ligature was placed around the 
celiac trunk. Two days af ter the operation acute liver ischemia was 
Induced by tightening the wire around the celiac trunk A blood 
sample was taken just before, and othsr samples wsrs taken at 4 and 8 
hotre after liver ischemia. For further details sss rsf IB 
Experiments with dogs 
The experiments in the dogs followed the National Research 
Council'e criteria for the care and use of laboratory animals In 
rsssarch. 
The 19 doge, which were suffering from HE dus to chronic liver 
dysfunction, were epontaneously diseased animals that had bsen 
referred to the department of Small Animal Medicine, University of 
Utrecht. Ten of theee doge had an inborn portocaval shunt, 4 suffered 
from clrrhoeis, 2 from chronic hepatitis, 1 from necroeis of the 
liver, 1 from hepatic phosarcoma, and 1 acquired porto-systemlc 
collateral circulation due to portal vein thromboeis. The animals did 
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n o t r e c e i v e any m e d i c a t i o n . Blood s a m p l e s w e r e t a k e n by jugular 
v e n i p u n c t u r e and ur ine w a e c o l l e c t e d o v e r 24 h o u r s . The d o g s with HE 
w e r e c o m p a r e d w i t h 19 h e a l t h y c o n t r o l d o g s in which p h y s i c a l 
e x a m i n a t i o n and plasma c o n c e n t r a t i o n s of alanine and a e p a r a g i n e 
a m l n o t r a n s f e r a s s . and alkaline p h o s p h a t a s e r e v e a l e d no indication f o r 
liver dysfinction. 
Evaluation of HE 
The l e v e l s of HE f r o m i t s f i r s t s i g n s t o d e e p coma w e r e g r a d e d 
as follows: 
S t a g e I mild lethargy. 
S t a g e II : d e c r e a s e d m o t o r a c t i v i t y , p o o r c o n t r o l of p o s t u r e and 
dimiehed r e s p o n s e t o painfull stimuli. 
Stage III: г a t a x i a , no righting r e f l e x . 
Stage IV coma. 
S t a t i s t i c a l a n a l y s e s w e r e p e r f o r m e d ueing Wilcoxon's t w o s a m p l e 
t e a t (P) and W i l c o x o n ' s p a i r e d rank t e s t ( P ' ) . Mean v a l u e s ±SEM a r e 
given. 
RESULTS 
Rats 
Exposure via the inspired air (group A). 
Eight r a t e w e r e e x p o s e d t o a n o n - c o m a t o g e n i c d o s e of 3 0 umol 
MT/I air f o r 1 5 0 mm. A f t e r 4 5 mm t h e s e r a t e s h o w e d a s i g n i f i c a n t 
(P' <0.01) mean i n c r e a s e in MT mixed d i s u l f i d e s in s e r u m of 2 9 t i m e s 
t h e mean u n e x p o s e d l e v e l of 0.10 ± 0 . 0 1 umol/l (Fig 1). In u r i n e , 
which w a s c o l l e c t e d on t h e day of MT e x p o s u r e , t h e mean c o n c e n t r a t i o n 
of MT mixed d i s u l f i d e s d e m o n s t r a t e d a e i g m f i c a n t (P' <0.01) I n c r e a e e 
of 2.2 t i m e e t h e mean u n e x p o s e d l e v e l of 6 . 6 ±0.B mmol/mol c r e a t i n i n e 
(Fig. 2 ) . The mean s u l f a t e c o n c e n t r a t i o n In urine a l s o i n c r e a s e d 
s i g n i f i c a n t l y (P' < 0 . 0 1 ) , viz. 1. t i m e s t h e u n e x p o s e d l e v e l of 9.4 
±0.9 mol/mol creatinine (Fig. Э). 
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Fig. 1. Mean c o n c e n t r a t i o n s (±SEM) of MT mixed dieulf ides in serum of 
θ r a t e which were e x p o s e d t o a non-comatogenic dose of MT (30 μπιοΙ/Ι 
air) for 150 mm via the inspired a r (group A). 
Fig. 2. Mean c o n c e n t r a t i o n s (±SEM) of MT mixed dieulf ides in urine of 
θ r a t e which w e r e e x p o s e d t o a non-comatogenic dose of MT (30 umol/l 
air) f o r 150 mm via the inspired air on day zero (group A). 
0 I 2 3 4 5 6 7 
Fig. Э. Mean c o n c e n t r a t i o n s (±SEM) of s u l f a t e in urine of В r a t s 
which w e r e e x p o s e d t o a non-comatogenic dose of MT (30 umol/l air) 
for 150 mm vja the Inspired air on day zero (group A). 
102 
Exposire vla the caecum (ф-оир θ and С). 
In 6 anestheslzed r a t s , MT (40 u m o l / r a t ) was i n j e c t e d in ae a 
gas Into the upper caecum (group B). In a p i lot s t u d y we o b s e r v e d 
t h a t In r a t e the comatogenic dose of In t raper i toneal administered MT 
Is at least 55 umol f o r r a t s with an average weight of 250g. It may 
be e x p e c t e d t h a t in caecum a larger dose of MT can be i n j e c t e d b e f o r e 
t h e animal becomes c o m a t o e e , because of the d e t o x i f y i n g s y s t e m of the 
g u t . In th is exper iment the comatogenic dose of MT could not be 
establ ished because the exper iment was p e r f o r m e d with anestheaized 
r a t s . Two min a f t e r MT in ject ion the mean c o n c e n t r a t i o n of the MT 
mixed dlsulf idee in eerum had increased signif icant ly (Ρ' <D.05) 
(Fig. 4). Ten min and 30 min a f t e r MT in ject ion, the i n c r e a s e . 
although stil l significant (P' <0.05) was much smaller. 
Fig. 4. Mean c o n c e n t r a t i o n s (±SEM) of MT mixed disulf ides in serum of 
6 r a t s which w e r e e x p o s e d t o a non-comatogenic dose of MT (48 
umol/rat) via the caecum (group Θ). 
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Fig. 5. Mean c o n c e n t r a t i o n e (±SEM) of MT( • ), dimethyleulf idef φ ). and 
dimethyldieulfide( • ) in the e x p i r e d air of 5 r a t s which w e r e e x p o s e d 
t o a non-comatogenic doee of MT (16 u m o l / r a t ) via the caecum (group 
C). 
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The mean c o n c e n t r a t i o n s of MT, d lmethylsul f ide and d l m e t h y l -
d isul f ide in t h e air e x p i r e d by t h s f i v s r a t s (group C) which w e r e 
e x p o s e d t o 16 umol MT v ia t h e caecum. I n c r e a s e d In all animals f r o m 
below t h e d e t e c t i o n limit up t o v e r y high l e v e l s (Fig 5 ) . Ths MT 
l é v e l e fo l lowed more or l e s s t h e sams p a t t e r n as t h a t of MT mixed 
d leu l f ides in serum ( e e e group B). A f t e r a f a s t i n c r e a s e , the mean MT 
c o n c e n t r a t i o n d e c r e a s e d v e r y f a s t and could hardly be d e t e c t e d a f t e r 
10 mm. M o d e r a t e l y e l e v a t e d c o n c e n t r a t i o n s o f d lmethylsul f ide and 
d imethyld isul f ids w e r e s t i l l o b s e r v e d 20 mm a f t e r MT in jec t ion . 
Table 1. Mean c o n c e n t r a t i o n s of methaneth io l mixed dieul f ides and 
ammonia (mean ±SEM, n=6) in ssrum of r a t s b e f o r e and a t d i f f e r e n t 
s t a g e s of liver dissass (group D). 
RATS 
METHANETHIOL MIXED 
DISULFIDES (nmol / l ) 
AMMONIA 
(umol / l ) 
Normal 
P o r t o c a v a l ehunt 
4 houre a f t e r l iver ischemia 
θ h o u r s a f t s r l iver ischemia 
0.10 ± 0 . 0 1 
0 0 9 ± 0 . 0 1 
0.10 ± 0 . 0 1 
0 11 ± 0 . 0 1 
4 2 . 7 ± 3 . 5 
120 ±10» 
0 ±99«'b 
10Э ±174«.ь 
a = ρ' <0.05 v e r s u s normal r a t s 
b = p' <0.05 v e r s u s r a t s with a p o r t o c a v a l shunt 
Acute HE due t o liver ischemia (group • ) . 
Among t h e r a t s w i t h fulminant h e p a t i c f a i l u r e due t o l i v s r 
ischemia t h e g r a d e of HE v a r i e d H o w e v e r , a t 4 h o u r s a f t e r ischemia 
all r a t s had a t l e a s t HE g r a d s I, and a t θ h o u r s a f t s r ischemia t h e 
g r a d e of HE v a r i e d b e t w e e n g r a d e II and g r a d e IV. Placement of a 
p o r t o c a v a l shunt did n o t r e s u l t in any change o f t h e mean c o n c e n t r a ­
t i o n of MT mixed d i s u l f i d e s m s e r u m (Table 1). When s u f f e r i n g f r o m 
HE due t o l iver lechemia t h e mean l e v e l of MT mixed d i s u l f i d e s did 
n o t d i f f e r s i g n i f i c a n t l y f r o m t h a t of t h s r a t s j u s t b e f o r e lechemia, 
nor f r o m t h a t of normal r a t s (Table 1). Ths mean c o n c e n t r a t i o n of 
ammonia i n c r e a s e d s i g n i f i c a n t l y ( p ' < 0 . 0 5 ) in b l o o d of r a t e w i t h a 
p o r t o c a v a l shunt when c o m p a r e d with t h a t b e f o r e t h e o p e r a t i o n . In 
r a t s w i t h HE t h e mean c o n c e n t r a t i o n s of ammonia s h o w e d a l a r g e and 
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s i g n i f i c a n t (ρ* < 0 . 0 5 ) I n c r e a s e b o t h a t 4 and a t θ h o u r s a f t e r l iver 
ischemia (Table 1). 
Doge 
The d o g e , which w e r e s u f f e r i n g f r o m HE due t o chronic h e p a t i c 
d y s f u n c t i o n , w e r e d i v i d e d into t w o g r o u p e - one g r o u p of 9 d o g e with 
g r a d e l-ll and a n o t h e r g r o u p of 10 d o g e with g r a d e l l l-IV. The mean 
c o n c e n t r a t i o n of MT m i x e d d i e u l f i d e s in e e r u m of b o t h g r o u p s of d o g e 
with HE g r a d e l-ll and with g r a d e ll l-IV did n o t d i f f e r s i g n i f i c a n t l y 
f r o m t h a t of t h e 19 c o n t r o l d o g s (Table 2) The mean c o n c e n t r a t i o n of 
MT mixed d i s u l f i d e s In urine of t h e d o g e with g r a d e l-ll a s well a s 
with g r a d e l l l- IV did n o t d i f f e r s i g n i f i c a n t l y f r o m t h a t in ur ine of 
the control dogs (Table 2). 
The mean c o n c e n t r a t i o n s of ammonia in s e r u m of b o t h g r o u p s of 
dogs w i t h g r a d e l-ll and with g r a d e lll-IV w e r e s i g n i f i c a n t l y (p 
<0 0G1) higher t h a n t h e mean value of ammonia in t h e c o n t r o l d o g s 
(Table 2) The mean ammonia c o n c e n t r a t i o n in d o g s w i t h g r a d e l-ll w a e 
n o t s i g n i f i c a n t l y d i f f e r e n t f r o m t h a t in d o g s w i t h g r a d e ll l-IV 
Table 2. M e a n c o n c e n t r a t i o n s of m e t h a n e t h l o l mixed d i s u l f i d e e and 
ammonia in c o n t r o l d o g s and in d o g s s u f f e r i n g f r o m h e p a t i c e n c e ­
phalopathy grade l-ll and grade lll-IV. 
DOGS 
C o n t r o l s (n=19) 
G r a d e l-ll n = 9 ) 
G r a d e lll-IV(n=.10) 
METHANETHIOL MIXED 
DISULFIDES 
SERUM 
Oimol/I) 
0 . 2 8 ±0 0 3 
0 . 3 8 ±0.10 
0.42 ±0.12 
URINE 
(mmol/mol c r e a t i n i n e ) 
1 5 ± 0 2 
1.7 ±0.5 
1.4 ±0.3 
AMMONIA 
SERUM 
( u m o l / l ) 
2 3 ± 2 
1 9 0 ± 3 7 · 
2 3 9 ± 2 1 · 
a • ρ <0.001 v e r s u s control doge 
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DISCUSSION 
According t o Z i e v e ( 4 ) , 7 0 umol MT/I air ie t h e dose a t which 50% 
of t h e e x p o s e d r a t s become c o m a t o s s . This r e s u l t is in a g r e e m e n t with 
our unpublished p i lo t é t u d i é e on the c o m a t o g e m c e f f e c t s of MT. An 
e x p o s u r e of r a t s t o a non-comatogenic d o s e of MT v la t h e inspired air 
(g roup A) or v ia t h s caecum (group B) r e e u l t e d in an increase in t h e 
MT mixed disul f ides in serum as well a s in ur ine . T h e r e f o r e , t h e 
m s a e u r s m e n t of t h e s e MT mixed dieul f ides is a good e s t i m a t e f o r an 
e x p o s u r e t o MT and can be ueed f o r t h e I n v e s t i g a t i o n of the r o l e of 
MT in the pathogeneeis of HE i. 
I t has been r e p o r t e d t h a t i n t r a p e r l t o n e a l l y admin is te red MT is 
ox id ized t o s u l f a t s ( 1 9 , 2 0 ) In our e x p e r i m e n t s an e x p o s u r e t o MT 
r e s u l t e d In a e igmf ican t increase in s u l f a t e c o n c e n t r a t i o n s in 
u r ine , indicating t h a t MT admin is tered v i a t h e inspi red air is indeed 
p a r t l y ox id ized t o e u l f a t e (group A). The e x p o s u r e of r a t s (group C) 
t o a non-comatogenic d o s e of MT v ia t h s caecum r e s u l t e d in a highly 
s ign i f icant e l e v a t i o n of MT. but a lso of d imethylsul f ide and d i -
msthyld isul f ids In t h e air e x p i r e d by t h e r a t . Obviously, d imethy l -
su l f ide and dlmethyldisul f ide a r e f o r m e d f r o m MT in v i v o . Besides t h e 
caecum and t h e l i ver (21 ) , a lso blood may c o n t r i b u t e t o the m e t h y l a -
t ion of MT into d imsthylsul f ide(13) . The ox ida t ion of MT into 
dlmethyldisul f ide wae not o b e e r v e d in b lood(13) . and t h e r e f o r e most 
likely takes place in ths caecum or in the liver. 
In t h e r a t s with HE caused by fulminant h e p a t i c fa i lure induced 
by l iver ischemia no i n c r e a s e in t h e c o n c e n t r a t i o n s of MT mixed 
d isu l f ides in serum was o b s e r v e d . In ur ine and in serum of dogs 
s u f f e r i n g f rom HE caused by chronic l iver d y s f u n c t i o n , the mean 
l e v e l s o f MT mixed d isul f ides did also no t i n c r e a s e e igmf icant ly In 
c o n t r a s t with t h e s e r e s u l t s , t h e mean c o n c e n t r a t i o n s of ammonia 
showed a la rge i n c r e a s e in r a t s with a c u t e HE ae well as in dogs with 
HE due t o chronic l iver dys funct ion . From our r e s u l t s it must be 
concluded t h a t MT d o e s not play a s igni f icant r o l e in t h e p a t h o -
genesis of HE In these two animal HE models. 
1. Ths c o n c e n t r a t i o n of t h e s o - c a l l s d acid- labi le MT f r a c t i o n , ae 
d e s c r i b e d p r s v i o u s l y ( 1 2 ) , was not r e l a t e d t o an e x p o s u r e of r a t s 
t o MT. This ind ica tes t h a t th ia ac id- labi le MT f r a c t i o n ie 
preeumably not a metabolite of MT. 
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P r e v i o u s l y , we descr ibed(14 ) t h a t o r a l methionine a d m i n i s t r a t i o n 
(0.1 0 / k g body w e i g h t ) t o human v o l u n t e e r s r e s u l t e d In an endogenous 
e x p o s u r e t o MT. This e x p o s u r e t o MT r e s u l t e d In a marked i n c r e a s e In 
MT and d imethy leuf ide in b r e a t h , and in MT mixed d isul f ides in s e r u m 
ae well as in u r ine , resembl ing t h e r e s u l t e obta ined in th is s t u d y 
wi th r a t s e x p o s e d t o MT. The human v o l u n t e e r s did not d e v e l o p any 
signs o f e n c e p h a l o p a t h y . R e c e n t l y , we have d e e c r i b e d a 2 0 - f o l d 
e l e v a t i o n of d imethylsul f lde In t h e e x p i r e d air and a 1 0 0 - f o l d 
e l e v a t i o n o f MT mixed disul f ides in serum and urine of a p a t i e n t with 
a de f ic iency in h e p a t i c methionine a d e n o s y l t r a n s f e r a e e ( 2 2 ) This 
we l l -documented p a t i e n t ehowed no eigne of e n c e p h a l o p a t h y , and 
b e e i d e e his de f ic iency t h e p a t i e n t a p p e a r e d t o be clinically normal 
and h e a l t h y . Obviously , an e l e v a t i o n of MT mixed d isul f ides up t o 
c o n c e n t r a t i o n s 100 t imes the normal c o n c e n t r a t i o n in hea l thy p e r s o n s 
does not lead t o encepha lopathy . These f indings, t o g e t h e r wi th t h o s e 
obta ined f r o m our animale é t u d i e s in t h e p r e s e n t s t u d y s u g g e s t t h a t 
t h e r o l e o f MT in t h e p a t h o g e n e s i s of HE ie probably insignif icant 
Even some s y n e r g i s t i c i n t e r a c t i o n b e t w e e n ammonia and MT is m o s t 
likely of no i m p o r t a n c e in our e x p e r i m e n t a l animal models of l i ver 
fa i lu re . Whether or not this conclusion a lso holds t r u e f o r humans 
suffering from HE etili neede t o be veri f ied 
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ABSTRACT 
Methanethiol (MT) mixed d isu l f ides, methionine. 4 - m s t h y l t h i o - 2 -
o x o b u t y r a t e . and ammonia were measured In p a t i e n t s wi th d i f f e r e n t 
s t a g e s of hepat ic encephalopathy (HE), in p a t i e n t s with chronic renal 
fa i lure, and In healthy s u b j e c t s . In p a t i e n t a with HE the mean 
c o n c e n t r a t i o n s of all t h e s e compounds w e r e e l e v a t e d . The e levat ions 
of the levels of MT mixed disulf ides in t h e s e p a t i e n t s w e r e small and 
p a r t l y due t o a decreased renal funct ion in t h e s e p a t i e n t s . In 
addit ion, between the d i f f e r e n t g r a d e s of HE no aignif icant d i f f e r ­
ences in the levels of MT mixed disulf ides w e r e found. As decr lbed 
p r e v i o u s l y , much higher c o n c e n t r a t i o n s of MT mixed disulf ides w s r s 
o b s e r v e d In healthy s u b j e c t s a f t e r ora l methionine loading and in a 
p a t i e n t with a def iciency in methionine a d e n o s y l t r a n s f s r a s e , wi thout 
causing encephalopathy. It is t h e r e f o r e concluded t h a t the r o l e of MT 
in the pathogenesis of HE is minor, if not insignif icant, s v s n in 
сэ HE may be mediated through a s y n e r g i s t i c i n t e r a c t i o n between MT 
and ammonia. 
In th ie s t u d y , we aleo produce evidence t h a t the increase in MT 
mixed disulf ides in p a t i e n t s with l iver disease is probably due t o 
degradat ion of methionine via the transaminat ion pathway and is 
probably not the r e s u l t of methionine degradat ion in the gut. 
F u r t h e r m o r e , evidence le prov ided t h a t . besides the methionine 
t r a n s s u l f u r a t i o n pathway, the transaminat ion pathway is also impaired 
in patients with HE. 
INTRODUCTION 
Mors than 30 y e a r s ago Challenger and Walahed) i s o l a t e d MT f rom 
the urine of a p a t i e n t with massive l i vsr csl l n e c r o s i s and a s t r o n g 
f e t o r h e p a t i c u e , which resembled the t y p i c a l smsll of the urine of 
the p a t i e n t . MT is a v e r y t o x i c compound and low c o n c e n t r a t i o n s can 
cause r e v e r s i b l e coma(2,3). These findinge have led t o t h e h y p o t h e s i s 
t h a t MT may play a r o l e in the p a t h o g e n e s i s of HE. This h y p o t h e s i s 
was s u p p o r t e d by the o b s e r v e d s y n e r g i s t i c t o x i c e f f e c t s of MT with 
ammonia and f a t t y acide(3). These t o x i c e f f e c t s may even be increased 
in the presence of liver damaged). 
L i t t l e Is known about the p r o c e e e e e in the body leading t o the 
f o r m a t i o n of MT. It is general ly bel ieved t h a t MT is f o r m e d f r o m 
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Fig 1 Catabolism of methionine 
methionine. In case of an impaired liver function, msthiomns induced 
coma In r a t e , dogs, and топкеуэ(5- ). In cirrhotic patients who 
previously endured HE, methionine can induce neurological d e t e n o r a -
tionO). MT formation may proceed through degradation of methionine 
into MT in the gut(4,1Q) or through a cellular mechanism, viz 
catabolism of methionine via the transamination pathway In this 
l a t t e r pathway (Fig. 1) methionine is f i r s t transammated into 4 -
methylthio-2-oxobutyrate. Oxidative decarboxylation of 4-methylthio-
2-oxobutyrate results in the formation of 3-methylthiopropionate. and 
MT can be formed from thie latter compound(11,12). 
MT ie a r e a c t i v e agent and it is t h e r e f o r e difficult to d e t e c t 
in body fluids. Doizaki and 2іе (1Э) developed a method for the 
measurement of MT in blood by using zinc and acid Using this method 
three different groups of investigators have r e p o r t e d increased 
levels of MT in blood of patients suffering from HE(14-16) However. 
the reliability of this zinc and acid method is at least question­
able, because of the finding that the concentratione of MT differed 
at least a 100 fold between theee three groups In experiments with 
labeled MT, we ehowed that the zinc and acid method is unreliable for 
the determination of MT in blood and it was concluded that new 
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t e c h n i q u e s had t o b e d e v e l o p e d f o r t h e m e a s u r e m e n t of MT in body 
f l u l d s d ? ) . We r e c e n t l y d e m o n s t r a t e d t h a t t h e c o n c e n t r a t i o n of MT 
mixed d l e u l f i d e s in s e r u m can b e u s e d a s a r e l a t i v e e s t i m a t e f o r an 
sxposLre t o ΜΤ(11.1β-20). 
To s t u d y t h e r o l e of MT in t h e p a t h o g e n e e i s of HE, w e m e a s u r e d 
t h e l e v e l s of MT m i x e d disulf ides In s e r u m of p a t i e n t e w i t h v a r y i n g 
g r a d e s o f HE. In o r d e r t o I n v e s t i g a t e w h e t h e r HE is m e d i a t e d by a 
e y n e r g i s m b e t w e e n MT and ammonia(3,4) t h e l e v e l s o f ammonia w e r e also 
d e t e r m i n e d in t h e s e p a t i e n t e . The c o n c e n t r a t i o n e of MT m i x e d d i s u l ­
f i d e s in t h e s e p a t i e n t e a r e c o m p a r e d with t h o s e in normal s u b j e c t s , 
and w i t h t h o s e in p a t i e n t s with chronic r e n a l f a i l u r e and w i t h t h o s e 
d e s c r i b e d in p r e v i o u s p a p e r s ( 1 1 , 1 B ) , c o n c e r n i n g normal s u b j e c t s a f t e r 
o r a l methionine loading, and a p a t i e n t with h y p e r m e t h m n i n e m i a due t o 
hepatic methionine a d e n o s y l t r a n s f e r a s e deficiency. 
For t h e s t u d y of t h e mechanism leading t o MT f o r m a t i o n , viz. v i a 
i n t e s t i n a l methionine d e g r a d a t i o n and v i a t h e methionine t r a n s a m i n a ­
t i o n p a t h w a y , w e a l e o m e a s u r e d t h e c o n c e n t r a t i o n s of methionine and 
4 . - m s t h y l t h i o - 2 - o x o b u t y r a t e in t h e s u b j e c t s of t h e p r e s e n t s t u d y . 
THE PATIENTS 
P a t i e n t s w i t h v a r y i n g g r a d e e of HE w e r e s t u d i e d i r r e s p e c t i v e of 
t h e e t i o l o g y of t h e l i v e r d i s e a s e . The f i r s t g r o u p of p a t i e n t s w a s 
a d m i t t e d t o t h e U n i v e r s i t y of Vienna, A u s t r i a (Group A). The s e c o n d 
g r o u p of p a t i e n t s (Group B) w a s f r o m m u l t i c s n t s r s in The N e t h e r l a n d s 
( U n i v e r e i t y H o s p i t a l Ni jmsgsn, U n i v e r s i t y H o s p i t a l Di jkzigt H o t t e r -
dam, Academic Medical C e n t r e A m e t e r d a m and Ziekenhuis Z i e k e n z o r g 
Enschede). E n c e p h a l o p a t h y w a s g r a d e d a c c o r d i n g t o Conn e t al ( r e f 
1 0 , p. 5 - Θ ) . HE w a s e v a l u a t e d b e f o r e m e a e u r i n g MT m i x e d d i s u l f i d e s , 
4 - m e t h y l t h l o - 2 - o x o b u t y r a t e , methionine and ammonia. 
Group A. Blood s a m p l e s f r o m t h e p a t i e n t s with HE w e r e o b t a i n e d 
f r o m a c a t h e t e r p l a c e d in t h e s u p e r i o r v e n a c a v a . Blood s a m p l e s f r o m 
p a t i e n t s w i t h l i v e r d i e e a e e but w i t h o u t e igne of e n c e p h a l o p a t h y , and 
p a t i e n t s w i t h c h r o n i c r s n a l f a i l u r e w e r e o b t a i n e d f r o m t h e cubital 
vein. Some c h a r a c t e r i s t i c s of t h e p a t i e n t s with l i v e r d i s e a s e a r e 
shown in Table 1. In thie group 3 3 p a t i e n t e s u f f e r e d from HE: 
- 9 p a t i e n t s w i t h HE g r a d e I: 7 w i t h chronic l i v e r d i s e a s e ( 3 
alcoholic c i r r h o s i s , 3 c r y p t o g e n i c c i r r h o s i s , and 1 c i r r h o e i e due t o 
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h e p a t i t i s В) and 2 w i t h fulminant h e p a t i c 
h e p a t e c t o m y and 1 Amanita phalloïdes poieomng). 
- 6 p a t i e n t s wi th HE g r a d e II: 5 with chronic 
alcoholic c i r r h o s i e . 3 c r y p t o g e n i c c i r r h o s i s ) and 
hepatic failLre (alcohol hepati t is); 
- 7 p a t i e n t s with HE g r a d e I I I : 6 wi th chronic 
alcoholic c i r r h o e i e , 4 c r y p t o g e n i c c i r r h o e i e , and 1 
and 1 with fulminant hepatic failLre (following hepatectomy); 
-11 p a t i s n t s with g r a d e IV· 6 wi th chronic l iver d i e e a s e (5 alcoholic 
c i r r h o s i s and 1 c r y p t o g e n i c c i r rhos is ) and 5 wi th fulminant hepa t ic 
fa i lu re (3 h e p a t i t i s B. 1 ha lothane, and 1 Amanita phal loidee 
poisoning), 
fa i lu re (1 following 
l iver d ieease (2 
1 with fulminant 
l iver d isease (1 
Wilson d i s e a s e ) 
Jsb\e 1. Some character ist ics of the patients of group A. 
Grade of encephalopathy 
Number 
Female /ma le 
20 
9 /11 
g 
6 / 3 
6 
2 / 4 
III 
7 
4 / 3 
IV 
11 
6 / 5 
Normal 
Values 
Age(yeare) 
Mean ±SD 
Range 
5 0 ±13 
(21-69) 
44 ±13 
(29-67) 
46 ±16 
(21-65) 
5 3 ±12 
(32 -67 ) 
4Θ ± 2 0 
( 6 - 7 2 ) 
Bilirubmedimol/I) 
Mean ±SD 125 ±166 
Range (5-5B1) 
159 ±193 
(24-513) 
4 4 4 ±154 
(17-581) 
3 7 6 ±256 2 9 0 ±171 
( 5 6 - 6 6 7 ) (101-564) (3-17) 
ASAT(U/I) 
Mean ±50 
Range 
241 ±528 
( 5 - 2 1 5 0 ) 
4 0 ±35 
(10-111) 
B8 ±44 
( 5 0 - 1 4 7 ) 
151 ±186 531 ± 7 3 2 
( 1 0 - 5 2 6 ) ( 1 5 - 2 2 5 7 ) « 1 8 ) 
ALAT(U/I) 
Mean ± 5 0 
Range 
3 7 5 ± 9 0 0 
( 4 - 3 4 5 0 ) 
3 7 ±42 
( 2 - 1 1 9 ) 
5 0 ±42 
(7-103) 
8 3 ± 8 8 6 4 0 ±823 
( 1 5 - 2 4 1 ) ( 9 - 2 4 6 4 ) « 2 3 ) 
Alk. Phosph.(U/l) 
Mean ±50 2 6 0 ±156 168 ±76 201 ±55 
Range ( 5 8 - 6 8 2 ) ( 8 0 - 2 9 4 ) (111-267) 
4 0 0 ± 4 6 7 2 8 9 ±285 
(109-1405) (98-1100) « 1 7 0 ) 
t-GT(U/l) 
Mean ±SD 
Flange 
64 ±51 
(4-187) 
30 ±17 
(14-63) 
9 0 ±94 
(16-265) 
81 ±112 4 6 ±33 
( 1 5 - 3 3 2 ) (11-95) ( 4 - 2 8 ) 
G r e a t mine (μ mol/l) 
Mean ±SD 9 7 ± 5 3 195 ±301 2 5 7 ±212 
Range (18-239) (62-991) ( B 9 - 5 7 5 ) 
Died (X) 3 0 5 0 8 3 
266 ±221 2 4 8 ±186 
(35-637) (35-522) (44-133) 
8 6 8 2 
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Of the 20 p a t i e n t s with l iver disease but wi thout eigne of HE, 
16 s u f f e r e d f r o m chronic l iver dieease (10 with alcoholic c i r r h o e i e , 
2 with c r y p t o g e n i c c i r r h o s i s . 1 with pr imary bi l iary c i r r h o e i e . 1 
with c i r r h o s i s due t o h e p a t i t i s В. and 2 with Wilson dieeaee) and 4 
f rom acute h e p a t l t i e (1 fol lowing e x t e n d e d r i g h t - s i d s d h s p a t e c t o m y 
and Э with Amanita phalloidee poisoning). 
Serum eamplee w e r e also c o l l e c t e d f r o m 10 p a t i e n t s w i t h chronic 
renal fa i lure on hemodialysis (mean creat in ine c o n c e n t r a t i o n about 
500 umol/l). 
Group B. Blood samples were obtained f rom the cubital vein. This 
group contained 21 patients euffering from HE grade I t o IV: 
-12 p a t i e n t s wi th grade l- l l : 11 with chronic l iver d isease (4 
alcoholic c i r r h o s i s , 5 c r y p t o g e n i c c i r r h o s i s , 1 unknown e t i o l o g y , and 
1 pr imary bi l ia iry c i r r h o s i s ) and 1 with fulminant hepat ic fa i lure 
(hepat l t ie non А поп В). Mean creat in ine c o n c e n t r a t i o n in eerum was 
131 ±25 umol/l. 
-9 p a t i e n t s with grade lll-IV: 4 with chronic l iver d isease (1 
c i r r h o s i s due t o h e p a t i t i s B. 1 alcoholic c i r r h o s i s , 1 c r y p t o g e n i c 
c i r r h o s i s . and 1 pr imary bi l iary c i r r h o s i s ) and 5 wi th fulminant 
hepatic fa i lure (1 non А поп В h e p a t i t i s , 1 h e p a t i t i s A, 1 ¡soniazid, 
1 depaklne, and 1 with unknown e t io logy) . Mean creat in ine concen t ra -
tion in eerum amounted to 207 ±104 umol/l. 
Control eerum samples were co l lec ted f rom 12 healthy sub jec t s . 
MATERIALS AND METHODS 
MT was obtained f rom Merck (Darmetadt, FRG). D i th io thre i to l and 
4 -me thy l t h i o -2 -oxobu ty ra te came f rom Sigma (St. Louis, USA) and L-
methionins f rom Bufa Chsmis (Castr icum, The Netherlands). Chemicals 
wers of analytical p j - l t y . 
Analysée 
Ammonia and creat in ine were analyzed by etandard l abo ra to ry 
techniques. Methionine was measured by ion-exchange chromatography 
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(LC 2000 Amino Acid Analyser, Biotronik Wlsssnechaftliche Gerate, 
Munich, FRG). 
The MT mixed disulfides in serum, consisting of protein-S-S-CHa 
and X-S-S-СНз (X yet unknown), were measured through convereion to MT 
by means of dithiothreitol, as previously described (11,18). The 
compoeition of MT mixed disulfides has been discussed elsewhsreCH). 
The released gaseous MT. originating from the MT mixed disulfides, 
was concentrated on Tenax t r a p tubes and measured using a Packard gas 
Chromatograph, type 429 (Packard-Becker. Delft, The Netherlanda). 
supplied with a sulfur-specific flame photometric detector (Packard. 
model 906). Further detalle about the gaschromatographic method are 
given in references 21 and 22. 
Statistical analysis wae performed using Wilcoxon's two sample 
t e e t ( p ) . Mean values iSEM are given. Correlations were calculated 
according to Spearman (p'). 
RESULTS 
Group A. 
The Individual concentrations of methionine (Fig. 2). 4-methyl-
thio-2-oxobutyrate (Fig. 3 ) , MT mixed disulfides (Fig. 4), and 
ammonia (Fig. 5) were measured in serum of this group of patients. 
Their mean concentrations are given in Table 2. 
Methionine and 4-methylthio-2-oxobutyrate 
In the patients with HE grade II, III, and IV of group A. the 
mean methionine concentration wae significantly higher than that in 
normal eubjects (p <0.002, ρ <0.02. ρ <0.002, reepectively). Patiente 
with HE grade IV had also significantly higher valuee than patients 
with liver disease without signs of HE (p <0.002) and patients with 
HE grade I (p <0.02). The patients with HE grade II had significantly 
higher values than those with liver disease without signs of 
encephalopathy (p <0.05). 
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Fig. 2. C o n c e n t r a t i o n s of methionine In s e r u m of c o n t r o l s u b J e c t s ( B ) , 
and of p a t i e n t e w i t h d i f f e r e n t g r a d e s of h e p a t i c e n c e p h a l o p a t h y ( · = 
chronic l i v e r d i s e a s e . • » a c u t e l iver d i s e a s e ) ( g r o u p A). M e a n v a l u e s 
a r e shown by solid b a r e . 
4 methylthio 2 oxobutyrate 
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Flg. 3 . C o n c e n t r a t i o n s o f 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e in в г и т of 
c o n t r o l e u b j e c t s ( a ) , and of p a t i e n t e w i t h d i f f e r e n t g r a d e e o f h e p a t i c 
e n c e p h a l o p a t h y C · = c h r o n i c l iver d i s e a s e , • = a c u t e l i v e r d i s e a s e ) ( g r o u p 
A). Mean values a r e shown by solid bars. 
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Fig. 4. Concentrations of MT mixed dieulfidee in eerum of control 
subjecteC M ). patients with different grades of hepatic 
encephalopathy(#=chronic liver dieease. • =acute liver disease) (group 
A), and patiente with chronic renal failure ( C R F H B ) Mean values are 
ehown by solid bars. 
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Fig. 5. The concentrations of ammonia in serum of control eubjects 
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Table 2. Mean l e v e l s ±SEM of MT mixed d i s u l f i d e s , m e t h i o n i n e , 4 -
m e t h y l t h i o - 2 - o x o b u t y r a t e , and ammonia In h e a l t h y c o n t r o l s . In p a ­
t i e n t s with l i v e r d l e e a e e w i t h o u t e i g n e of HE (HE 0 ) . in p a t i e n t s 
with HE g r a d e I. I I . I I I . and IV ( g r o u p A), and In p a t i e n t s with 
chronic renal f a l l i r e (CFF). 
Normale 
n=12 
HE 0 
n=2Q 
HE I 
n=9 
HE M 
n=6 
HE III 
n=7 
HE IV 
n=11 
CRF 
n=10 
MT mixed 
dieulfides 
(umol/ l ) 
0.21 ± 0 . 0 2 
0 . 3 9 ± 0 . 0 9 
0 . 7 6 ± 0 . 2 5 
0 5 0 ±0.16 
1.26 ± 0 . 4 0 
1.59 ± 0 B6 
0 5 0 ±0 0 7 
M e t h i o n i n e 4 - M e t h y l t h i o -
2 - o x o b u t y r a t e 
(umol/ l ) (wmol/l) 
Ammonia 
( u m o l / l ) 
2 4 ±2 
52 ±11 
344 ±147 
489 ±148 
14 ±2 
0.09 ±0.01 
0.26 ±0 04 
0 49 ±0 18 
0.42 ±0 09 
0 74 ±0.19 
1.16 ±0.38 
0 58 ±0 07 
< 3 0 
40 ±5 
80 ±16 
94 ±21 
99 ±17 
200 ±36 
In eerum of patients with liver disease without signs of 
encephalopathy and in serum of patients with HE (I, II. III. and IV) 
the mean level of 4-methylthio-2-oxobutyrate was significantly higher 
than that in normal controls (p <0.001 for all cases) Patients with 
HE grade II, III, and IV had also significantly higher values of 4-
methylthio-2-oxobutyrate than thoee with liver diseaae without eigne 
of encephalopathy (p <0 0 5 . ρ <0 0 1 . ρ <0 001 . reepectively) No 
eigmficant differencee in the mean valuee of 4-methylthio-2-oxobuty-
r a t e were observed between the different gradee of HE (I, II, III, 
and IV). 
MT mixed disulfides 
The mean concentration of MT mixed disulfides In serum of the 
patiente of group A with HE grade III as well as grade IV was 
elgniflcantly elevated when compared to that of normal eubjecte (p 
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<0.02, and ρ <0.002, respectively) and aleo when compared to that of 
patients with liver disease without signs of encephalopathy (p <0.02, 
and ρ <0.05, respectively). No significant differences were observed 
between normal subjects and patients with HE grade I and II, between 
normal subjects and patients with liver dieease without signs of 
encephalopathy, nor between the different grades of HE (I, II. III. 
and IV). 
To investigate the possible contribution of gastrointestinal 
bleeding to the formation of MT. the levels of MT mixed dleulfides in 
patients suffering from gastrointestinal bleeding were compared with 
those of patiente without gastrointestinal bleeding. Each group was 
subdivided Into a group with HE grade l + ll and into a group with HE 
grade lll+IV. In the group of patiente with HE l + l l , the mean level 
of MT mixed disulfides in patients with gastrointestinal bleeding 
(0.42 ±0.16 umol/l: n=6) did not differ eigmficantly from that of 
patiente without gastrointestinal bleeding (0 Θ1 ±0.24 umol/l: n=9). 
Also among the group with HE lll + IV the mean concentration of MT 
mixed disulfides in patisnts with gastrointestinal bleeding (2.63 
±1.29 umol/l; n=7) was not significantly different from that of 
patlente without gastrointestinal bleeding (0 72 ±0.15 umol/l. n=11). 
In patients with HE grade l + ll + lll+IV, a significant correlation 
was observed between their individuai concentrations of MT mixed 
disulfides and their individual concentrations of 4-methylthio-2-
oxobutyrate (correlation=0 74. p' <0 001) and also between their 
individual concentrations of 4-methylthio-2-oxobutyrate and their 
individual methionine concentrations (correlatlon=0 61, p' <0 001). 
However, no significant correlation was found between their indivi­
dual concentrations of MT mixed disulfides and methionine. Signifi­
cant correlations between MT mixed dieulfides, 4-methylthio-2-oxobu-
t y r a t e and methionine were not present in normal subjects nor in 
patients with liver dieease without эют of HE 
The mean concentration of MT mixed disulfides in serum of 
patients with chronic renal failure was significantly elevated when 
compared to normal subjects (p <0 001) and patients with livsr 
disease without eigne of HE (p <0 01) but did not differ signifi­
cantly from those of patients with HE grade I, II, III. and IV. 
Ammonia 
In patients with liver disease with HE as well ae without signs 
of HE. the mean ammonia concentration was significantly higher than 
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that in normal eubjecte (P <0.D01 for all patients, except for HE II: 
ρ <0.01). In patients with HE grade I, I I. III. and IV the mean 
ammonia level wae significantly higher than in patiente with liver 
disease without signs of encephalopathy (ρ <0.02, ρ <0.D5, ρ <0.01, 
and ρ <0.001. respectively). In patiente with HE grade IV the mean 
ammonia level was significantly higher than in patiente with HE grade 
I (p <0.01), II (p <0.02). and III (p <0.05). No eignificant 
differences were foind between HE grade I. II. and III. 
Group B. 
The individual concentrations of 
thio-2-oxobutyrate (Fig. 7 ) . and MT 
measured in serum of this group of 
tions ars given in Table 3. 
Methionine and 4-methylthio-2-oxobutyratB 
In group θ the patients with HE grade lll-IV had a significantly 
higher mean methionine level than normal eubjects (p <0.001), 
patiente with liver disease without signs of HE (p <0.002), and 
patiente with HE grade l-ll (p <0.01). The mean methionine level In 
patiente with HE grade l-ll was aleo significantly higher than that 
in normal subjects (p <0.001). 
The mean level of 4-methylthio-2-oxobutyrate in patients with HE 
grade lll-IV and in thoee with HE grade l-ll was significantly higher 
than that in normal eubjects (p <0.001 in both casse). The mean level 
In patiente with HE ' lll-IV wae aleo eigniflcantly higher than that in 
patients with liver disease without eigne of HE. No significant 
differences in the mean values of 4-methylthio-2-oxobutyrate were 
observed between HE grade l-ll and lll-IV. 
MT mixed disulfides 
The mean level of MT mixed disulfides in patients with HE grade 
lll-IV as well ae those with HE grade l-ll wae significantly elevated 
when compared t o that of normal subjecte (p < 0.05 in both casee). No 
eignificant differences were observed between the patiente with 
different etages of liver disease (no signs of HE. HE grade l-ll, and 
HE grade lll-IV). 
methionine (rig. 6 ) . ¿-methyl-
mixed disulfides (Fig. 8) were 
patients. Their mean concsntra-
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Flg. 6. Concentrat ione of methionine In serum of c o n t r o l s u b j e c t s ( B ) . 
and of p a t i e n t e with d i f f e r e n t g r a d e s of hepat ic encephalopathy ( · = 
chronic l iver diseaee, • =acute l iver dieeaseHgroup B) Mean аіиеэ 
are shown by solid bars. 
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Fig. 7. Concentrat ions of 4 - f n e t h y l t h i o - 2 - o x o b u t y r a t e in serum of 
c o n t r o l e u b j e c t e ( B ) , and of p a t i e n t s with d i f f e r e n t gradee of hepatic 
encephalopathy ( • - c h r o n i c l iver d isease, A = acute l iver dieeaseHgroup 
). Mean valuee are shown by solid bars. 
MT mixed disulfides ( μπιοΙ / I ) 
2 -
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controls О I + I Ш+Ш CRF 
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Fig B. Concentrat ions of MT mixed disulf ides in serum of c o n t r o l 
s u b j e c t B ( a ) , p a t i e n t e with d i f f e r e n t grades of hepat ic encephalopathy 
( # = c h r o n i c l iver d isease, A=acute l iver d iseassXgroup B), and 
p a t i e n t s with chronic renal fai lure (CRFX • ). Mean values are shown 
by solid bars. 
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Table Э. Mean levels ±SEM of MT mixed d isu l f ides, methionine, and 4 -
m e t h y l t h i o - 2 - o x o b u t y r a t e In healthy c o n t r o l s . In p a t i e n t s wi th l iver 
disease wi thout signs of HE (HE 0 ) , In p a t i e n t s with HE grade l-ll 
and grade lll-IV (group B), and In p a t i e n t s with chronic renal 
fallu-e (CRF). 
Normals 
n=12 
HE 0 
n=20 
HE l-ll 
n=12 
HE lll-IV 
n=9 
CRF 
n=10 
MT mixed 
disulfides 
(nmol/l) 
0.21 ±0.02 
0.Э9 ±0.09 
0.43 ±0.0B 
0.43 ±0 10 
0 . 5 0 ±0.07 
Methionine 
(umol/l) 
24 ±2 
5 2 ±11 
105 ±45 
3 3 4 ±112 
14 ± 2 
4-Methylthio-
2-oxobutyr! 
(umol/l) 
0 . 0 9 ±0.01 
0.26 ±0.04 
0.49 ±0 23 
0.79 ±0.26 
0.5B ±0.07 
In p a t i e n t s with HE grade l-ll + l l l-IV, a s ignif icant c o r r e l a ­
t ion was o b s e r v e d between their individual concentrat ions of MT mixsd 
disulf ides and t h s i r individual c o n c e n t r a t i o n s of 4 - m e t h y l t h i o - 2 -
o x o b u t y r a t e (corre lat ion=0 6 7 , p' <0.002) and also b e t w e e n their 
individual c o n c e n t r a t i o n s of 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e and their 
individual methionine c o n c e n t r a t i o n s ( c o r r e l a t i o n = 0 . 5 4 , p' <G 025. 
However, no s ignif icant c o r r e l a t i o n was found between t h e i r indivi­
dual concentrations of MT mixed disulfides and methionine. 
DISCUSSION 
From the r e s u l t s i t is apparent t h a t in p a t i e n t e with HE, in 
par t icu lar t h o s e with HE grade III and IV. the c o n c e n t r a t i o n s of MT 
mixed d isul f ides, 4 - m e t h y l t h i o - 2 - o x o b u t y r a t e , methionine, and ammonia 
are Increased when compared with t h o s e in normal s u b j e c t s , and also 
when compared with t h o s e in p a t i e n t s s u f f e r i n g f rom l iver disease 
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without eigne of HE (grade 0). 
Among the MT mixed disul f ides, X-S-S-СНэ is quant i ta t ive ly the 
most Important one and is under normal c i rcumetancss e x c r e t e d in 
urine (11,IB). The Increaee in serum c o n c e n t r a t i o n s of MT mixed 
disulf ides in p a t i e n t s wi th chronic renal fa i lure ie probably caused 
by a decreased ur inary e x c r e t i o n of X-S-S-СНэ. Since the p a t i e n t s 
with HE o f t e n B u f f e r e d f r o m a decreased renal funct ion the increaee 
in lévele of MT mixed dieulf ides in pa t ien ts with HE may at least 
part ly bs due to their impaired renal function. 
In a recent s t udyOD, we demonst ra ted tha t the mean level of MT 
mixed disulf ides in ssrum of normal sub jec ts a f t e r oral methiomns 
loading (0.1 g /kg body weight) was e leva ted t o about 2.5 umol/ l We 
also de tec ted v e r y high lévele of MT mixed disulf ides (21.9 umol/ l ) 
in ssrum of a pa t ien t with hypermethionmemia due to hepat ic 
methionine adenosy l t rans fe rase deficiency(IB) This pat ient and the 
normal sub jec ts loaded wi th methionine did not show any signs of 
encephalopathy, although thei r MT mixed disulf ides concent ra t ions 
were about 2-4-0 t imes higher than those of pa t i en ts with HE grade III 
and IV. Fur thermore, an increase in the grade of HE did not 
cor respond with higher concent ra t ions of MT mixed disul f ides. Thsss 
findings indicate t ha t MT is not d i rec t l y responsib le fo r the 
occurrence of HE. 
In our group of p a t i e n t s , an incrsass in the grade of HE tended 
t o cor respond wi th an increase in the levels of methionine. These 
r e s u l t s ars in concordance with ear l ier r epo r te (23 -28 ) . It is 
general ly bel ieved tha t MT is der ived f rom methionine. The s ign i f i -
cant cor re la t ions found between the concent ra t ions of methionine and 
4 -me thy l t h i o -2 -oxobu ty ra te as well as between 4 -me thy l t h io -2 -oxobu ty -
r a t e and MT mixed disul f ides indicate tha t MT is formed via the 
methionine transamination pathway 
In addition t o the transaminat ion pathway, MT may also be formed 
through degradat ion of methionine in the gut(4,10) In a prev ious 
papsr(20) , we ehowed tha t an expoeure of r a t e t o a non-comatogemc 
doss of MT via the in teet ine resu l ted in an increase in the serum 
levels of MT mixed disul f idee. There fo re , e levated levels of MT mixed 
disulf ides may bs e x p e c t e d in pa t ien ts su f fe r ing f rom g a s t r o i n t e s t i -
nal bleeding. However, in th is s tudy no signi f icant d i f fe rences in MT 
mixed disulf ides lévele were obeerved between HE pa t ien ts with and 
wi thout gas t ro in tee tma l bleeding. Theee reeu l t s t h e r e f o r e do not 
suppo r t the general ly accepted theory tha t e leva ted levels of MT in 
pa t i en ts with HE ar ise f rom degradat ion of p ro te ins in the gut . 
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The f i rs t Intermediate in the transamination pathway, 4-methyl-
thio-2-oxobutyrate. may also be formed from 5'-S-methylthioadenoeine. 
generated from S-adenosylmethiomne via polyamme eynthesis or via 
direct cleavage of S-adenoeylmethionine(29) However, an increased 
degradation of methionine into MT via this route ie unlikely, because 
the formation of S-adenosylmethiomne from methionine ie diminished 
in patients with liver diseaee(30-32) 
The increased methionine concentrations in patients with liver 
disease, in particular in those with HE, are suppoeed to be caueed by 
a impaired catabohsm of methionine via the transsulfuration pathway 
due to a decreased enzyme activity of methionine adenoeyltransferase 
(Fig 1)(30-32) A high methionine level in the body may induce an 
increased degradation of methionine via alternative routes such as 
the tranaamination pathway It was calculated that the patient with 
hypermethionmemia (716 umol methionine/l serum) due to methionine 
adenoeyltraneferase deficiency catabolized at least 20% of his 
dietary methionine via the transamination pathway(IB) In patients 
with HE grade IV. the mean methionine level was about as high as in 
the patient with methionine adenoeyltransferase deficiency However, 
the patients with HE grade IV had much lower values of MT mixed 
disulfides and 4-methylthio-2-oxobutyrate than the patient with 
methionine adenosyltransferass deficiency. indicating that besides 
the tranesulfuration pathway also the transamination pathway is 
probably impaired in patiente with HE This may be caused by 
decreased activities of the enzymes involved in the transamination 
pathway in these patiente 
In conclusion, the impaired methionine degradation via the 
traneeulfuration pathway in patients suffering from HE doee not 
reeult in a high degradation of methionine via the traneammation 
pathway, ae was observed in the patient with methionine adenoeyl-
transferase deficiency We have produced evidence that MT mixed 
disulfides in patients with HE are derived from methionine cataboliem 
via the transamination pathway The mcreaae in the eerum levels of 
MT mixed disulfides m patienta with HE ie partly attributable to 
their decreased renal function Comparison with subjects with in-
creased levels of MT mixed disulfides without any eigne of encephalo-
pathy revéale that the role of MT In the pathogenesis of HE is minor 
if not insignificant 
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CHAPTER IX 
SUMMARY AND CONCLUSIONS 
Chapter I of thie thesis gives a summary of the relevant 
l iterature concerning the pathobiochemical aspects of methionine. 
Special attention ю paid to the following subjects: 
-methionine metabollarn (transsulfuration pathway, polyamme biosyn­
thesis, methionine sulfoxide metabolism). 
-clinical implications of the disorders concerning the tranesulfura-
tion pathway. 
-the existence and the quantitative significance of methionine 
catabolism via the transamination pathway. 
-formation of methanethiol (MT) from methionine via the transamina­
tion pathway. 
-MT metabolism 
-the role of methionine and MT in the pathogenesis of hepatic 
encephalopathy. 
Chapter II demonetratee that in r a t e with liver dysfunction 
induced by D-galactosamms, orally administered methionine is toxic 
when given one day a f t e r D-galactosamme injection However, methio­
nine appears to be a good antidote in case it is administered at the 
same time as D-galactosamme. 
Chapter III describes new methods for measuring metabolites 
involved in the transamination pathway of methionine. These metaboli­
t e s are 4-msthylthio-2-oxobutyrate. 3-methylthiopropionate, and the 
newly discovered MT mixed disulfides. Evidence is provided that the 
traneammation pathway exiete in normal subjects and that ths 
quantitative significance of methionine degradation via the t r a n s ­
amination pathway is relatively small in normal subjects. However, 
sulfur and labile methyl group balance studies in a patient with 
hypermethionmemla due to a partial hepatic methionine adenoeyl-
traneferase deficiency demonstrates that at least 20% of his dietary 
methionine IB catabolized via the traneammation pathway (chapter 
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IV). This suggests that the transamination pathway may also be of 
quantitative importance in other forme of hypermethioninemla, as 
there are patiente with cyetathionine synthase deficiency and 
patients with liver disease. However, in patiente with hypermsthio-
ninemia due to cyetathionine synthase deficiency, catabolism of 
methionine via the transamination pathway proved to be of little or 
no quantitative significance (chapter V). It is concluded that 
catabolism of methionine via the transamination pathway is not solely 
regulated by the concentration of methionine. In patients with 
hypermethionmemia due to liver disease, the transamination pathway 
is probably impaired and of l ittle or no quantitative Importance in 
methionine catabolism (chapter VIII B). 
In chapter VI it is demonstrated that in premenopaueal women the 
levels of homocysteine are lower and the concentrations of the 
transamination metabolites are higher than those in men of comparable 
age. It is speculated that a higher transamination r a t e in premeno­
pausal women accounts, at least partly, for the lower homocysteine 
levels. Because of the arteriosclerotic p r o p e r t i e s of homocysteine, a 
possibis relation to the low incidence of vascular disease in 
premenopausal women ie discussed. 
The metabolism of MT is studied in chapter VII. The formation of 
MT from 3-methylthiopropionate, one of the metabolites of the 
methionine transamination pathway, has been studied by incubating 3 -
methylthiopropionate with hepatocytes from both man and rat (chapter 
VII A). MT mixed disulfides and the volatile sulfur compounds MT and 
dimethylsulfids appear to be formed from 3-methylthlopropionate, 
Indicating that MT and dimsthylsulfide are products of methionine 
catabolism via the transamination pathway. 
The metabolism of MT in whols blood is described in chapter VII В. 
The carbon-eulfur bond of labeled MT proved to split a f t e r incubation 
with blood. This indicates that MT added to blood cannot quantitati­
vely be recovered. However, the current method in l iterature for the 
measurement of MT In blood ie baeed upon a quantitative recovery of 
MT. This method is often used to inveetigate the role of MT in 
hepatic encephalopathy. Our results demonstrate that this method is 
unreliable. Therefore, in this chapter, it ie concluded that new 
techniques for measuring an exposure of the body to MT have to be 
developed. 
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For the study of the role of MT In the pathogenesis of hepatic 
encephalopathy we have developed a new method for monitoring an 
exposure of the body to MT This method ie based on measuring MT 
which Is released from MT mixed dieulfidee, by using dithiothreithol 
The concentrations of MT mixed disulfides in serum and In urine 
prove to be a good eetimate for a MT exposition, which has been 
demonstrated in humane after oral methionine loading (chapter III) 
and in rate after an exposure to MT via the inspired air or via the 
caecum (chapter Vili A) 
The levels of MT mixed dieulfidee are neither elevated in rats 
with acute hepatic encephalopathy induced by liver ischemia nor In 
dogs suffering from hepatic encephalopathy due to chronic liver 
disease (chapter Vili A) The concentrations of MT mixed disulfides 
show a email increaae in humans suffering from hepatic encephalopathy 
(chapter VIII B) Thie increase can partly be ascribed to a decreased 
renal function in these patients Much higher concentrations of MT 
mixed dieulfidee have been observed in normal humans after methionine 
loading and in a patient with a deficiency in methionine adenoayl-
transferase. both without any signe of encephalopathy These results 
suggest that the role of MT in the pathogenesis of hepatic encephalo-
pathy le insignificant 
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SAMENVATTIKC EN CONCLUSIES 
In hoofdetuk I van dit proefachrift wordt een eamenvatting 
gegeven van de relevante literatuur betreffende de pathobiochemleche 
aepecten van methionine. Specials aandacht is beeteed aan de volgende 
onderwerpen: 
-methionine metabolisme (degradatie van methionine via de transeulfu-
rerlngeroute, polyamme bioeynthese en methionine sulfoxide metabo-
lleme). 
-klinische coneequentiee bij afwijkingen in de trans-aulfurennge-
route. 
-het bestaan van de traneamineringsroute en de kwantitatieve beteke-
nis van de transaminenngsroute ten opzichte van de tranesulfure-
rlngeroute 
-de vorming van methaanthlol (MT) via de traneaminsringaroute 
-het metabolisme van MT 
-de rol van MT en methionine in de Pathogenese van hepatische 
encsfalopathie. 
Hoofdstuk II gaat over de invloed van methionine op de hepato-
toxicitsit van D-galactosamme in ra t ten . Het blijkt dat methionine 
toxisch is in r a t t e n , wanneer methionine één dag na D-galactosamme 
oraal toegediend wordt. Methionine blijkt echter een uitstekend 
tegengif te zijn wanneer het tegelijkerti jd met D-galactosamme 
toegediend wordt 
In hoofdstuk III worden nieuwe bepalingsmethoden beschreven van 
de belangrijkste metabolieten van de transaminenngsroute. Deze 
metabohten zijn: 4-methylthio-2-oxobutyraat, 3-methylthiopropionaat 
en de door ons ontdekte metabolieten van MT. de zogenaamde MT 
gemengde dieulfiden In dit hoofdetuk wordt aangetoond dat de 
transaminenngsroute beetaat in de mene, maar dat de kwantitatieve 
betekenis van deze route voor het methionine catabolisme waarschijn-
lijk klein Is. Echter, In een man met hypermethioninemie ten gevolge 
van een deficiëntie in de lever van het enzym methionine adenoeyl-
t ransferaee, wordt minimaal 20% van het via het eten opgenomen 
methionine afgebroken via de traneamineringsroute (Hoofdetuk IV) 
Deze bevinding geeft aanleiding to t de hypothese dat de traneamine-
ringeroute kwantitatief van belang kan zijn in andere vormen van 
hypermethioninemie, zoals bij patiënten met cystathionine synthase 
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deficiëntie en patiënten met leverziekten In patiënten met hyperme-
thioninemie ten gevolge van cyetathionine eynthaee deficiëntie, 
blijkt echter dat de methionine afbraak via de transaminenngaroute 
kwantitatief gering ie (hoofdstuk V) Geconcludeerd wordt dat de 
methionine afbraak via de transaminermgsroute niet alleen geregu-
leerd wordt door de methionine concentratie In patiënten met 
hypermethionlnemle ten gevolge van sen leverziskts is de kwantita-
tieve betekenis van ds transaminermgsroute gering, waarschijnlijk 
tsn gevolge van een blokkade van de afbraak van methionine via deze 
route (hoofdetik Vili В) 
In hoofdstuk VI is beschreven dat in jonge vrouwen de concentra­
ties van homocystsïns lager en van de metabolieten van de transamine-
nngeroute hoger zijn, dan in mannen van vergelijkbare leefti jd Er 
wordt gespeculeerd over de bijdrage van een verhoogde afbraak van 
methionine via the traneaminenngsroute aan de verlaagde homocysteine 
concentraties in jonge vrouwen Aangezien homocysteine een verbinding 
ie met arteriosclerotischs eigenschappen, wordt in dit hoofdstuk 
ingegaan op de relatie tussen de lage homocysteine spiegele en de 
lage incidentie van hart - en vaatziekten in jonge vrouwen, dit in 
vergelijking met jonge mannen 
Hoofdstuk VII behandelt de vorming en afbraak van MT Oe vorming 
van MT uit 3-methylthiopropionaat, een mstaboliet van de t rans-
ammeringeroute, is bestudeerd door incubatie van 3-methylthio-
propionaat met hepatocyten van zowel de mens als de ra t (hoofdstuk 
VII A) Tijdens de incubatie worden de gemengde disulfiden van MT sn 
de vluchtige zwavel verbindingen MT en dimethylsulfide gevormd Dit 
geeft aan dat MT en dimethylsulfide gevormd kunnen worden via de 
transaminermgsroute 
Het metabolisms van MT in bloed wordt beschreven in hoofdstuk VII В 
Met behulp van radio-actief gemerkt MT wordt aangetoond dat ds 
koolstof-zwavel band van MT verbroken wordt tijdens incubatie van MT 
met bloed Dit betekent dat MT na incubatie met bloed niet kwantita­
tief teruggewonnen kan worden Deze bevinding ondergraaft de m de 
literatuur vaak beschreven meetmethode van MT in bloed, welke 
gebasserd is op een kwantitatieve recovery van MT Aangezien deze 
meetmethode veelvuldig ie gebruikt bu de bestudering van de rol van 
MT In hepatische encefalopathle, is het zeer wenselijk dat deze rol 
van MT opnieuw bestudeerd wordt, gebruikmakend van een nieuwe methode 
voor de bepaling van een blootstelling van het lichaam aan MT 
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Het Ie zeer vaak gepos tu leerd dat MT een ro l spee l t In de 
Pathogenese van hepat ieche encefaiopathie. Een bet rouwbare methode om 
een b lootete l l ing aan MT t e meten ie daarvoor van g r o o t belang. De 
concent ra t iee van de gemengde dieulfiden van MT in serum en urine 
bli jken een goede maat t e zijn voor een b loote te l l ing aan MT. Dit Ie 
gedemons t reerd In gezonde vr i jw i l l igere na orale toediening van 
methionine (hoofdstuk III) en in r a t t e n na toediening van MT via de 
Inademingelucht en vla het caecum (hoofdetik Vili A). 
De concent ra t iee van de gemengde dieulfiden van MT waren niet 
verhoogd in r a t t e n met acute hepat ieche encefaiopathie ten gevolge 
van lever iechemis. en ook niet in honden met hepat ische encefaiopa-
th ie ten gevolge van chronisch lever falen (hoofdstuk Vili A). De 
concent ra t iee van de gemengde dieulfiden van MT zijn wel l icht 
verhoogd in pat iënten li jdend aan hepatieche encefaiopathie (hoofd-
s tuk VIII B). Deze verhoging kan gedeel te l i jk toegeschreven worden 
aan een s lechte n ier funct ie van deze pat iënten. De concent ra t ies van 
ds gemengde dieulfiden van MT in gezonde vr i jw i l l igere na methionine 
inname en in een pa t iën t met methionine adenoey l - t ranaferaee d e f i -
c iënt ie zijn vele malen hogsr dan in pat iënten met hepatische 
encefa iopath ie . zonder dat in ds e e r s t e twee groepen encefalopat ieche 
verschi jneelen waargenomen werden. Deze bevindingen leiden t o t de 
conclusie dat de ro l van MT in de Pathogenese van hepatische 
encefaiopathie waa~echijnlijk onbetekenend ie. 
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LIST OF ABBREVIATIONS 
MT = methanethiol 
HE s hepatic encephalopathy 
AdoMet = S-adenoeylmethionine 
AdoHcy « S-adenosylhomocyeteine 
QMS = dimethylsulfide 
MTP = 3-methylthiopropionate 
KMTB = A-methyl thio-2-oxobi j tyrate 
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transamination pathway of methionine to reduce hypermsthionme-
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STELLINGEN 
1. S-Adenosylmethionine speelt mogelijk een regulerende rol in het 
catabolisme van methionine via zowel de tranesulfurenngs- als de 
trans aminenngeroute. 
dit proefschrift 
2. Hemoglobine kan een belangrijke rol spelen in de biotraneformatie 
van methaanthiol en waterstofsulfide. 
dit proefschrift 
3. De posit ieve werking van pyndoxine op homocystinune-patiènten 
berust mogelijk voor een deel op het opheffen van de pyndoxins-
depletie, welke ontstaan is door de interaktie van pyndoxine met 
gestapeld homocysteine. 
Pestana A et al Arch Biochem Biophys (1971)146:373-379 
Mudd et al Am J Human Genet (1985)37:1-31 
dit proefschrift 
4. Heterozygoten voor homocystinune« die met of onvoldoende reage-
ren op pyndoxinetherapie, zijn gebaat bu betaine toediening 
Boers GHJ, persoonlijke mededeling 
5. De relat ie tussen glutathion S-transferasen en de bescherming van 
het lichaam tegen tumoren is ambivalent. Deze enzymen beschermen 
enerzijde gezond weefsel tegen carcinogenen doch kunnen ander-
zijds tumoren beschermen tegen een groot aantal cy tostat ica 
Kaplowitz N. Am J Physiol (1980)239:G439-6444 
Moscow JA. Cowan KH. J Nat Cancer Inst (1988)80:14-20 
6. Al het leven op aarde komt mogelijk voor t uit zwavel-etende 
bacteriën. 
Lake JA. Nature (1988)331:184-186 
7. Hoewel in het algemeen wordt aangenomen dat thiolen het lichaam 
kunnen beschermen tegen de toxische effecten van radikalen, kun-
nen thiolen echter zelf ook aanleiding geven t o t radikaal-
vormmg. 
Svensson BE, Biochem J (1988)253:441-449 
В. Naast het vermelden van t e e r - en nicotinegehalte op een -sigaret­
tenpakje l i jkt ook het vermelden van de concentraties van 
metaalionen zoals Cu2+ relevant met betrekking t o t het rleico 
voor longkanker en hart- en vaatziekten. 
OHEW Publication No. PHS 79-50066 (1979)Chap. 14:35-72 
Parthasarathy S et al. Proc Natl Acad Sci USA (19Β5)βΖ:3000-3004 
9. Bij galzuuretudiea m r a t t e n moet men bedacht zijn op het fe i t 
dat r a t t e n een groot gedeelte van hun faecee opeten (coprofagle). 
Tanuerman A, van Schalk A, Gastroenterology (1988)94-A455 
10. Het door ethische motieven ingegeven etreven naar vervanging van 
dierproeven door m vitro experimenten met humane cellen kan 
ernatig worden belemmerd door een "copyright op eigen lichaame-
cellen" van de donor. 
tota, oktober 1988 
11. Vluchtige zwavelverbindingen veroorzaken in het algemeen een 
weerzinwekkende geur. Echter in lage concentraties kunnen ze hst 
reuk- en emaakorgaan aangenaam prikkelen. 
Annes BJ. Bamforht CW. J Inst Brew (1982)88:244-252 
12. Naast waterstofsulf ide zijn andere vluchtige zwavelverbindingen 
zoale methaanthiol en dimethylsulfide eveneens - belangrijke deur-
componenten van de flatus. 
Blom HJ. Tangerman A. eigen waarnemingen ν 
13. Periodieke wisseling van rechtsnjdend in linksrijdend verkeer en 
omgekeerd (bijvoorbeeld om de 2 jaar) kan de verkeereveiligheid 
in grote mate bevorderen. 
Nijmegen. 30 november 19ΘΒ HJ Blom 


